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ABSTRACT 
The High Mobility Group A family is composed of non-histone chromosomal proteins that 
orchestrate the assembly of the nucleoprotein complexes involved in gene transcription, 
replication, and chromatin structure. HMGA1 overexpression is a feature of human cancer, and 
has a causal role in cell transformation. However, the molecular basis of this upregulation has 
not been completely elucidated. The identification and validation of numerous HMGA1-targeting 
microRNAs demonstrates that cells are sensitive to even subtle increases in HMGA1 abundance, 
thus highlighting the importance of microRNA-mediated HMGA1 regulation in cancer. 
Pseudogenes have long been considered as non-functional genomic sequences. However, 
recent evidence suggests that many of them might have some form of biological activity, and the 
possibility of functionality through a microRNA-mediated pathway. In fact, recent studies show 
that microRNAs could act as a regulatory language, through which messenger RNAs, transcribed 
pseudogenes, and long non-coding RNAs crosstalk with each other and form a previously 
unknown regulatory network. RNA transcripts involved in this network have been termed 
“competitive endogenous RNAs”, since they influence each other's level by competing for the 
same pool of microRNAs through microRNA response elements on their target transcripts. 
Our research group identified two HMGA1 pseudogene-derived RNA transcripts, 
HMGA1P6 and HMGA1P7, that competing with HMGA1 for microRNA binding, lead to the 
upregulation of HMGA1 cellular levels, exerting an oncogenic role. We demonstrate that the 
overexpression of these HMGA1 pseudogenes increases the levels of HMGA1 and other cancer-
related genes by inhibiting the suppression of their synthesis mediated by microRNAs. 
Moreover, HMGA1 pseudogenes were found overexpressed in several human cancer types. 
Interestingly, preliminary results showed that mice engineered to overexpress HMGA1P6 or 
HMGA1P7 develop malignant B cell lymphomas. Therefore, the HMGA1-pseudogene 
engineered mouse models demonstrate the oncogenic potential of these pseudogenes and 
indicate that ceRNA-mediated microRNA sequestration may contribute to the development of 
cancer.  
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1. BACKGROUND 
 
1.1 HMGA proteins 
The high mobility group A (HMGA) family is constituted by four proteins: HMGA1a, 
HMGA1b, HMGA1c and HMGA2. Two different genes encode them: HMGA1 gene produces 
the HMGA1 proteins through alternative splicing1,2. HMGA1 is situated at chromosomal locus 
6p21 in human and in the t-complex locus on chromosome 17 in mice, whereas HMGA2 is 
located at chromosomal locus 12q14-15 in humans and at the pigmy locus on chromosome 10 in 
mice, and they are well preserved during the evolution: only rare differences can be found 
between the human and the murine HMGA sequences. 
 
 
Figure 1.  Characteristics of the HMGA genes and proteins. a) The human HMGA1 gene consists of 8 exons, among 
which only exons 5 to 8 are transcribed and translated. Each exon from 5 to 7 encodes a single AT-hook domain; the 
8th encodes the acidic C-terminal tail and contains the 3’ Untraslated Region. Between the first and the second AT-
hook there are 11 additional amino acids in HMGA1a protein compared to HMGA1b. b) HMGA2 gene consists of 5 
exons coding for only one protein and each of the first three exons codes for ah AT-hook domain. A huge intronic 
sequence separates the third from the fourth exon. From: Fusco, A. & Fedele, M. Roles of HMGA proteins in 
cancer. Nature Reviews Cancer 7, 899-910 (2007). 
 
HMGA proteins bind the minor groove of DNA in AT-rich sequences. Their DNA-binding 
domain is situated in the amino-terminal region of the protein and contains three short basic 
domains, the so-called AT-hooks3. HMGA proteins do not have transcriptional activity per se; 
however, by interacting with the transcriptional machinery they alter chromatin structure and 
thereby regulate, negatively or positively, the transcriptional activity of several genes4,5 (Table 
1). 
 
 
 
2. INTRODUCTION
2 1 HMGA proteins
The high mobility group A (HMGA) family is composed of four proteins: HMGA1a, 
HMGA1b, HMGA1c and HMGA2. They are encoded by two distinct genes, the HMGA1 
proteins being products of the same gene generated through alternative splicing (1,2). 
HMGA1 is located at chromosomal locus 6p21 in humans and in the t-complex locus on 
chromosome 17 in mice whereas HMGA2 is located at chromosomal locus 12q14-15 in 
humans and at the pigmy locus on chromosome 10 in mice, and they are well conserved 
during the evolution: only a few differences can be detected between the human and the 
murine HMGA sequences.
HMGA proteins bind the minor groove of AT-rich DNA sequences. Their DNA-binding 
domain is located in the amino-terminal region of the protein and contains three short basic 
repeats, the so-called AT-hooks3.  HMGA proteins do not have transcriptional activity per se; 
however, by interacting with the transcription machinery they alter chromatin structure and 
thereby regulate, negatively or positively, the transcriptional activity of several genes (3-6).
Figure 1. Characteristics of the HMGA genes and proteins. a) The human HMGA1 gene consists of 8 
exons, among which only exons 5 t  8 are transcribed in mRNA and code for the protein. Each exon from 
5 to 8 encodes a single AT-hook domain; the 8th encodes for the acidic C-term tail and contains the 3’ 
untranslated region. b) HMGA2 gene consists of 5 exons coding, normally, for only one protein and each 
of the first three exons codes for an AT- hook domain. A huge intronic sequence separates the third from 
the fourth exon. 
from: Fusco, A. & Fedele, M. Roles of the HMGA proteins in cancer. Nat. Rev. Cancer. 7, 899-910 (2007).
                                                                                                                                                                4
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Table 1. Genes regulated by HMGA proteins 
  
POSITIVE REGULATION Cell cycle related 
Vascular endothelial tissue related Cyclin A (Tessari et al. 2003)  
E-selectin (Lewis et al. 1994) Cyclin E (Fedele et al. 2006) 
IGFBP-1 (Allander et al. 1997) CDC2 (Fedele et al. 2006) 
COX-2 (Ji et al. 1998) CDC6 (Fedele et al. 2006) 
SM22q (Chin et al. 1998) CDC25A (Fedele et al. 2006) 
INOS (Perrella et al. 1999) Others 
CD44 (Foster et al. 2000) Tyrosinase (Sato et al. 1994) 
Immune system related PKCγ (Xiao et al. 1996) 
IL-2 (Reeves et al. 1987) Rhodopsin (Chau et al. 2000) 
TNF-β (Fashena et al. 1992) Neurogranin IRC3 (Xiao et al. 2000) 
INF-β (Thanos et al. 1992) Leptin (Melillo et al. 2001) 
IL-2Rα (John et al. 1995) Mdm2 (Pierantoni et al. 2006) 
HLA-II (Abdulkadir et al.1995) Bcl-2 (Esposito et al. 2008) 
MSGA/GROα (Wood et al. 1995)  
GM-CSF (Himes et al. 1996) NEGATIVE REGULATION 
IgG heavy chain (Sobasjima et al. 1997) GP 91-phox (Skalnik et al. 1992) 
c-fos (Chin et al. 1998) IL-4 (Chuvpilo et al. 1993) 
CXCL1 (Nirodi et al. 2000) IgE (Kim et al. 1995) 
Viral genes TCRα (Bagga et al. 1997) 
JV virus early and late genes (Leger et al. 1995) b-globin (Chase et al. 1999) 
HSV-1 IE3 (French et al.1996) a-EnaC (Zentner et al 2001) 
HIV-1 LTR (Farnet et al. 1997) BRCA1 (Baldassarre et al. 2003) 
HSV-1 EBNA1 (Sears et al. 2003) RAG2 (Battista et al. 2005)  
BV EBNA1 (Sears et al. 2003) Bax (Pierantoni et al 2006) 
 p21 (Pierantoni et al. 2006) 
 Hand-1 (Martinez Hoyos et al. 2008) 
 CBX-7 (Forzati et al. 2012) 
 
 
1.2 HMGA functions in development 
The high expression of HMGA proteins during embryogenesis suggests that they have a 
key role in development. Indeed, the phenotype characterization of mice knockout for each of 
the HMGA genes revealed the involvement of these proteins in different aspects of development. 
Cardiac hypertrophy and type 2 diabetes were observed in Hmga1-null and heterozygous mice6, 
suggesting that quantitatively appropriate expression of the HMGA1 proteins are required for 
cardiomyocitic cell growth and function of the insulin pathway. Hmga2-null and heterozygous 
mice showed a pigmy phenotype with a decreased body size and a drastic reduction of the fat 
tissue7, suggesting a critical role of the Hmga2 gene in the control of body growth and adipocyte 
proliferation and differentiation. Besides HMGA1 is present in mitotic cells (spermatogonia and 
primary spermocytes), whereas HMGA2 is highly expressed in meiotic and post-meiotic cells8,9. 
Therefore, even though HMGA1 and HMGA2 may have overlapping functions, they seem to 
have different role in development. 
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1.3 HMGA expression in normal and neoplastic tissues 
In normal adult tissues the HMGA protein expression is absent. In particular, HMGA2 
gene is not expressed in any of the several adult mouse and human tissue tested, whereas 
HMGA1 gene is expressed at very low levels in adult murine and human tissues: a higher 
expression was observed only in testis, skeletal muscle and thymus. 
However, in malignant tumours HMGA proteins are expressed at high levels. In particular, 
HMGA are expressed in all malignant tissues analysed, including pancreas, thyroid, colon, 
breast, lung, ovary, uterine cervix and body, prostate, gastric carcinomas and in some forms of 
leukaemia (Table 2). Importantly, overexpression of HMGA1 correlated with malignancy and 
especially with metastatic ability. Therefore, HMGA1 expression might be a candidate 
biomarker for cancer diagnosis and prognosis10. 
The induction of the HMGA genes in malignant transformation probably occurs through 
oncofetal transcriptional mechanisms, which have not yet been well characterized. It is known 
that the elevated expression of HMGA1 in cancer cells requires a complex cooperation between 
SP1 family members and AP1 factors, induced by the activation of Ras GTPase signaling11. 
 
1.4 HMGA as cellular oncogene 
Several studies, both in vitro and in vivo, clearly established the oncogenic potential of 
HMGA proteins. Transfection of an antisense construct for the HMGA2 cDNA into normal 
thyroid cells (FRTL5), followed by infection with transforming myeloproliferative sarcoma virus 
or Kirsten murine sarcoma virus (KiMSV), generated cell lines that expressed significant levels 
of retroviral transforming oncogenes v-mos or v-ras-Ki and removed the dependency on thyroid-
stimulating hormones12. However, in contrast with the untransfected cells or cells transfected 
with the sense construct, those containing the antisense construct did not demonstrate the 
appearance of any malignant phenotypic markers12.  
Also the block of HMGA1 protein expression prevented thyroid cell transformation by 
KiMSV13, thus strongly indicating that HMGA1 protein plays a crucial role and HMGA2 an 
accessory role in thyroid cell transformation. Consistent with these data, the expression of an 
adenovirus carrying the HMGA1 gene in an antisense orientation suppressed HMGA1 protein 
synthesis and induced cell death of two human thyroid anaplastic carcinoma cell lines, but not 
normal thyroid cells14.  
More direct evidence of the role of HMGA proteins in malignant transformation came 
from work by Wood et al. They showed that increased expression of HMGA1 and HMGA2 
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leads to neoplastic transformation of Rat1a and CB33 cells, and induced distant metastasis when 
these cells are injected into athymic mice15. Moreover, human breast epithelial cells harbouring a 
tetracycline-regulated HMGA1 transgene form both primary and metastatic tumours in nude 
mice only when the transgenes are actively expressed16. The generation of transgenic mice 
overexpressing either the HMGA1 or the HMGA2 gene confirmed their oncogenicity in vivo. In 
fact, both the HMGA1 and HMGA2 transgenic mice develop GH/PRL-secreting pituitary 
adenomas and T/NK lymphomas17-19.  
 
Table 2. Cancers associated with aberrant expression of HMGA proteins 
  
Overexpression of full-length proteins 
Lewis lung carcinoma (Giancotti et al. 1989)  
Prostate (Tamimi et al. 1993) 
Thyroid neoplasias (Chiappetta et al. 1995) 
Colorectal (Fedele et al. 1996) 
Squamous carcinoma of uterine cervix (Bandiera et al. 1998) 
Non-small cell lung carcinoma (Rogalla et al. 1998) 
Neuroblastomas (Giannini et al. 1999) 
Burkitt’s lymphoma (Wood et al. 2000) 
Lipomas (Fedele et al. 2001) 
Pancreatic duct cell carcinoma (Abe et al. 2002) 
Breast (Baldassarre et al. 2003) 
Lymphoblastic leukemia (Pierantoni et al. 2003) 
Ovarian carcinoma (Masciullo et al. 2003) 
Pituitary tumors (Fedele et al. 2006) 
Testicular germ cell tumors (Esposito et al. 2008) 
Oesophageal squamous cell carcinoma (Palumbo et al. 2016) 
 
Chromosomal translocation/AT hook rearrangements 
Myeloid leukemias (Elton et al. 1986) 
Thyroid neoplasias (Chiappetta et al. 1995) 
Pulmonary chondroid hamartomas (Kazmierczak et al. 1996) 
Uterine leiomyomas (Henning et al. 1996) 
Endometrial polyps (Henning et al. 1996) 
Breast hamartoma (Dal Cin et al. 1997) 
Lipomas (Fedele et al. 2001) 
 
 
1.5 Role of HMGA proteins in neoplastic transformation  
Several mechanisms have been proposed to account for the transforming ability of HMGA 
proteins and most of them are based on the ability of these proteins to regulate the expression of 
genes that have a crucial role in the control of cell proliferation and invasion. For example, 
HMGA proteins increase the activity of several members of AP-1 transcription factors family, 
which play an important role in the regulation of cell proliferation, tumorigenesis and 
metastasis20.  
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HMGA1 also improves the transcriptional activity of NF-kB causing the expression of 
inflammatory proteins (iNOS, COX2, E-selectin, IL-2, IL-4 and GM-CSF) and it has been 
demonstrated that inflammation represents a risk factor for most types of cancer21. Moreover 
HMGA proteins overexpression impairs DNA repair negatively modulating the expression of 
some genes involved in this process and because they compete with p53 and human MutS 
homologue proteins for Holliday junction binding, exert a negative influence on the DNA 
mismatch repair response22. In addition, HMGA1 interacts with p53 and interferes with p53-
mediated transcription of genes involved in regulation of apoptosis and cell cycle but promotes 
the transcription of the p53 inhibitor MDM223. This results in a reduction of p53-dependent 
apoptosis. In particular, HMGA1 antagonizes the p53-mediated transcriptional repression of Bcl-
2 gene24.  
Finally, HMGA1 alters the expression of genes involved in epithelial-mesenchymal 
transition (EMT), which is a common phenomenon in epithelial tumours25.  
Therefore, HMGA overexpression is a feature of human cancer, and has a causal role in 
cell transformation. However, the molecular basis of this upregulation has not been completely 
elucidated.  
 
1.6 MicroRNA and HMGA microRNA-dependent regulation  
MicroRNAs (miRNAs) are endogenous, small non-coding single-stranded RNAs of ~22 
nucleotides in length, which function at post-transcriptional level as negative regulators of gene 
expression.  
The analysis of genomic positions of miRNAs shows that most miRNAs genes are situated 
in intergenic regions, but they are also found within exonic or intronic regions in either sense or 
antisense orientation. The miRNAs situated within introns are called “mirtrons”26. miRNAs 
genes can be structured as individual ones or organized as clusters representing miRNAs 
families, which are commonly associated in sequence and function. miRNAs are primarily 
produced by RNA polymerase II (RNA pol II) from their own promoter or from promoter of the 
host gene in which they are localized. RNA pol II synthesized large miRNA precursors called 
primary-miRNAs (pri-miRNAs)27. Clustered miRNAs might be transcribed from a single 
transcription unit as polycistronic primary-miRNA.  
miRNAs biogenesis takes place both in the nucleus and in the cytoplasm: firstly, pri-
miRNAs are cleaved into the nucleus by RNAse III Drosha, associated to a double stranded 
RNA-binding protein DGCR8 known as the microprocessor complex, producing ~70 nucleotides 
precursor miRNA (pre-miRNA) products, which locally fold into stable secondary stem-loop 
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structures28. Then, pre-miRNAs stuctures are recognized by the transporter Exportin 5, which 
mediates the translocation to the cytoplasm29. Here the second cleavage process (dicing) occurs, 
carried out by the RNAse III enzyme Dicer associated to TRBP (TAR RNA-binding protein) or 
protein activator of the interferon induced protein kinase (also known as PRKRA), and 
Argonaute (AGO1-4), which cuts pre-miRNA hairpin producing a transitory miRNA/miRNA* 
duplex, which is composed of the mature miRNA guide (miRNA), generally selected according 
to thermodynamic properties, and the complementary passenger strand (miRNA*), usually 
subjected to degradation. miRNA/miRNA* duplex is then loaded into the miRNA-associated 
RNA-induced silencing complex (RISC), where the mature miRNA is able to control gene 
expression at post-transcriptional level by binding through or partially through the so-called 
miRNA response element (MREs), mainly situated on 3’Untraslated Region (3’UTR), and 
leading to mRNA degradation or translation inhibition, respectively 30 (Figure 2).  
Bionformatic analyses show that miRNAs account for 1-5% of the human genome but they 
can control at least 30% of protein-coding genes31,32. To date, 1800 distinct miRNAs molecules 
have been identified within the human genome, and lot of these are very well conserved through 
the evolution33.  
 
Figure 2. The current model for the biogenesis and post-transcriptional suppression of miRNAs. From: Winter, J. et 
al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nature Cell Biology 11, 228 - 234 
(2009) 
 
Recent studies have shown that HMGA protein levels are regulated by miRNAs. Indeed, 
the presence of negatively acting regulatory elements within the HMGA2 3’UTR was first shown 
by experiments that found an upregulation in luciferase activity by truncating the HMGA2 
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3’UTR34. However, a mechanism accounting for these results, based on the involvement of 
miRNAs, was described: multiple target sites for let-7, one of the founding members of the 
miRNA family, were found in the 3’UTR of the HMGA2 gene, suggesting a role for this miRNA 
in the negative regulation of HMGA235,36. Indeed, ectopic expression of let-7 reduced HMGA2 
expression by promoting degradation of its mRNA35. These findings were similar to those 
obtained by other groups, who showed that the let-7 family of miRNAs suppresses HMGA2 in a 
mouse model system36, in head and neck cancers37 and in uterine leiomyomas38. Other studies 
demonstrate the direct targeting of HMGA1 by miR-1539, miR-1639, miR-26a40, miR-196a39, 
miR-21441, miR-76141 and let-7, and of HMGA2 by miR-1639 and let-735. Taken together, all 
these reports underline the importance exerted by the HMGA1 and HMGA2 miRNA-dependent 
regulation in cancer progression.  
 
Figure 3. Binding sites of HMGA1/2-targeting miRNAs. Schematic representation of human HMGA1 and HMGA2 
3’UTR, and the relative position of some predicted binding sites for HMGA-targeting miRNAs. 
 
1.7 Pseudogenes and the RNA languages 
Discovered in 1977, pseudogenes were dismissed as “junk DNA”42. They were not 
formally studied; indeed, extensive effort went into developing strategies to avoid their 
accidental detection42-44. 
However, over the past two decades, multiple classes of regulatory RNAs, both long RNAs 
(>few hundred nucleotides) and short RNAs (<200 nucleotides) that do not encode proteins, 
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have been identified. Long noncoding RNAs (lncRNAs) comprise intronic and intergenic 
ncRNAs and natural antisense transcripts (NATs)45-47.  
Extensive study of the short and long types of ncRNAs has shown that the noncoding part 
of our genome is far from non-functional46. Furthermore, the use of tiling arrays and high-
throughput sequencing strategies has shown that more than 90% of the human genome is 
transcribed, whereas only 1 to 2% encodes proteins48. Thus, it may be that there are more 
biologically functional ncRNAs than protein-encoding ones, which provides a rationale for the 
annotation of the noncoding transcribed genome.  
The attribution of function to specific pseudogenes has raised these underappreciated 
molecules to the status of a new class of regulatory lncRNAs involved in both physiological and 
pathological processes49. Pseudogenes are structurally similar to genes that encode functional 
proteins, but pseudogenes contain “defects” that, in most cases, render them unable to encode 
fully functional proteins50. Two categories of pseudogenes have been identified: non-processed 
and processed pseudogenes. In particular, the non-processed pseudogenes are often found in 
clustered gene families. These faulty genes have arisen by tandem duplication, representing an 
example of non-processed pseudogenes. The non-processed pseudogenes contain counterparts of 
both exons and introns and sometimes also of upstream promoter regions because they originate 
from a duplication at genomic DNA level. However, even if the non-processed pseudogene has 
an high homology rate with the functional gene, closer examination will identify several 
“molecular defects” such as inappropriate termination codons in exons, aberrant splice junctions, 
and so on. Certain types of subchromosomal region, especially pericentromeric and subtelomeric 
regions, are highly unstable. They are prone to recombination events that can result in duplicated 
gene segments (containing both exons and introns) being distributed to other chromosomal 
locations.  
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Figure 4. Pseudogene classes. (Upper) Non-processed pseudogenes originate from gene duplication and are located 
on the same chromosome of the parental gene from which they are derived. (Lower) Processed pseudogenes arise by 
retrotransposition and they are located on a different chromosome than the parental gene. 
 
Processed pseudogenes are defective copies of a gene that contain only exonic sequences 
and lack an intronic sequence or upstream promoter sequences. They originate from an ancestral 
retrotransposition: cellular reverse transcriptases can use processed mRNAs to produce cDNA 
that may then fuse into DNA. Processed pseudogenes are common in interspersed gene families. 
The human genome is estimated to contain more than 18000 pseudogenes, two-thirds of which 
are processed. Lower organisms such as Caenorhabditis elegans have a comparable number of 
protein-coding genes as humans51. However, the human genome is ~30 times larger than that of 
Caenorhabditis elegans, suggesting that the noncoding portion of the genome is of crucial 
importance in dictating the greater complexity of higher eukaryotes52,53. Several lines of 
evidence suggest that pseudogenes may have physiological functions. The low frequency of 
nonsynonymous versus synonymous mutations that characterize pseudogenes indicates that their 
sequence is prevented from neutral drifting54. The active preservation of pseudogene sequence 
explains why, after millions of years since they arose, examples still exist of gene-pseudogene 
pairs that show more than 90% sequence identity55. It also explains the numerous examples of 
actively transcribed processed pseudogenes that show high evolutionary conservation among 
primates56,57. Consistent with the notion that they exert biological functions, the expression of 
pseudogenes is a regulated process. Studies that employed high-throughput techniques and 
 14 
included pseudogenes in the analysis of differentially expressed RNAs have reported that the 
global expression profile of pseudogenes differs in different lines and under different 
conditions58. For example, the pseudogene transcriptome can vary during physiological 
processes, such as neural differentiation59, as well as in association with patho-physiological 
conditions. Furthermore, various pseudogenes show a spatio-temporal expression pattern distinct 
from that of their coding counterparts.  
 
 
Figure 5. ceRNA interaction. (A) The interaction between mRNAs and miRNAs could be reciprocal, (B) producing 
a crosstalk between mRNA molecules through miRNAs and MREs. (C) In this scenario the 3’UTR region of a 
mRNA molecule can act not only in cis, but also in trans, regulating other mRNAs. From: Salmena et al. A ceRNA 
hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 146, 353-358 (2011). 
 
In this scenario, miRNAs can be sequestered by pseudogene RNAs. As above-mentioned, 
miRNAs can bind to several complementary sequences that mainly lie on the 3’UTR of targets 
genes to lead to RNA degradation or translation repression60. The activity of miRNAs is 
influenced by the concomitant presence of multiple legitimate targets (either coding or non-
coding). Therefore, the targets operate as competitive endogenous RNAs (ceRNAs) and shield 
each other from miRNA-mediated action by competing for the microRNA binding to the relative 
MREs. Thus, ceRNA activity confers to RNA molecules the capacity to crosstalk and to regulate 
in trans each other by influencing the availability of shared microRNAs61. Furthermore, ceRNA 
hypothesis gives a role to all transcripts carrying at least one MRE, regardless of their protein-
coding ability. Consequently, MREs can be considered as the letters of a ‘‘RNA language’’ by 
which transcripts can actively interact each other controlling their respective expression levels. 
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Indeed, coding RNAs62-64, and different classes of ncRNAs, including pseudogenes62,65,66, have 
been found to act as ceRNAs.  
Furthermore, the ceRNA hypothesis may expand the regulatory function of 3’UTRs. 
Indeed, 3’UTRs classically act as cis regulatory elements, regulating the stability of their own 
transcripts. However, following ceRNA hypothesis, 3’UTRs may also act in trans to modulate 
gene expression through microRNA binding67.  
 
 
Figure 6. Decoy function. Several RNA transcripts (e.g., RNA X and RNA Y) have seed sequences for the same 
miRNAs. As proposed by ceRNA hypothesis, the overexpression of a MRE-sharing transcript (e.g., by 
transcriptional activation) results in the increment of MRE concentration in the cell, leading to the derepression of 
other transcripts that contain the same MRE sequences. From: Salmena et al. A ceRNA hypothesis: the Rosetta 
Stone of a hidden RNA language? Cell. 146, 353-358 (2011). 
 
Pseudogenes are particularly well suited to function as ceRNAs for two reasons. First, 
many are not translated; therefore, they can take part in microRNA binding without interference 
from the translation machinery68. Second, pseudogenes have high sequence homology with their 
parental genes; thus, they should play the role of multifunctional decoys that can protect their 
parental genes from all shared microRNAs. In other words, when a specific mRNA is 
overexpressed, the repression exerted by its targeting microRNAs would be diluted because the 
total number of MREs exceeds that of the microRNAs themselves. Thus, altering the expression 
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levels of an individual ceRNA would have repercussions on other ceRNAs with which it shares 
MREs.  
Some specific features of pseudogenes suggest that they may be involved in the 
pathogenesis of human cancer. Indeed, Poliseno et al. reported that PTEN pseudogene 1 
(PTENpg1) is transcribed in human tissues and cancers and it contains MREs for some of the 
same miRNAs that target its corresponding protein-coding gene, PTEN62.  By sequestering 
miRNAs that would regulate PTEN, the corresponding pseudogene derepresses the protein-
coding gene from miRNA regulation. Moreover, the human BRAF pseudogene (BRAFP1) has 
been recently found overexpressed in various tumour types, suggesting that it may contribute to 
cancer progression69. Karreth et al. demonstrated the ceRNA role of both mouse Braf-rs1 
pseudogene (Braf-rs1) and its human orthologous, BRAFP1, eliciting the expression of BRAF 
and the activation of MAPK cascade both in vitro and in vivo. Indeed, miRNA bioinformatics 
analysis showed that murine Braf-rs1 and B-raf share 53 miRNAs, as well as human BRAFP1 
and BRAF share 40 miRNAs. Thus, the BRAF pseudogene, via sequestration of common 
miRNAs, may work as decoy for BRAF in mice and humans then upregulating BRAF and 
promoting MAPK signalling and tumorigenesis. Furthermore, mice overexpressing Braf-rs1 
develop an aggressive tumour similar to the human diffuse large B cell lymphoma. In addition, 
several transcriptional or genomic aberrations of BRAFP1 were frequently found in multiple 
human cancers, including B cell lymphomas. Taken together, pseudogenes are deeply involved 
in ceRNA hypothesis and give rise to large-scale controlling system across the transcriptome, 
critically increasing the functional data of human genome and acquiring main roles in 
physiological and pathological conditions. 
 
1.8 HMGA1 Pseudogenes 
The analysis of the human genome by bionformatic database revealed the presence of eight 
processed HMGA1 pseudogenes. 
HMGA1P1 and HMGA1P2 pseudogenes are located on Xp21.3 and 4q13.3 chromosome, 
respectively. They are not conserved during the evolution, but are only found in human genome. 
There are few mutations that distinguish HMGA1P1 and HMGA1P2 from HMGA1a. These 
changes in DNA cause few errors in protein sequence that importantly do not affect their 
translationability. Indeed, preliminary data show that expressing vectors for HMGA1P1 and 
HMGA1P2 are able to code for proteins. As shown in Figure 7, some HMGA1P1 and 
HMGA1P2 mutations hit aminoacidic residues that are frequently modified at post-translational 
level along the HMGA1 protein. Interestingly, these amicoacidic residues are deeply involved in 
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the regulation of several HMGA1 functions such as chromatin remodelling and protein-protein 
interactions70-74. Therefore, if HMGA1P1 and HMGA1P2 pseudogenes coded for proteins, they 
could represent a sort of competitor proteins for HMGA1 wild-type with different post-
translational modifications, altering HMGA1 properties in chromatin remodelling and protein-
protein interactions. 
HMGA1P3 pseudogene, only found in human genome, is classified as processed 
pseudogene and it is located on chromosome 12q24.11. Even though classified as non-coding 
RNA, it has only four aminoacidic mutations along the protein sequence compared to HMGA1 
sequence, without affecting its translationability (Figure 7). Moreover, HMGA1P3 lacks the C-
terminal acidic tail that is a future of HMGA proteins10. In fact, it has been revealed that 
HMGA1a and HMGA1b can be regulated by phosphorylation on three serines situated in the C-
terminal tail. Moreover, it is believed that HMGA C-terminal tail may be important in 
modulating protein-protein interactions and could be involved in enhancing transcription factor 
activity75,76. Finally, expression of truncated Hmga1b (Hmga1/T) gene, without both the acidic 
tail and the 3’UTR, significantly enhances growth rate and impairs adipocytic differentiation77, 
suggesting that Hmga1/T mutant works in a contrasting manner compared to Hmga1 wild-type. 
Given this scenario, if HMGA1P3 coded for a protein, it could represent a truncated form of 
HMGA1 wild-type with all molecular activities mentioned above.  
Interestingly, previous data showed that HMGA1P1, HMGA1P2 and HMGA1P3 locus can 
be affected by chromosomal rearrangements in benign human tumours78. This study unveils the 
existence of an interesting pseudogene activation mechanism in tumour, since they could 
translocate, after a chromosomal rearrangements, under a promoter region or within a functional 
gene, then coding for new fusion proteins. However, no studies have evaluated HMGA1P1, 
HMGA1P2 and HMGA1P3 expression in human normal and malignant tissues where it might 
have consequences on the function of wild-type HMGA1 protein and then influence cancer 
progression. 
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Figure 7. Structure of HMGA1Ps and their main mutations compared to HMGA1 proteins. Diagrams illustrating 
the domain structures of HMGA1a, HMGA1b, HMGA1P1, HMGA1P2 and HMGA1P3. Known post-traslational 
modifications of human HMGA1a and HMGA1b proteins impaired in HMGA1Ps are highlighted (Phosphorylation 
in blue, methylation in red). The three At-hooks are in red and the acidic tail in blue.  
The non-coding RNA HMGA1P4 pseudogene is classified as processed pseudogene and is 
located on the human chromosome 9q34.11. HMGA1P4 genomic sequence shows low homology 
with HMGA1, and bioinformatics analysis confirms its untraslationability. Another processed 
pseudogene related to HMGA1 is HMGA1P5, that is located on human chromosome 10q22.2. As 
HMGA1P4, HMGA1P5 has low homology along HMGA1 sequence and it may code for a 
peptide not related to HMGA1 protein. At the moment there are no published studies about these 
pseudogenes. 
The processed pseudogenes HMGA1P6 and HMGA1P7 are sited on 13q12.12 and 6q23.2 
chromosome, respectively. They are not conserved through the evolution, but they are present 
only in human genome. These pseudogenes have high sequence homology with HMGA1 both in 
the 5’ and 3’UTRs and in the coding region (Figure 8). A missense mutation of the start 
methionine codon avoids HMGA1P7 mRNA translation whereas HMGA1P6 bears a mutation in 
the stop codon, which is postponed several aminoacidic residues downstream, producing a non-
traslatable mRNA. In the homology sequences among HMGA1, HMGA1P6 and HMGA1P7, we 
retrieved conserved seed matches for miRNAs that have been predicted (miR-103, miR-142-3p, 
miR-370 and miR-432) or previously validated (miR-1539, miR-1639, miR-26a40, miR-21441, 
miR-548c-3p79 and miR-76141) able to target the HMGA1 gene. In this context HMGA1P6 and 
HMGA1P7 could act as decoys for HMGA1-targeting miRNAs, as competitive endogenous 
RNAs. 
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which influences PTEN protein by changing PTENpg1 
stability and miRNA decoy activity [17]. Therefore, the 
overexpression of PTENpg1 sustains PTEN expression 
acquiring oncosuppressive functions [12]. 
Moreover, the human BRAF pseudogene (BRAFP1) 
has been recently found overexpressed in various tumor 
types, suggesting that it may contribute to cancer 
development. Karret et al. demonstrated the ceRNA role of 
both mouse Braf-rs1 pseudogene (Braf-rs1)and its human 
ortholog, BRAFP1, eliciting the expression of BRAF 
and the activation of MAPK cascade both in vitro and in 
vivo. Indeed, miRNA bioinformatic analysis showed that 
murine Braf-rs1 and B-Raf share 53 miRNAs, equally 
human BRAFP1 and BRAF share 40 miRNAs. Thus, the 
BRAF pseudogene, via sequestration of common miRNAs, 
may work as a decoy for BRAF in mice and humans then 
upregulating BRAF and promoting MAPK signaling and 
tumorigenesis. Furthermore, mice overexpressing Braf-rs1 
develop an aggressive tumor similar to the human diffuse 
large B cell lymphoma. In addition, several transcriptional 
or genomic aberrations of BRAFP1 were frequently found 
in multiple human cancers, including B cell lymphomas 
[18]. Taken together, pseudogenes are deeply involved in 
ceRNA hypothesis and give rise to large-scale controlling 
system across the transcriptome, critically increasing the 
functional data of human genome and acquiring main roles 
in physiological and pathological conditions [19].
Besides pseudogene-derived small RNAs have been 
demonstrated to have a role in chromatin repression [20]. 
Latest evidences show contribution of pseudogenes in 
regulating development and disease by encoding peptides 
or proteins [21-23]. Interestingly, Kandouz et al. detected 
the expression of Cx43 pseudogene (psiCx43) in several 
cancer cell lines demonstrating its translationability 
in a protein of 43 kDa. Moreover, the psiCx43 protein 
overexpression was able to induce translational inhibition 
of Cx43 acting as a posttranscriptional regulator of Cx43, 
whose expression in cancer slows growth and renders the 
cells more sensitive to cytotoxic chemotherapeutics [23]. 
Finally, it has been reported that pseudogenes produce 
small interfering RNAs (siRNAs) in African Trypanosoma 
brucei and suppress several kinds of functional protein-
coding genes through RNA interference pathway [24]. 
The family of High-Mobility Group A (HMGA) 
is composed of four proteins, HMGA1a, HMGA1b, 
HMGA1c, encoded by HMGA1 gene at the end of 
alternative splicing, and HMGA2, encoded by the HMGA2 
gene [25]. HMGA1 is located on chromosome 6p21 in 
humans and in the t-complex locus on mouse chromosome 
17, whereas HMGA2 is found on chromosome 12q13-15 
in humans and at the pigmy locus on chromosome 10 in 
mice [26]. HMGA1 and HMGA2 genes are well conserved 
through the species, in fact, only few differences have been 
found between the human and the murine HMGA sequence 
Figure 1: Structure of HMGA1Ps and their main mutations with respect to H GA1 proteins. Diagrams illustrating the 
domain structures of HMGA1a, GA1b, HMGA1P1, HMGA1P2 and HMGA1P3. Known post-traductional modifications of human 
HMGA1a and HMGA1b proteins impaired in HMGA1Ps are highlighted (Phosphorylation in blue, methylation in red). The three AT-hooks 
are red and the acidic tail in blue
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Figure 8. HMGA1, HMGA1P6 and HMGA1P7 share the same MREs. HMGA1 (top), HMGA1P6 (middle) and 
HMGA1P7 (bottom) mRNAs sequences are reported in blue, whereas the red boxes represent the HMGA1-targeting 
miRNA seed matches shared by these transcripts.  
Finally, HMGA1-p is located on chromosome 2p13.2. Its expression is able to induce 
destabilization of HMGA1 mRNA. Indeed, it has been demonstrated that the HMGA1-p RNA 
competes with HMGA1 3’UTR for a critical RNA stability factor, the alpha C-binding protein 
(αCP1)80. The HMGA1-p was found overexpressed in diabetic patients then causing a significant 
destabilization of HMGA1 mRNA with consequent loss of INSR expression, which is regulated 
by HMGA1, and then generating an insulin resistance phenotype80. Therefore, this study 
established a novel mechanistic linkage between HMGA1-p pseudogene expression and type 2 
diabetes mellitus. 
 
2. AIM 
Non-coding RNAs, including pseudogenes, have long been considered as non-functional 
genomic relicts of evolution, but a large body of evidence now suggests they are important in 
both physiology and disease. Pseudogenes are usually defined as defunct copies of genes that 
have lost their potential as DNA templates for functional products because they harbour 
premature or delayed stop codons, deletions/insertions and frameshift mutations that abrogate 
their translation into functional proteins. Since miRNAs repress target gene expression by 
binding to complementary sequences in the 3’UTR of target mRNA, pseudogenes can be 
Oncotarget4www.impactjournals.com/oncotarget
may occur through oncofetal transcriptional mechanisms, 
which have not been elucidated yet. It is known that 
the high expression of HMGA1 in cancer cells needs 
a close cooperation between SP1 family elements 
and AP1 proteins, stimulated by the activation of Ras 
GTPase cascade [80]. Furthermore, recent studies have 
demonstrated the miRNAs HMGA proteins regulation 
by binding its 3’ untranslated region (UTR), provoking 
mRNA degradation or inhibition of its translation [81, 
82]. In particular, several studies reported a strong HMGA 
regulation by miRNAs in pituitary adenomas (mir-15, 
mir-16, miR-34b, mir-214, miR-326, miR-432, miR-548c-
3p, miR-570, miR-603 and mir-761) [83-85], in thyroid 
carcinomas (let-7) [86], in breast cancer (mir-26a, miR-
33b) [87, 88]. Moreover, the loss of HMGA2 3’UTR, 
commonly found in benign tumors of mesenchymal 
origin, abolishes the inhibition of HMGA2 expression 
by several miRNAs [89, 90], leading to HMGA2 protein 
overexpression that accounts for neoplastic transformation. 
HMGA1 PSEUDOGENES
The analysis of the human genome by bioinformatic 
database revealed the presence of eight processed HMGA1 
pseudogenes (HMGA1Ps): HMGA1-p, HMGA1P1, 
HMGA1P2, HMGA1P3, HMGA1P4, HMGA1P5, 
HMGA1P6, and HMGA1P7 (Table 1). 
HMGA1P1 AND HMGA1P2
HMGA1P1 and HMGA1P2 pseudogenes, classified 
as processed pseudogenes, are located on Xp21.3 and 
4q13.3 chromosome, respectively. They are not conserved 
during the evolution, but are only found in human genome. 
There are few mutations that distinguish HMGA1P1 and 
HMGA1P2 from HMGA1a. These changes in DNA cause 
few errors in protein sequence that importantly do not 
affect their translationability. Indeed, our preliminary 
data show that expressing vectors for HMGA1P1 and 
HMGA1P2 are able to code for proteins detectable by 
western blotting analysis. In fact, lysates from HMGA1-
null cells transfected with the both vectors were positive 
to HMGA1 antibodies, which recognize the N-terminal 
aminoacids shared by HMGA1P1, HMGA1P2 and 
HMGA1. As shown in Figure 1, some HMGA1P1 and 
HMGA1P2 mutations hit aminoacidic residues that are 
frequently modified at post-translational level along 
the HMGA1 protein. Indeed, HMGA1P1 is mutated at 
position 25 where a tryptophan residue substitutes an 
arginine, within the first AT-hook of HMGA1, which has 
been shown to be a major site of modification in tumor 
cells [91]. In fact, Sgarra et al. demonstrated that the 
arginine residue 25 is strictly related to the execution of 
programmed cell death in tumor cell lines [92]. HMGA1P1 
is also mutated at threonine residue 53 that is substituted 
Figure 2: HMGA1P6 and HMGA1P7 mRNA sequence sh res HMGA1-targeting miRNAs. HMGA1 (top), HMGA1P6 
(middle) and HMGA1P7 (bottom) mRNA sequ nc s a e shown in blue. HMGA1-ta geting miRNA s ed matches (red boxes) withi  the 
high homology regions are shared among HMGA1, HMGA1P6 and HMGA1P7. 
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targeted by miRNAs that modulate the expression of coding genes. Indeed, several pseudogene 
transcripts exert regulatory control of their ancestral gene expression levels by competing for the 
same miRNAs, which is in keeping with the notion that miRNA activity is theoretically affected 
by the availability of target MREs in the cellular milieu. Given this scenario, the aim of the 
present study is to investigate the possible oncogenic function of HMGA1P6 and HMGA1P7 
exerted by a competitive endogenous RNAs mechanism and the consequences of this new 
mechanism especially in the process of carcinogenesis.  
This dissertation is based upon the following publications (attached at end): 
  
Esposito, F., De Martino, M., Petti, M. G., Forzati, F., Tornincasa, M., Federico, A., Arra, C., 
Pierantoni, G. M. & Fusco, A. HMGA1 pseudogenes as candidate proto-oncogenic competitive 
endogenous RNAs. Oncotarget 5, 8341-8354 (2014). 
 
Esposito, F., De Martino, M., Forzati, F. & Fusco, A. HMGA1-pseudogene overexpression 
contributes to cancer progression. Cell Cycle 13, 3636-3639 (2014). 
 
Esposito, F., De Martino, M., D'Angelo, D., Mussnich, P., Raverot, G., Jaffrain-Rea, M. L., 
Fraggetta, F., Trouillas, J. & Fusco, A. HMGA1-pseudogene expression is induced in human 
pituitary tumors. Cell Cycle 14, 1471-1475 (2015). 
 
De Martino, M., Forzati, F., Arra, C., Fusco, A. & Esposito, F. HMGA1-pseudogenes and 
cancer. Oncotarget 7, 28724-28735 (2016). 
 
De Martino, M., Forzati, F., Marfella, M., Pellecchia, S., Arra, C., Terracciano, L., Fusco, A. & 
Esposito, F. HMGA1P7-pseudogene regulates H19 and Igf2 expression by a competitive 
endogenous RNA mechanism. Sci Rep. 6, 37622 (2016). 
 
 
 
 
 
 
 21 
3. MATERIALS AND METHODS 
 
3.1 Cell culture and transfections 
HEK293, MCF7, 8505c, and MEF (from 12.5-day-old embryos) cells were maintained in 
DMEM supplemented with 10% foetal calf serum (Thermo Fisher Scientific), glutamine and 
antibiotics. NIH3T3 cells were cultured in DMEM supplemented with 10% calf serum (Thermo 
Fisher Scientific), glutamine and antibiotics. MycoAlert (Lonza) was regularly used to test that 
cells were not infected by mycoplasma. Lipofectamine plus (Thermo Fisher Scientific) reagent 
was used to transfect the cells according to manufacturer’s instructions. The transfected cells 
were selected in a medium containing geneticin (Sigma). Transfection efficiency was tested for 
each experiment by assessing GFP signal. To inhibit HMGA1P6, HMGA1P7, DICER and Dicer 
expression, small interfering RNAs and corresponding scrambled small interfering RNAs were 
designed and used as suggested by the manufacturer (RIBOXX).  
 
3.2 Human cancer samples 
Neoplastic and normal human thyroid tissues were obtained from surgical specimens and 
immediately frozen in liquid nitrogen. Thyroid tumours were collected at the Service 
d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Bénite, France. The tumour samples 
were frozen until required for RNA or protein extraction. TissueScan Ovarian Cancer Tissue 
qRT-PCR Panel were purchased from Origene (HORT302).  
Surgical samples of pituitary tumours were obtained from patients operated in 2 centers: 
Lyon, France (29 tumours) and at the Neuromed Institute, Pozzilli, Italy (12 tumours).  
Normal and neoplastic human breast tissues were obtained from surgical specimens and 
immediately frozen in liquid nitrogen. 32 breast samples were collected at the Institute of 
Pathology, University of Basel, Switzerland. The tumour samples were frozen until required for 
RNA extraction. We declare that informed consent for the scientific use of biological material 
was obtained from all patients. 
 
3.3 RNA extraction and quantitative reverse transcription PCR 
Total RNA was extracted from tissues and cell cultures with Trizol (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. For mRNA detection, we reverse 
transcribed total RNA by using the QuantiTect Reverse Transcription Kit (Qiagen), and then 
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Real-time PCR (qRT-PCR) was performed by using Power SYBR Green PCR Master Mix 
(BioRad) and the following primers:  
hHMGA1-Fw 5’-aaggggcagacccaaaaa-3’  
hHMGA1-Rev 5’-tccagtcccagaaggaagc-3’  
hHMGA1P6-Fw 5’-gcagacccacaaaactgga-3’  
hHMGA1P6-Rev 5’-gagcaaagctgtcccatcc-3’  
hHMGA1P7-Fw 5’-gctccttctcggctcctc-3’  
hHMGA1P7-Rev 5’-gcttgggcctcttttatgg-3’  
hG6PD-Fw 5’-acagagtgagcccttcttcaa-3’  
hG6PD-Rev 5’-ataggagttgcgggcaaag-3’  
mHmga1-Fw 5’-ggcagacccaagaaactgg-3’  
mHmga1-Rev 5’-ggcactgcgagtggtgat-3’  
mG6pd-Fw 5’-cagcggcaactaaactcaga-3’  
mG6pd-Rev 5’-ttccctcaggatcccacac-3’  
mHmga2-Fw 5’-aaggcagcaaaaacaagagc-3’  
mHmga2-Rev 5’-ttgtggccatttcctaggtc-3’  
mEzh2-Fw 5’-tggaagcagcggaggata-3’  
mEzh2-Rev 5’-gtcactggtgactgaacactcc-3’  
mVegf-Fw 5’-aaaaacgaaagcgcaagaaa-3’  
mVegf-Rev 5’-tttctccgctctgaacaagg-3’  
mIgf2 Fw 5′-cctccttacccaacttcaggt-3′  
mIgf2 Rv 5′-aagagatgagaagcaccaacatc-3′  
mh19 Fw 5′-atgtcttcatttctccctatagcc-3′  
mh19 Rv 5′-gtcatcctcgccttcagtg-3′  
mCol6a3 Fw 5′-ggaggtgtacaggaagttccac-3′  
mCol6a3 Rev 5′-gactgagccgtcaaagagga-3′  
mMki67 Fw 5′-gctgtcctcaagacaatcatca-3′  
mMki67 Rev 5′-ggcgttatcccaggagact-3′  
mGpx3 Fw 5′-gtgaacggggagaaagagc-3′  
mGpx3 Rev 5′-tgagcccaggagttctgc-3′  
mLeprel1 Fw 5′-tggaccctctttaccgagaa-3′  
mLeprel1 Rev 5′-tgatccaagatggcaatcac-3′  
hActin Fw 5′-ccaaccgcgagaagatga-3′  
hActin Rv 5′-ccagaggcgtacagggatag-3′  
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hH19 Fw 5′-ttacttcctccacggagtcg-3′  
hH19 Rv 5′-gagctgggtagcaccatttc-3′ 
hIGF2 Fw 5′-gctggcagaggagtgtcc-3′ 
hIGF2 Rv 5′-gggattcccattggtgtct-3′ 
The 2−ΔΔCt formula was used to calculate the differential gene expression81.  
 
3.4 Plasmids 
For transfection of miRNA oligonucleotides, cells were transfected with 50 nmol/ml of 
miRNA precursors or with a control no-targeting scrambled oligonucleotides (Thermo Fisher 
Scientific) using siPORT neoFX Transfection Agent (Thermo Fisher Scientific).  
For the HMGA1P6 expression construct (pCAG-HMGA1P6) and the HMGA1P6 luciferase 
reporter construct (pGL3-HMGA1P6), the entire sequence of HMGA1P6 gene 
(ENST00000418454.1) was amplified by using the primers  
Fw HMGA1P6 5’-tcctctaattgggactccga-3’  
Rev HMGA1P6 5’-ttactcagatcccaggcaga-3’ 
The amplified fragment was cloned into pCAG vector and into pGL3-Control firefly 
luciferase reporter vector (Promega), respectively. For the HMGA1P7 construct (pCAG-
HMGA1P7) and the HMGA1P7 luciferase reporter construct (pGL3-HMGA1P6), the entire 
sequence of the HMGA1P7 gene (ENST00000406908.1) was amplified by using the primers  
Fw HMGA1P7 5’-agccagtcgagctggaggtc-3’  
Rev HMGA1P7 5’-ctgcaatgtgtactcagagc-3’ 
The amplified fragment was cloned as described for the HMGA1P6 constructs. For Igf2 
luciferase reporter construct (pGL3-Igf2), the miRNA seed sequence containing fragment of Igf2 
gene (ENSMUST00000000033) was amplified by using the primers:  
Igf2 Fw 5′-aatttctagacccaaaatctcacttttccc-3′ 
Igf2 Rev 5′-aatttctagagatggcccataggtgtgctc-3′ 
The amplified fragment was cloned into pGL3-Control luciferase reporter vector 
(Promega). 
 All the generated vectors were confirmed by sequencing. The Renilla luciferase vector 
(pRL-CMV), for transient transfection efficiency, was purchased from Promega. The 3′UTR 
region of the HMGA1 gene has been previously described79.  
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3.5 Protein extraction, western blotting and antibodies 
Cells were lysed in lysis buffer containing 1% NP40, 1 mM EDTA, 50 mMTris-HCl (pH 
7.5) and 150 mM NaCl, supplemented with complete protease inhibitors mixture (Roche 
Branford, CT, USA). Total proteins were separated by SDS-polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes (Amersham, Rainham, UK) by elettroblotting. 
Membranes were blocked with 5% non-fat dry milk and incubated with primary antibodies. 
The primary antibodies used were anti-EZH2 (AC22) from Cell Signaling; anti-Vinculin 
(sc-7649), anti-Actin (sc-1615), anti-γ-Tubulin (sc-17787), anti-GAPDH (sc-32233) from Santa 
Cruz Biotechnology; Anti-VEGF from Abcam; anti-IGF2 (#32592) from Sabbiotech. Antibodies 
versus HMGA1 and HMGA2 are polyclonal Ab raised against a synthetic peptide located in the 
NH2-terminal region82,83. 
 
3.6 Dual-luciferase reporter assay 
For dual-luciferase reporter assay, 3×105 HEK293 cells were co-transfected in 6-well 
plates with the pGL3-HMGA1P6 or the pGL3-HMGA1P7 luciferase reporter vectors, together 
with the Renilla luciferase plasmid and miRNA precursors or a control no-targeting scrambled 
oligonucleotides (Ambion), using siPORT neoFX Transfection Agent (Ambion). pGL3-Igf2 
luciferase reporter vector was co-transfected in NIH3T3 cells using the same experimental 
conditions. The pRL-TK control vector expressing Renilla luciferase (Promega) was used for 
normalization of cell number and transfection efficiency. Luciferase activity was measured 48 
hours after transfection using the Dual-Luciferase Reporter.  
 
3.7 Growth curve assay 
For each experimental point 3×104 cells were plated in a 60 mm plate. Cells were counted 
in triplicate with Burker hemocytometer chamber84.  
 
3.8 Cell migration and invasion assay 
Transwell motility and invasion assays were done using 8 micron pore, 6.5-mm 
polycarbonate transwell filters (Corning Costar Corp.). Cells (3x104) suspended in serum-free 
medium were seeded on the upper surface of the filters and allowed to migrate toward 10% FBS-
containing media in the bottom compartment for 24 hours. The cells remaining on the upper 
surface were wiped off with a cotton swab and the cells that had migrated to the underside of the 
transwell filters were fixed, stained with crystal violet. For cell invasion assay 1x105 cells were 
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placed on Matrigel basement membrane (BD Biosciences) in the upper chamber of the filters in 
24-well with 300 µl DMEM/10%FBS in the lower chamber and incubated for 48 hours. Invaded 
cells on the lower surface of the Matrigel membrane were fixed and stained with crystal violet85.  
 
3.9 Flow cytometric analysis 
HEK293 cells were transfected with HMGA1P6, HMGA1P7 and the empty vector, and 
analysed by flow cytometry after 48 hours of growth under normal culture conditions. Primary 
MEFs were obtained from 12.5-day-old embryos. The MEFs were minced and used to establish 
single cell suspensions and then analysed by flow cytometry after 48 hours of growth under 
normal culture conditions. Briefly, cells were harvested in PBS containing 2 mmol/l EDTA, 
washed once with PBS, and fixed for 2 hours in cold ethanol (70%). Fixed cells were washed 
once in PBS and treated with 40 µg/ml RNase A in PBS for 30 minutes. They were then washed 
once in PBS and stained with 50 µg/ml propidium iodide (Roche). Stained cells were analysed 
with a fluorescence activated cell sorter (FACS) Calibur (Becton-Dickinson), and the data were 
analysed using a mod-t cell cycle analysis programme.  
For spleen FACS analyses, organs from transgenic and WT mice were removed, pressed 
through a stainless steel mesh, and suspended in PBS. After one wash in PBS, the cells were 
resuspended in NH4Cl and washed twice more in PBS. Aliquots of lymphocytes (1x106) were 
placed in 96-well round-bottom plates. For hematopoietic lineage analysis, we used monoclonal 
antibodies specific for the following: NK-FITC (PK146), CD3 APC-H7 (560176), CD19 PE/cy7 
(HIB19). All antibodies were from BioLegend. 
 
3.10 Generation and genotyping of transgenic mice 
The 3.5 kb HMGA1P7 of the pCAG-HMGA1P7 expression plasmid was excised with SalI 
& HindIII restriction endonucleases by cleaving 10 µg of the plasmid. The fragment was purified 
from SeaKem GTG agarose (avoiding exposure to UV light) using the Qbiogene Geneclean Spin 
kit, then dialysed 24 hours against 2l microinjection buffer (10 mM Tris.HCl pH 7.2, 0.1 mM 
EDTA), and diluted to a concentration of 4 ng/µl. The DNA was injected in three sessions into 
C57BL/6N- derived zygotes. For this purpose, C57BL/6N female mice (bred at PolyGene from 
parents obtained from Charles River) were superovulated at 28-34 days of age and mated in the 
PolyGene mouse facility to C57BL/6N breeder males, originally also obtained from Charles 
River. Injected zygotes were cultivated overnight and transferred into pseudopregnant B6CBAF1 
females, also from Charles River. The animals were kept in individually ventilated cages. 
Injections were performed at the PolyGene labs in Rümlang, Switzerland. The same 
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methodology was used to generate HMGA1P6 transgenic mice. Pups were biopsied at weaning 
and analysed for transgene integration by PCR. All mice were maintained under standardized 
nonbarrier conditions in the Laboratory Animal Facility of the Istituto dei Tumori di Napoli 
(Naples, Italy), and all studies were conducted in accordance with Italian regulations for 
experimentations on animals.  
 
3.11 SA-beta-gal assay 
4×104 MEFs, plated 24 hours before the assay, were washed twice with PBS and immersed 
in fixation buffer (2% [w/v] formaldehyde, 0.2% [w/v] glutaraldehyde in PBS) for 7 minutes. 
After 3 additional PBS washes, the cells were allowed to stain overnight in staining solution (40 
mM citric acid/sodium phosphate, pH 6.0; 150 mM NaCl; 2.0 mM MgCl2; 1 mg/ml X-gal) at 
37°C without CO2 to avoid changes in pH. The next day, the staining solution was replaced with 
PBS, and the stained and unstained cells were counted by light microscopy (at least 24 fields).  
 
3.12 RNA-sequencing 
RNA samples were initially checked for quality and quantity using a Bioanalyzer with the 
total RNA Pico chip (Agilent Technologies, Inc) and a Qubit® with RNA Assay Kit (Thermo 
Fisher Scientific Inc) respectively.  
Spike-In Mix 1 and Spike-In Mix 2, each containing the full complement of 92 
polyadenylated transcripts from the ERCC plasmid reference library, were added to samples. 
SOLiDTM Total RNA-Seq Kit (Life Technologies Corporation) was used to convert RNA 
transcripts into a cDNA library, starting from low input amounts of poly(A) RNA, for analysis 
on the 5500 Genetic Analysis System. First of all, mRNA was incubated in a thermal cycler at 95 
°C for 10 minutes to fragment the RNA by chemical hydrolysis. The RNA digested was 
hybridized and ligated with Solid specific adaptors. Two rounds of size selection using 
Agencourt® AMPure® XP Reagent were performed to increase the percentage of library inserts 
that were in the desired size range, >150 bp. The purified DNA was amplified and barcoded by 
18 PCR cycles to enable sequencing of all the samples in a single multiplexed SOLiD System 
sequencing run.  
The yield and size distribution of the amplified DNA libraries was assessed running the 
samples on an Agilent® 2100 BioanalyzerTM Instrument with the DNA HS Kit following the 
manufacturer’s instructions and Qubit® dsDNA HS kit®.  
Ninety nanograms of each library was pooled together and one E80 emulsion was prepared 
following SOLiD EZ BeadTM System. About 400 millions of pooled templated beads were 
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deposited on a 4 lanes of a 6 lanes slide and the sequencing was performed up to a read length of 
50 bp, based on 5500 Genetic Analysis System Run sequencer protocol.  
 
3.13 Bionformatic analysis 
Four samples were analysed: two from WT and two from HMGA1P7 transgenic MEFs. 
The comparison performed was WT versus transgenic, two biological replicates for condition.  
Sequencing reads in SOLiD “xsq” format were mapped against the reference genome 
(UCSC GRC38/mm10); reference gene structure was Refseq from the refGene.txt file of the 
UCSC genome browser FTP site; the mapping so ware was the Whole Transcriptome Analysis 
module from the Lifescope 2.5.1 Genomic Analysis So ware analysis suite from Applied 
Biosystems/ThermoFisher Scientific.  
A filter file, containing 6415 sequences (sequencing adaptors; barcodes; tRNAs; rRNAs; 
rRNA fragments; repetitive sequences; ERCC RNA sequences) was used to filter the transcripts 
for non-significant reads and (2) to quantify the absolute expression using the External RNA 
Controls Consortium (ERCC) RNA Spike-In Mix.  
The genome-mapped reads were then correlated with Refseq genes and the resulting gene-
associated read counts were analysed with a Genomnia proprietary procedure based on the 
Bioconductor library edgeR86. The chosen limit for evaluating differential expression was 5 
counts per millions in at least half of the examined samples. The normalization procedure used 
was the standard for edgeR (TMM). Genes were called differentially expressed when the 
comparison was evaluated with a FDR < 0.05. Absolute gene expression was evaluated from the 
read counts in RPKM (Reads per kilo base per million mapped reads).  
Primary gene annotation was performed using the Bioconductor libraries biomaRt and 
GOstats, while functional clustering of the genes was performed using the DAVID functional 
annotation web site (https://david. ncifcrf.gov/).  
 
3.14 Histological analysis 
For light microscopy, tissues were fixed by immersion in 10% formalin and embedded in 
paraffin by standard procedures. Sections of 5 µm were stained with hematoxylin and eosin 
reagents. Frozen sections, 4–8 µm thick, of WT and transgenic tissues were cut in a frozen 
microtome and allowed to dry for 1h at room temperature, before fixing in acetone for 10 min. 
The slides were air dried for 2 h at room temperature and then placed in PBS for 5 min before 
the immunoperoxidase staining procedure, using anti-CD79 (ab79414) from Abcam. 
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3.15 Statistical analysis 
Data were analysed using a two-sided unpaired t test (GraphPad Prism, GraphPad 
Software, Inc.). Values of P < 0.05 were considered statistically significant. Regression analysis, 
correlation coefficients and statistical analysis were generated using GraphPad Prism, GraphPad 
Software, Inc.  
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4. RESULTS 
4.1 HMGA1P6 and HMGA1P7 act as ceRNAs for HMGA1 
Firstly, to assess the capability of HMGA1-targeting miRNAs to bind HMGA1P6 and 
HMGA1P7 (HMGA1Ps), we transfected miR-15, miR-16, miR-214, miR-761 into MCF7 cells 
(human breast adenocarcinoma), and evaluated HMGA1P6, HMGA1P7 and HMGA1 mRNA 
levels by qRT-PCR. As shown in Figure 9a, the transfection of the HMGA1-targeting miRNAs 
significantly reduced HMGA1, HMGA1P6 and HMGA1P7 mRNA levels.  
To evaluate the direct interaction between HMGA1-targeting miRNAs and HMGA1Ps 
mRNAs, we cloned the full-length HMGA1P6 and HMGA1P7 mRNAs downstream of the 
luciferase open reading frame. These reporter vectors were transfected into human embryonic 
kidney (HEK293) cells together with miRNA precursors and a control scrambled 
oligonucleotide. As shown in Figure 9b, the luciferase signal was lower in miRNA-transfected 
cells compared with the scrambled oligonucleotide. These data suggest that the HMGA1Ps and 
HMGA1 are subjected to the same miRNA-mediated post-trascriptional regulation. 
 
Figure 9. HMGA1P6 and HMGA1P7 are targeted by HMGA1-targeting miRNAs. (A) qRT-PCR analysis of 
HMGA1P6 (left), HMGA1P7 (middle) and HMGA1 (right) mRNA from MCF7 cells transfected with scrambled-
oligonucleotide, miR-15, miR-16, miR-214 and miR-761.(B) HMGA1Ps were cloned into the pGL3 control vector. 
Relative luciferase activity in HEK293 cells transiently transfected with miR-15, miR-16, miR-214, miR-761 and a 
control scrambled oligonucleotide. (C) The 3’UTR of HMGA1 was cloned into the pGL3 control vector. Relative 
luciferase activity in HEK293 cells transiently transfected with the empty vector, HMGA1P6 and HMGA1P7. The 
results are reported as the mean of values. Error bars represent mean ± SD; n=3. *, P < 0.05 **, P < 0.01 ***, P < 
0.001 (t test).  
Subsequently, we transfected a reporter vector carrying HMGA1 3’UTR downstream of the 
luciferase open reading frame to verify the ability of HMGA1Ps to act as decoy for HMGA1-
targeting miRNAs. We transfected this reporter vector into HEK293 cells together with 
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HMGA1P6- and HMGA1P7- expressing vectors. As expected, luciferase activity was higher in 
HMGA1Ps-transfected cells compared with control (Figure 9c). Moreover, the transfection of 
growing amounts of HMGA1P6- or HMGA1P7- expressing vectors resulted in the 
overexpression of HMGA1 levels (Figure 10a) due to the reduction of negative regulation 
exerted by miRNAs. Conversely, HMGA1Ps knockdown produced a reduction of HMGA1 
mRNA and protein levels (Figure 10b), reflecting the results obtained by HMGA1Ps 
overexpression. Therefore, both HMGA1P6 and HMGA1P7 compete for the endogenous 
miRNA-binding sites. 
 
 
Figure 10. HMGA1 is positively regulated by HMGA1Ps. (A) (Upper panels) qRT-PCR analysis of HMGA1 
mRNA levels in HEK293 and 8505c cells transfected with the empty vector, HMGA1P6 and HMGA1P7. (Lower 
panels) Western blot analysis of HMGA1 protein levels from the same samples shown in the upper panels. (B) 
(Upper panel) qRT-PCR analysis of HMGA1 mRNA levels in 8505c cells transfected with the scrambled 
oligonucleotide, siRNA-HMGA1P6 and siRNA-HMGA1P7s. (Lower panel) Western blot analysis of HMGA1 
protein levels from the same samples shown in the upper panel. (C) HMGA1 mRNA levels 24 h after the 
transfection of HMGA1P6 and HMGA1P7 in scrambled oligonucleotide or siRNA-DICER 8505c transfected cells. 
The results are reported as the mean of values; Error bars represent means ± SD; n =3. *, P < 0.05 **, P < 0.01 ***, 
P < 0.001 (t test).  
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Furthermore, the upregulation of HMGA1 induced by overexpression of HMGA1Ps was 
decreased in DICER-knockdown cells (Figure 10c). In fact, silencing of DICER, the enzyme that 
catalyses the last step of miRNA maturation, results in a reduction of mature miRNAs compared 
with control cells. These results support the notion that HMGA1Ps need mature miRNAs to 
regulate HMGA1 levels, acting as ceRNAs. 
 
4.2 HMGA1P6 and HMGA1P7 exert oncogenic activity 
HMGA1Ps can be transcribed but not translated. However, they can act as miRNA decoys, 
derepressing HMGA1 mRNA and protein levels (Figure 10a). To evaluate the functional effects 
of HMGA1P6 and HMGA1P7 overexpression, we analysed their role in cellular proliferation, 
apoptosis, migration and invasion. 
As shown in Figure 11a and 11b, HEK293 cells and 8505c cells (derived from human 
anaplastic thyroid carcinoma) transfected with HMGA1P6- or HMGA1P7- expressing vectors 
grew faster than the empty-vector transfected cells. Cell cycle data of HMGA1P6 and HMGA1P7 
overexpressing cells showed an increased number of cells in the S phase and a reduced number 
of cells in G1 compared with control cells (Figure 11c). These results were confirmed also by 
HMGA1Ps silencing. In fact, the silenced cells for both HMGA1P6 and HMGA1P7 grew slower 
than the control (Figure 11d). 
To analyse the role of HMGA1 pseudogenes in apoptotic cell death, we incubated HEK293 
cells with doxorubicin in the presence or absence of the HMGA1Ps. As shown in Figure 11e, 
HMGA1P6 and HMGA1P7 overexpressing cells showed a reduced apoptosis rate induced by 
doxorubicin. These results are in agreement with the finding that HMGA1 overexpression 
induces resistance to apoptosis10.  
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Figure 11. HMGA1P6 and HMGA1P7 expression increases cell proliferation and reduces apoptosis. (A) and (B) 
HEK293 and 8505c cell proliferation in HMGA1P6- and HMGA1P7-transfected cells. (C) HEK293 cells were 
transfected with the control, HMGA1P6 or HMGA1P7 vectors. The DNA content of the transfected HEK293 cells 
was analysed by flow cytometry after propidium iodine staining. (D) 8505c cell proliferation in siRNA-HMGA1P6- 
and siRNA-HMGA1P7-transfected cells. (E) HMGA1P6- and HMGA1P7-transfected cells were treated with 
doxorubicin, and apoptosis was assessed by FACS. The results are reported as the mean of values; Error bars 
represent means ± SD; n =3. *, P < 0.05 **, P < 0.01 ***, P < 0.001 (t test).  
 
Furthermore, we performed cell migration and invasion assays in HMGA1Ps transfected 
cells. As expected, cell migration was significantly higher in two cell lines overexpressing 
HMGA1Ps than in control cells (Figure 12a). Suitably, the invasion matrigel assay reported a 
higher invasion capability in HMGAPs overexpressing cells compared to control (Figure 12b). 
These results indicate that HMGA1Ps are strongly involved in cell proliferation, motility and 
invasion. 
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Figure 12. The expression of the HMGA1Ps affects cell migration and invasion. (A) Cell migration assays of 
HEK293 and 8505c cells transfected with HMGA1P6 or HMGA1P7 or with a control vector. One representative 
experiment is reported. (B) Cell invasion assays of HEK293 cells transfected with HMGA1Ps or with the backbone 
vector. One representative experiment is reported. (C) Extracts from HEK293 transfected with HMGA1P6 or 
HMGA1P7 or with a control vector were analysed by Western blotting.  
 
Interestingly, although HMGA1Ps exert a miRNA decoy activity on HMGA1 oncogene, 
bioinformatic analysis revealed that they contain sequences that can be targeted by miRNAs that 
target High Mobility Group A2 (HMGA2), Vascular Endothelial Growth Factor (VEGF) and 
Enhancer of Zeste Homolog 2 (EZH2), all of which are known to be involved in carcinogenesis. 
Thus, we found that HMGA1Ps overexpression increased the level of the proteins coded for by 
these genes (Figure 12c). Taken together these data underline the role of HMGA1 pseudogenes in 
cancer progression by acting as decoys for cancer-related genes other than HMGA1. 
 
4.3 Correlation of HMGA1 and the overexpression of HMGA1Ps in human 
cancer 
To analyse whether HMGA1Ps act as decoys in the regulation of HMGA1 protein levels 
also in human cancer, we evaluated HMGA1 and HMGA1Ps expression in a panel of 
differentiated and undifferentiated thyroid carcinomas by Western-Blotting and qRT-PCR. As 
shown in Figure 13a, papillary thyroid carcinomas (PTC), which are well differentiated and 
poorly aggressive, expressed low levels of HMGA1P6 and HMGA1P7, as well as low levels of 
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HMGA1 protein (Figure 13b). Conversely, anaplastic thyroid carcinoma (ATC), which is one of 
the most aggressive human neoplasia, expressed very high HMGA1Ps levels that, moreover, 
correlated with HMGA1 protein levels (Figure 13a and 13b). Similar data were obtained in 
human ovarian carcinomas (Figure 13c and 13d). The direct correlation between HMGA1 and 
HMGA1P6 expression (r=0.6553, P<0.0001) and between HMGA1 and HMGA1P7 expression 
(r=0.7001, P<0.0001) indicates that these genes are co-regulated.  
 
Figure 13. HMGA1 protein expression positively correlates with the expression of the HMGA1Ps in ATC. (A) 
HMGA1P6 and HMGA1P7 qRT-PCR analysis in normal thyroid tissue (NT), papillary thyroid carcinoma (PTC) 
and anaplastic thyroid carcinoma (ATC). The results are reported as the mean of expression values. The error bars 
represent mean ± SD; n = 3. (B) Western blot analysis of HMGA1 protein expression in the same samples as in A. 
(C) and (D) Ovarian sample expression values derived from commercial sources were combined for correlation 
analysis. Linear regressions of HMGA1 vs. HMGA1P6 (C) and HMGA1 vs. HMGA1P7 (D) are shown.  
 
Furthermore, we analysed HMGA1Ps expression in a panel of 41 human pituitary tumours 
(PT), including 14 growth hormone tumours (GH) with acromegaly and 27 non-functioning 
pituitary adenomas (NFPA) or gonadotroph FSH-LH tumours. In fact, several evidences showed 
that HMGA proteins act as drivers of human PT10,87-89, and that HMGA expression levels are 
associated to several miRNAs able to target both HMGA1 and HMGA2 mRNAs in PT39,79. As 
shown in Figure 14a and 14b, HMGA1P6 and HMGA1P7 were differently expressed with regard 
to the immunohistochemical type. Furthermore, we analysed the HMGA1 in the same samples 
(Figure 14c). Intriguingly, a significant linear correlation was found between HMGA1 and 
HMGA1P6 expression (r=0.5952, P<0.0001), suggesting that these genes are co-regulated 
(Figure 14d).  On the contrary, there was no correlation between HMGA1 and HMGA1P7 in the 
whole tumours panel. However, further analysis of HMGA1 and HMGA1Ps co-regulation 
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revealed some differences according to tumour type. Indeed, in the subset of GH tumours, 
HMGA1 strongly correlated with both HMGA1P6 (r=0.8593, P<0.0001) and HMGA1P7 
(r=0.6772, p<0.0001) expression (Figure 14e). Moreover, other evidences show a direct co-
regulation of HMGA1 and HMGA1Ps levels also in other human carcinomas such as squamous 
laryngeal carcinomas and endometrial carcinomas. Taken together, these data strongly support 
the hypothesis that HMGA1Ps act as ceRNAs in several human cancer types, represent a novel 
potential mechanism by which HMGA1 expression levels are upregulated. 
 
 
Figure 14. HMGA1 and HMGA1Ps expression positively correlates in pituitary tumours. (A) HMGA1P6, (B) 
HMGA1P7 and (C) HMGA1 qRT-PCR analysis in normal pituitary gland (N), GH, FSH/LH and null cell tumours. 
(D, E) The obtained values were then combined for correlation analysis. (D) Linear regression of HMGA1 vs. 
HMGA1P6 in the whole series of PT. (E) Linear regressions of HMGA1 vs. HMGA1P6 (left panel) and HMGA1 
(right panel) vs.HMGA1P7 in GH tumours.  
 
 
4.4 HMGA1P7 transgenic mouse embryonic fibroblasts grow faster and 
senesce later 
To investigate the role of HMGA1Ps in a more physiological context, we generated 
transgenic mice overexpressing HMGA1P7. Firstly, we verified the expression of HMGA1P7 in 
transgenic mice using RNA derived from several organs such as liver, spleen, lung and mouse 
embryonic fibroblasts (MEFs). As expected, HMGA1P7 levels were high in the tissues of 
transgenic mice (TG) and not revealed in wild-type (WT) counterpart (Figure 15a). Then, to 
verify the HMGA1P7 ceRNA mechanism also in vivo, we analyse hmga1 levels. Consistently, 
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hmga1 transcript and protein levels were upregulated in HMGA1P7-transgenic MEFs in 
comparison to WT control (Figure 15b). Remarkably, HMGA1P7-transgenic MEFs also 
expressed higher levels of the Hmga2, Ezh2 and Vegf proteins that are involved in 
carcinogenesis and are coded for by genes that share miRNAs with HMGA1P7 (Figure 15c). 
 
 
Figure 15. HMGA1P7 overexpressing MEFs show a higher growth rate, and lower susceptibility to senescence. (A) 
qRT-PCR analysis of total RNA from livers, spleens, lungs, and MEFs of WT and HMGA1P7 transgenic mice. (B) 
(upper panel) qRT- PCR analysis of HMGA1 mRNA levels in WT and HMGA1P7 transgenic MEFs. (Lower panel) 
Western blot analysis of HMGA1 protein expression in the same samples. (C) qRT-PCR and Western blot analysis 
of genes that share common miRNAs with HMGA1. (D) MEFs were prepared from WT and HMGA1P7 
overexpressing embryos at 12.5 dpc. At culture passage 3, they were plated and counted daily for 8 days. (F) 
Propidium iodide flow cytometry of asynchronous growing WT and HMGA1P7 overexpressing MEFs. (G) Light 
microscopy of representative WT and HMGA1P7 overexpressing MEFs stained for β-galactosidase activity at 
culture passages 6. The results are reported as the mean of values with error bars indicating SD (mean ± SD); n =3. 
*, P < 0.05 **, P < 0.01 ***, P < 0.001 (t test).  
 
In agreement with the previous results, the growth rate of HMGA1P7 transgenic MEFs was 
significantly higher than the wild-type counterpart (Figure 15d). Indeed, we evaluated whether 
the higher growth rate of HMGA1P7-MEFs was triggered by an altered cell cycle. So, we 
examined asynchronously growing MEFs by flow cytometry. The number of HMGA1P7-MEFs 
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was lower in G1 and higher in the S phase of the cell cycle compared with WT MEFs (Figure 
15e). 
Then, we assessed the susceptibility of MEFs to senescence by evaluating senescence-
associated β-gal (SA-β-gal) activity. In particular, SA-β-gal activity was detected in WT MEFs 
but not in HMGA1P7-transgenic ones (Figure 15f). Importantly, analogous data were obtained 
for HMGA1P6 transgenic MEFs (data not shown). Therefore, these results suggest that 
HMGA1Ps overexpression decreased susceptibility to cellular senescence.  
 
4.5 RNA-seq on HMGA1P7 transgenic MEFs 
Since HMGA1 pseudogenes contain several seed sequences for miRNAs their 
overexpression should derepress the expression of some other genes. In particular, we focused on 
the identification of novel HMGA1P7 ceRNA interactors differentially expressed in HMGA1P7 
transgenic MEFs with respect to wild-type ones. To identify the genes controlled by HMGA1P7 
pseudogene, we examined the whole transcriptome of WT and HMGA1P7 transgenic MEFs by 
RNA-seq analyses. To this aim, the entire population of RNA transcripts extracted from WT and 
HMGA1P7-MEFs were sequenced. The genome-wide RNA expression profiles studies reveal 
that about one hundred fifty transcripts (32 upregulated and 116 downregulated) were controlled 
by HMGA1P7 expression with a significant fold-change variation (FDR adjusted p-value of 
0.05). To validate the results obtained by RNA-seq, we analysed the expression of some 
upregulated genes such as Collagen Type VI Alpha 3 (Col6a3), Marker of Proliferation Ki-67 
(Mki67), H19, Insulin-like growing factor 2 (Igf2) and downregulated genes such as Glutathione 
Peroxidase 3 (Gpx3), Leprecan-Like 1 (Leprel1) by qRT-PCR. As shown in Figure 16, the 
quantitative qRT-PCR analyses confirmed the data obtained from the RNA-seq analyses. 
Interestingly, these genes have been related to several human cancers (colon, gastric, liver, breast 
and haematological cancers), and are considered possible therapeutic targets90-95. 
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Figure 16. Validation of RNA-seq analyses on HMGA1P7 MEFs. qRT-PCR analysis of selected deregulated genes 
from RNA-seq performed on WT and HMGA1P7 transgenic MEFs. The results are reported as the mean of values. 
The error bars represent mean ± SD; *P < 0.05 **P < 0.01 ***P < 0.001 (t test).  
 
Among the differentially expressed mRNAs found in HMGA1P7 overexpressing MEFs, 
we focused our attention on H19 and Igf2 since they, other than to be involved in carcinogenesis, 
showed the highest fold change among the upregulated genes, and are also targeted by several 
miRNAs that are able to bind to the HMGA1P7 mRNA. H19 and IGF2 genes are closely linked, 
showing highly similar patterns of gene expression, but they are reciprocally imprinted (Figure 
17). In fact, H19 is expressed solely from the maternally inherited chromosome, whereas IGF2 
expression is from the paternal chromosome. In particular, the noncoding H19 has a critical role 
in genomic imprinting during cell growth and development96. The loss of imprinting results in 
misexpression of H19 and was detected in many tumours including hepatocellular97, bladder98, 
gastric99,100 and colon101 cancer. IGF2 codes for a mitogenic growth factor that is active in early 
development and has a critical role in embryonic and foetal growth102. Increased expression of 
IGF2 is a common feature of both paediatric and adult malignancies102, and mounting evidence 
implicates IGF2 as a major factor contributing to oncogenesis102-104.  
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Figure 17. Regulation of the paternal and maternal expression in the IGF2–H19 imprinted locus. The white 
lollipops represent unmethylated CpG islands and the black lollipops represent methylated CpG islands. The red box 
represents IGF2 gene whereas the blue box represents H19 gene. The yellow and green circles represent the CTCF 
insulator protein and a downstream enhancer, respectively. 
 
 Therefore, we confirmed the upregulation of both Igf2 and H19 in several HMGA1P7 
transgenic mice derived organs, such as heart, spleen and kidney (Figure 18a, 18b and 18c). 
Moreover, as expected from previous results, qRT-PCR and Western blot data showed an 
upregulation of both Igf2 and H19 levels in HMGA1P7 overexpressing NIH3T3 cell line (Figure 
18d), supporting the hypothesis that HMGA1P7 should act as ceRNA for H19 and Igf2. 
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Figure 18. H19 and Igf2 are positively regulated by HMGA1P7. (A) qRT-PCR analysis of H19 from hearts, spleens 
and kidneys of WT and HMGA1P7 transgenic mice. (B) qRT-PCR analysis of Igf2 from hearts, spleens and kidneys 
of WT and HMGA1P7 transgenic mice. (C) Western blot analysis of Igf2 from heart, spleen and kidney of WT and 
HMGA1P7 transgenic mice. (D) Left Panel, qRT-PCR analysis of H19 and Igf2 from control and HMGA1P7 
overexpressing NIH3T3 cells. Right Panel, Western blot analysis of Igf2 from control and HMGA1P7 
overexpressing NIH3T3 cells. The results are reported as the mean of values. The error bars represent mean ± SD; 
*P < 0.05 **P < 0.01 ***P < 0.001 (t test).  
 41 
4.6 HMGA1P7 is a sponge for H19 and Igf2 targeting miRNAs 
To verify whether the effect of HMGA1P7 pseudogene on H19 and Igf2 expression is 
dependent on sharing targeting-miRNAs, we assessed the capability of HMGA1P7-targeting 
miRNAs to bind to H19 and Igf2 mRNAs. To this aim, we transfected the above-mentioned 
HMGA1P7-targeting miRNAs (miR-15, miR-16, miR-214, miR-761) into NIH3T3 cells, 
analysing H19 and Igf2 mRNA levels. As reported in Figure 19a, after the transfection of 
HMGA1P7-targeting miRNAs we found a significant reduction of H19 and Igf2 levels. To 
establish whether the HMGA1P7-targeting miRNAs directly interacted with Igf2 transcript, we 
cloned the Igf2 3’UTR downstream of the luciferase open reading frame. This reporter vector 
was transfected into NIH3T3 cell line together with miRNA precursors and a control non-
targeting scrambled oligonucleotides. The luciferase signal was considerably lower after 
transfection with miR-15, miR-16, miR-214, miR-761 in comparison with the cells transfected 
with the scrambled oligonucleotide (Figure 19b). 
  
Figure 19. H19 and Igf2 are targeted by HMGA1P7-targeting miRNAs. (A) qRT-PCR analysis of H19 (left Panel) 
and Igf2 (middle Panel) mRNA from the NIH3T3 cells transfected with scrambled-oligonucleotide, miR-15, miR-
16, miR-214 and miR-761. Right Panel, Western blot analysis of Igf2 in the same samples as in the middle panel. 
(B) Igf2 was cloned into the pGL3 control vector. Relative luciferase activity in HEK293 cells transiently 
transfected with miR-15, miR-16, miR-214, miR-761 and a control scrambled oligonucleotide. (C) H19 and Igf2 
mRNA levels 24h after the transfection of HMGA1P7 in scrambled oligonucleotide or siRNA-Dicer NIH3T3 
transfected cells.  
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Finally, the overexpression of H19 and Igf2 exerted by HMGA1P7 upregulation was 
depleted in Dicer-knockdown cells, suggesting that HMGA1P7, H19 and Igf2 follow the same 
miRNA-mediated post-transcriptional regulation (Figure 19c). These data are consistent with the 
hypothesis that HMGA1P7 requires mature miRNAs to regulate H19 and Igf2 levels.  
 
4.7 HMGA1P7, H19 and IGF2 expression positively correlates in human 
breast cancer 
Then, we investigated whether HMGA1P7 works as ceRNA through, or partially through 
H19, IGF2 and HMGA1 in breast cancer human cells. As expected, we found the upregulation of 
H19, IGF2 and HMGA1 following HMGA1P7 overexpression in MCF7 cells (Figure 20a). 
Moreover, MCF7-HMGA1P7 cells grew faster than the control transfected cells as consequence 
of HMGA1P7 ceRNA pathway activation (Figure 20b). 
To confirm the ceRNA role of HMGA1P7 and the regulation on H19 and IGF2 expression 
levels also in human cancer, we evaluated the expression these genes in a panel of breast 
carcinoma samples by qRT-PCR, since H19 and IGF2 have been reported to be overexpressed in 
this type of tumor105,106. As reported in Figure 20c, HMGA1P7 was overexpressed in most of 
carcinoma samples as well as H19 and IGF2. Moreover, the direct correlation between 
HMGA1P7 and H19 expression (Spearman r = 0,8656; p < 0,001) and between HMGA1P7 and 
IGF2 expression (Spearman r = 0,7958; p < 0,001) underlines that these genes are co-regulated 
(Figure 20d). Altogether, these results strongly support the idea that HMGA1P7 could act as 
ceRNAs in human breast cancer and represent a novel potential mechanism accounting for H19 
and IGF2 upregulation in these tumours.  
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Figure 20. H19 and IGF2 expression positively correlates with HMGA1P7 in breast cancer. (A) Left Panel, Western 
blot analysis of HMGA1 and IGF2 protein levels in control and HMGA1P7-overexpressing MCF7 cells. Right 
Panel, qRT-PCR analysis of H19 expression of control and HMGA1P7-overexpressing MCF7 cells. (B) MCF7 cell 
proliferation of control and HMGA1P7-overexpressing cells (C) qRT-PCR analysis in tumour and normal breast 
tissues. The fold change indicates the relative change in expression levels between tumour samples and normal 
samples, assuming that the value of normal sample is equal to 1. (D) Correlation analysis of HMGA1P7 vs. H19 and 
HMGA1P7 vs. IGF2 are shown. The Spearman’s rank correlation coefficient is shown.  
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4.8 HMGA1Ps act as oncogenes also in vivo 
Remarkably, preliminary results showed that about 50% of HMGA1Ps mice killed at 20 
months of age displayed a lymphoid pathology. In fact, the HMGA1Ps transgenic mice spleens 
were characterized by splenomegaly and by a lymphoid hyperplasia (Figure 21a). In particular, 
by histological analysis, we found the expansion and merging of adjacent white pulp areas with 
loss of normal structures and germinal centers. In addition, a higher magnification showed a 
monotonous lymphoid population composed of fairly large rounded cells with scant cytoplasm 
and round nuclei with finely dispersed chromatin and inconspicuous nucleoli (Figure 21b). 
Immunohistochemical analysis showed that the examined samples were all positive to CD79, a 
marker of B-cell population. Moreover, organ-infiltrated cells were detectable in the liver, 
kidneys and lungs (Figure 21c). Furthermore, FACScan analysis of lymphocytes isolated from 
pathological spleens using the CD19, CD3, and NK anti-mouse antibodies revealed a 
predominantly CD19+ population (Figure 21d), confirming the neoplastic expansion of B-cells. 
Although further analyses are required, these preliminary results underlined the oncogenic role 
of HMGA1Ps also in vivo, indicating that ceRNA-mediated microRNA sequestration may 
contribute to the development of cancer.  
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Figure 21. HMGA1Ps expression in vivo results in lymphoid malignancy. (A) Size of WT and HMGA1Ps 
transgenic mouse spleens. (B) Histological analysis of WT and HMGA1Ps transgenic mouse spleens. Haematoxylin 
and Eosin staining. (C) Histological and immunohistochemical analyses of WT and HMGA1Ps transgenic mouse 
livers, kidneys and lungs. (D) FACScan analysis of splenic cells isolated from WT and HMGA1Ps transgenic mice 
using CD19, CD3, and NK1.1 anti-mouse antibodies. 
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5. DISCUSSION 
HMGA protein overexpression plays a critical role in carcinogenesis10. Even though recent 
results evidence that HMGA expression is deeply regulated by the action of several miRNAs39-
41,79, their upregulation in human cancer has not been completely elucidated. Recent findings 
ascribe an important role in the regulation of gene expression to pseudogenes. Indeed, the 
mammalian genome contains about 20.000 pseudogenes107, more than those present in other 
organisms. The biological meaning of pseudogenes was completely unknown until few years 
ago, but very recent studies have reported their pivotal role in controlling gene expression 
mainly functioning as sponge for miRNAs, since the presence of the same miRNA responsive 
elements in gene and in the pseudogene regions could inhibit the miRNA negative regulation of 
their protein-coding target gene. Accordingly, recent results demonstrate that some pseudogenes 
are able to modulate the expression of oncogenes or tumour suppressor genes suggesting a role 
of pseudogenes in carcinogenesis108,109. 
Then, looking for the presence of HMGA1 pseudogenes in the human genome by 
bioinformatic analysis, we have identified eight HMGA1 pseudogenes. From the examination of 
HMGA1 pseudogene sequences it emerges that they can regulate HMGA1 expression and 
function. In particular, three HMGA1 pseudogenes (HMGA1P1, HMGA1P2 and HMGA1P3), 
whose translationability seems not be altered by mutations, could represent a sort of competitor 
proteins for HMGA1 wild-type with different post-translational modifications, deregulating 
HMGA1 properties in chromatin remodelling and protein-protein interactions. Furthermore, 
Chiefari et al. reported the function of another HMGA1 pseudogene (HMGA1-p), which is able 
to compete with HMGA1 3’UTR for a critical RNA stability factor, αCP180. Interestingly, 
HMGA1-p was found upregulated in diabetic patients then causing a significant destabilization 
of HMGA1 mRNA with consequent loss of INSR expression, which is regulated by HMGA1, 
and then generating the insulin resistance phenotype80. However, we focused on the role of two 
pseudogenes, HMGA1P6 and HMGA1P7, which produced a non-translational mRNAs and can 
act on the stability of HMGA1 transcript by shielding it from miRNAs able to target this gene.  
Therefore, we investigated whether HMGA1 pseudogenes influence HMGA1 protein 
levels, and, consequently play a key role in cancer progression. Firstly, we demonstrated that the 
overexpression of HMGA1Ps was able to increase both HMGA1 mRNA and protein levels by 
protecting HMGA1 transcripts from the negative regulation of several HMGA1 targeting 
miRNAs, namely, miR-15, miR-16, miR-214, miR-76139-41,79. Consistent with these data, our 
functional analyses showed that HMGA1Ps overexpressing cell lines grew faster, exhibiting a 
lower number of G1-phase cells and a higher S-phase cells compared with the backbone vector-
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transfected ones. Therefore, HMGA1P6 and HMGA1P7 influences cell cycle progression 
through their ability to increase HMGA1 protein levels, which is involved in the regulation of 
the G1-S transition phase of the cell cycle79. Moreover, HMGA1P6 and HMGA1P7 
overexpression increased cell migration, and invasiveness, and decreased the apoptotic rate. 
These results encouraged us to verify a possible HMGA1Ps overexpression in human 
cancer. Interestingly, HMGA1P6 and HMGA1P7 were abundantly expressed in anaplastic 
thyroid carcinoma, which are very aggressive and express very high HMGA1 protein levels. 
Conversely, HMGA1P6 and HMGA1P7 expression was low in papillary thyroid carcinoma, 
which are well differentiated and poorly aggressive, and express moderate HMGA1 protein 
levels. Similar results were obtained analysing HMGA1Ps expression levels in human ovarian 
carcinomas. Moreover, we found a direct correlation between HMGA1 and HMGA1Ps in a series 
of human pituitary tumours, in particular in the somatotroph ones. Recent data confirmed the 
overexpression of HMGA1Ps also in endometrioid endometrial carcinomas (EEC). In particular, 
HMGA1P6 and HMGA1P7 expression was significant associated with tumor staging increasing 
and positively correlated with that of HMGA1 levels. Therefore, the evaluation of HMGA1Ps 
levels should be used as EEC diagnostic and prognostic marker. However, in oesophageal 
squamous cell carcinoma there was not a deregulation of HMGA1 pseudogenes. It is likely that 
the cellular context, the abundance of miRNAs and other ceRNA interactors should influence 
HMGA1 pseudogenes levels, promoting or inhibiting their oncogenic activity. 
Intriguingly, HMGA1 pseudogenes seem to affect cancer progression also by binding to the 
same miRNAs that can target other genes involved in carcinogenesis process. Indeed, we found 
in HMGA1P6, HMGA1P7 genes and also in HMGA1 UTR regions several sequences that are 
potential target sites for few miRNAs able to target some cancer-related genes such as HMGA2, 
EZH2, VEGF. These genes were effectively found upregulated in HMGA1Ps overexpressing 
cells with respect to the control ones. This has important consequences. In fact, it means that 
HMGA1-pseudogene expression can exert the upregulation of HMGA2 and EZH2 protein levels 
then deeply contributing to cancer progression. Such a mechanism is likely to occur in anaplastic 
thyroid carcinoma where the overexpression of EZH2 is a molecular feature85.  
The generation of transgenic mice overexpressing HMGA1P6 or HMGA1P7 has supported 
their oncogenic role. Indeed, MEFs deriving from HMGA1P6 and HMGA1P7 overexpressing 
mice showed a higher growth rate and lower susceptibility to senescence with respect to the WT 
counterpart. 
Then, to identify other additional mRNAs deregulated in HMGA1P7 transgenic MEFs, we 
performed an RNA-seq analysis. We found that the expression of several genes were influenced 
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by HMGA1P7 including also genes involved in cancer progression such as Col6a3, Mki67, H19, 
Igf2, Gpx3 and Leprel190-95,105,106. Indeed, oncomine analyses and tissue-microarray 
immunohistochemistry showed overexpression of COL6A3 in colorectal carcinomas that was 
significantly and directly correlated with Dukes stage, T stage, stage, recurrence and smoking 
status and then with a poor prognosis30. The MKi-67 protein (also known as Ki67) is a cellular 
marker for proliferation. Ki-67 protein is expressed during all active phases of the cell cycle (G1, 
S, G2, and mitosis), but is absent from resting cells (G0)92. GPX3 gene codes for the Glutathione 
peroxidase 3, also known as plasma glutathione peroxidase (GPx-P), the variations in activity of 
GPX1, GPX2, and GPX3 isoforms may be associated with the development of cancers, for 
example, prostate cancer or even colon cancer110. Leprecan-like 1 is a potential tumour 
suppressor gene since it has been demonstrated to be downregulated in the hepatocarcinoma 
tissues and its overexpression inhibits cancer cell proliferation and colony formation through 
regulation of the cell cycle by downregulation of cyclins111.  
Deregulation of H19 noncoding gene was found in many tumours such as hepatocellular 
and bladder cancer97,98. Finally, IGF2 overexpression is widely reported in paediatric and adult 
tumors102, and several studies involve IGF2 as a key factor leading to cancerogenesis102-104.  
Among the most deregulated genes, we selected and studied H19 non-coding gene and Igf2 
that share several miRNAs with HMGA1P7. Therefore, we demonstrate that HMGA1P7 
overexpression increases H19 and Igf2 levels inhibiting their mRNA suppression by miRNAs 
that target HMGA1P7 gene, namely, miR-15, miR-16, miR-214, and miR-761. Noteworthy, we 
showed that expression of HMGA1P7 significantly correlates with H19 and IGF2 levels in 
human breast cancer, suggesting the upregulation of HMGA1P7 may increase H19 and IGF2 
expression by a ceRNA mechanism then contributing to cancer progression.  
Furthermore, the oncogenic role of HMGA1Ps is also supported by preliminary data that 
report the development of malignant haematological neoplasias, diagnosed as B-cell lymphomas, 
in HMGA1Ps transgenic mice. In fact, pathological mice showed splenomegaly with the loss of 
the normal structures. Moreover, histological analysis revealed a splenic monotonous population. 
We determined the immunophenotype by flow citometry. The cells expressing CD19 were 
increased in spleens, suggesting an expansion of B-cell population. Accordingly, by 
immunohistochemistry tumour cells stained positive for CD79. These results seem to confirm 
the oncogenic role of HMGA1 pseudogenes also in vivo. In fact, besides the lines of evidence 
obtained by in vitro experiments, formal proof of the causal link existing between pseudogenes 
and the pathogenesis of human cancer has to be confirmed by genetically engineered mouse 
models. 
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 Recently, Karreth et al. reported the consequences of Braf-rs1 overexpression in vivo69. 
The effects of the induction of Braf-rs1 expression were dramatic: the mice were characterized 
by splenomegaly and enlarged lymph nodes, all symptoms that an in-depth flow cytometric 
analysis revealed to be the result of an aggressive form of diffuse large B-cell lymphoma. Braf-
rs1-induced lymphomas were further characterized. Indeed, histological analyses proved that, 
consistent with the ceRNA hypothesis, Braf-rs1-driven tumours are characterized by increased 
Braf and pErk levels69. Indeed, these genetically engineered mouse models represented a proof 
of principle that aberrantly expressed pseudogenes are necessary and sufficient to cause cancer 
by working as ceRNAs for their oncogenic parental genes.  
However, although HMGA1Ps transgenic mice develop B-cell malignancy, further 
investigations are required to unveil the molecular mechanisms underlying the development of 
this disease. Preliminary data showed that HMGA1Ps upregulation does not exert Hmga1 
overexpression in splenic cells. Thus, we investigated other HMGA1Ps ceRNA interactors 
involved in cancer progression. Interestingly, we found the upregulation of Ezh2 in pathological 
spleens consistently with previous our data demonstrating the interaction between HMGA1Ps 
and Ezh2 through a ceRNA mechanism in in vitro experiments. Interestingly, it has been 
previously shown that engineered mouse models for EZH2 develop B-cell lymphoma112,113, 
suggesting that EZH2 upregulation might should drive the HMGA1Ps transgenic mice 
malignancy114,115. However, further analyses are needed to confirm this new ceRNA pathway. 
Then, the data reported here confirm the oncogenic role of the HMGA1 pseudogenes that is 
exerted by the increased expression through a ceRNA mechanism of HMGA1 and other cancer-
related genes. Future studies are, however, needed to characterize other genes regulated by the 
HMGA1 pseudogenes and thereby better define the mechanisms by which they can contribute to 
cancer progression.  
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ABSTRACT
The High Mobility Group A (HMGA) are nuclear proteins that participate in 
the organization of nucleoprotein complexes involved in chromatin structure, 
replication and gene transcription. HMGA overexpression is a feature of human 
cancer and plays a causal role in cell transformation. Since non-coding RNAs and 
pseudogenes are now recognized to be important in physiology and disease, we 
investigated HMGA1 pseudogenes in cancer settings using bioinformatics analysis. 
Here we report the identification and characterization of two HMGA1 non-coding 
pseudogenes, HMGA1P6 and HMGA1P7. We show that their overexpression increases 
the levels of HMGA1 and other cancer-related proteins by inhibiting the suppression 
of their synthesis mediated by microRNAs. Consistently, embryonic fibroblasts from 
HMGA1P7-overexpressing transgenic mice displayed a higher growth rate and reduced 
susceptibility to senescence. Moreover, HMGA1P6 and HMGA1P7 were overexpressed 
in human anaplastic thyroid carcinomas, which are highly aggressive, but not in 
differentiated papillary carcinomas, which are less aggressive. Lastly, the expression 
of the HMGA1 pseudogenes was significantly correlated with HMGA1 protein levels 
thereby implicating HMGA1P overexpression in cancer progression. In conclusion, 
HMGA1P6 and HMGA1P7 are potential proto-oncogenic competitive endogenous RNAs.
INTRODUCTION
The High-Mobility Group A (HMGA) family 
consists of three proteins: HMGA1a, HMGA1b, and 
HMGA2 [1]. HMGA proteins do not have transcriptional 
activity per se; however, by interacting with the 
transcription machinery, they alter the chromatin structure 
and thereby regulate the transcriptional activity of various 
genes [2, 3]. The levels of HMGA proteins are low or 
absent in normal cells and adult tissues [4]. In contrast, 
their constitutive expression is remarkably high in 
neoplastically transformed cells and in embryonic cells 
[5-7]. Their overexpression is associated with a highly 
malignant phenotype and correlates with the presence of 
metastasis and reduced survival [8, 9]. Several studies 
implicate the expression of the HMGA genes in the 
process of carcinogenesis [10-18]. However, although 
HMGA overexpression is known to play a critical role in 
malignant cell transformation, the mechanisms regulating 
HMGA protein levels remain largely obscure.
Non-coding RNAs, including pseudogenes, have 
long been viewed as non-functional genomic relicts of 
evolution, but a large body of evidence now suggests they 
are important in both physiology and disease. Pseudogenes 
are usually defined as defunct copies of genes that have 
lost their potential as DNA templates for functional 
products [19-26] because they harbour premature or 
delayed stop codons, deletions/insertions and frameshift 
mutations that abrogate their translation into functional 
proteins. There are two types of pseudogenes: processed 
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pseudogenes, which have been retrotransposed back into 
a genome via an RNA intermediate; and nonprocessed 
pseudogenes, which are the genomic remnants of 
duplicated genes or residues of dead genes. Processed 
pseudogenes contain no introns, and share 5’ and 3’ 
untranslated region (UTR) sequences with their ancestral 
genes [27]. Since miRNAs repress target gene expression 
by binding to complementary sequences in the 3’ UTR of 
target mRNA, pseudogenes can be targeted by miRNAs 
that modulate the expression of coding genes. Indeed, 
several pseudogene transcripts exert regulatory control 
of their ancestral gene expression levels by competing 
for the same miRNAs [28], which is in keeping with the 
notion that miRNA activity is theoretically affected by 
the availability of target microRNA response elements 
(MRE) in the cellular milieu [28-30]. Given this scenario, 
we studied the possible functional relationship between 
the mRNAs produced by the HMGA1 oncogene and its 
pseudogenes (HMGA1Ps), and the consequences of this 
interaction especially in the process of carcinogenesis in 
which HMGA1 overexpression plays a critical role.
RESULTS
HMGA1P6 and HMGA1P7 are targeted by 
HMGA1-targeting miRNAs
We first identified seven HMGA1Ps by 
bioinformatics analysis. Of these, we focused on the 
HMGA1P6 and HMGA1P7 processed pseudogenes 
located at 13q12.12 and 6q23.2, respectively, because 
of their very high sequence homology with HMGA1 in 
the coding region and in the 5’ and 3’ UTRs (Figure 1A). 
A missense mutation of the initiator methionine codon 
prevents translation of HMGA1P7 whereas HMGA1P6 
is non-protein coding since it carries a mutation in the 
stop codon and so generates a non-translatable mRNA. 
Within the high homology regions, we found perfectly 
conserved seed matches for miRNAs that have been 
predicted (miR-103, miR-142-3p, miR-370, and miR-432) 
or already demonstrated (miR-15 [31], miR-16 [31], 
miR-26a [32], miR-214 [33], miR-548c-3p [34] and miR-
761 [33]) to target the HMGA1 gene (Figure 1B and 1C).
Figure 1: HMGA1P6 and HMGA1P7 show the same seed sequences of HMGA1-targeting miRNAs. (A) HMGA1 (middle), 
HMGA1P6 (top) and HMGA1P7 (bottom) UTRs contain highly conserved regions. HMGA1-targeting miRNA seed matches within the 
high homology region are conserved between HMGA1 and HMGA1Ps. (B) and (C) binding of HMGA1-targeting miRNAs to HMGA1P6 
(B) and HMGA1P7 (C).
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To evaluate the ability of these miRNAs to target 
HMGA1P6 and HMGA1P7, we transfected miR-15, 
miR-16, miR-214 and miR-761 into MCF7 cells (human 
breast adenocarcinoma), and measured HMGA1P6, 
HMGA1P7, and HMGA1 mRNA levels using Real-time 
PCR and PCR primer sets (see Methods) that discriminate 
the three mRNA transcripts. As shown in Figure 2A, 
the transfection of the HMGA1-targeting miRNAs led 
to a significant reduction of HMGA1, HMGA1P6 and 
HMGA1P7 mRNA levels.
To determine whether the HMGA1-targeting 
miRNAs directly interacted with the HMGA1P mRNAs, 
we inserted the full-length HMGA1P6 and HMGA1P7 
mRNAs downstream of the luciferase open reading 
frame. These reporter vectors were transfected into 
human embryonic kidney (HEK293) cells together with 
miRNA precursors and a control non-targeting scrambled 
oligonucleotide. The luciferase activity was much lower 
after miR-15, miR-16, miR-214 and miR-761 transfection 
compared with the scrambled oligonucleotide (Figure 2B). 
These results indicate that the HMGA1Ps and HMGA1 
undergo the same miRNA-mediated post-transcriptional 
regulation.
HMGA1P6 and HMGA1P7 act as decoys for 
HMGA1-targeting miRNAs
Subsequently, we examined the ability of HMGA1P6 
and HMGA1P7 to function as a decoy for HMGA1-
targeting miRNAs using a vector carrying the 3’ UTR of 
the HMGA1 mRNA downstream of the luciferase open 
reading frame. This reporter vector was transfected into 
HEK293 cells together with HMGA1P6- or HMGA1P7-
expressing vectors. As expected, luciferase activity was 
much higher in HMGA1Ps-transfected cells than in the 
control vector (Figure 2C). Moreover, overexpression of 
different amounts of HMGA1P6 or HMGA1P7 drastically 
and dose-dependently reduced the effects exerted by 
miRNA on the levels of both the HMGA1 transcript 
and protein (Figure 3A). Conversely, HMGA1P6 and 
HMGA1P7 knockdown resulted in decreased HMGA1 
mRNA and protein levels (Figure 3B) thereby mirroring 
the results obtained with HMGA1P6 and HMGA1P7 
overexpression (Figure 3A). Therefore, the HMGA1Ps 
compete for the endogenous miRNA-binding sites.
The upregulation of HMGA1 induced by 
overexpression of HMGA1P6 and HMGA1P7 was blunted 
Figure 2: HMGA1P6 and HMGA1P7 are targeted by HMGA1-targeting miRNAs. (A) qRT-PCR analysis of HMGA1P6 (left), 
HMGA1P7 (middle) and HMGA1 (right) mRNA from the MCF7 cells transfected with scrambled-oligonucleotide, miR-15, miR-16, miR-214 
and miR-761.(B) HMGA1Ps were cloned into the pGL3 control vector. Relative luciferase activity in HEK293 cells transiently transfected with 
miR-15, miR-16, miR-214, miR-761 and a control scrambled oligonucleotide. (C) The 3’UTR of HMGA1 was cloned into the pGL3 
control vector. Relative luciferase activity in HEK293 cells transiently transfected with the empty vector, HMGA1P6 and HMGA1P7. 
The results are reported as the mean of values. Error bars represent mean ± SD; n=3. *, P < 0.05 **, P < 0.01 ***, P < 0.001 (t test).
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in DICER-silenced cells (Figure 3C). In fact, silencing of 
DICER, the enzyme that catalyses the last step of miRNA 
maturation, leads to reduced levels of mature miRNAs 
compared to control cells. These results support the notion 
that HMGA1P6 and HMGA1P7 require mature miRNAs 
to regulate HMGA1 levels. Finally, as expected from our 
observation that HMGA1Ps increase HMGA1 levels, we 
found that the HMGA1 3’ UTR upregulates HMGA1P 
levels (Figure 3D).
HMGA1P6 and HMGA1P7 exert 
oncogenic activity
The HMGA1 pseudogenes can be transcribed but 
they cannot code for protein. However, the above-reported 
results suggest that they derepress HMGA1 transcript 
and protein levels (Figure 3A). To evaluate the 
functional consequences of HMGA1P6 and HMGA1P7 
overexpression, we investigated their role in cellular 
proliferation, apoptosis, migration and invasion in cells 
expressing HMGA1.
As shown in Figure 4A and B, HEK293 cells and 
8505c cells (derived from a human anaplastic thyroid 
carcinoma) transfected with HMGA1P6- or HMGA1P7-
expressing vectors grew significantly faster than the empty 
vector-transfected cells. Cell cycle analysis of the cells 
overexpressing HMGA1P6 and HMGA1P7 revealed an 
increased number of cells in the S phase and a reduced 
number of cells in G1 compared with control cells 
(Figure 4C). This was not unexpected given the increased 
Figure 3: HMGA1 is positively regulated by HMGA1Ps. (A) (upper panels) qRT-PCR analysis of HMGA1 mRNA levels in 
HEK293 and 8505c cells transfected with the empty vector, HMGA1P6 and HMGA1P7. (Lower panels) Western blot analysis of HMGA1 
protein levels from the same samples shown in the upper panels. (B) (Upper panel) qRT-PCR analysis of HMGA1 mRNA levels in 8505c 
cells transfected with the scrambled oligonucleotide, siRNA-HMGA1P6 and siRNA-HMGA1P7s. (Lower panel) Western blot analysis 
of HMGA1 protein levels from the same samples shown in the upper panel. (C) HMGA1 mRNA levels 24 h after the transfection of 
HMGA1P6 and HMGA1P7 in scrambled oligonucleotide or siRNA-DICER 8505c transfected cells. (D) HMGA1P6 and HMGA1P7 mRNA 
levels after the transfection of the 3’UTR of the HMGA1 plasmids in MCF7 cells. The results are reported as the mean of values; Error bars 
represent means ± SD; n =3. *, P < 0.05 **, P < 0.01 ***, P < 0.001 (t test).
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HMGA1 levels induced by HMGA1P6 and HMGA1P7 
expression. Moreover, in 8505c cells knocked down for 
the HMGA1Ps, we found that 8505c-siRNA-HMGA1P6 
and 8505c-siRNA-HMGA1P7 cells grew at a significantly 
slower rate than the 8505c-siRNA negative control 
(Figure 4D). Interestingly, cell cycle analysis of the 
8505C-siRNA-HMGA1P6 and 8505C-siRNA-HMGA1P7 
cells revealed an increase in the number of cells in the 
sub-G1 phase, which corresponds to apoptotic cells, 
compared with control cells (data not shown). This result 
is in agreement with the finding that HMGA silencing 
induces apoptosis in cancer cells [12].
To probe further the role of HMGA1 pseudogenes 
in apoptotic cell death, we incubated HEK293 cells with 
doxorubicin in the presence or absence of the HMGA1Ps. 
As shown in Figure 4E, HMGA1P6 and HMGA1P7 
overexpression significantly reduced the programmed 
cell death induced by doxorubicin. The same result was 
obtained with HEK293 cells in which apoptosis was 
induced by serum-starvation. Indeed, the overexpression 
of the HMGA1Ps counteracted caspase 9 cleavage 
(Figure 4F).
Since HMGA1 promotes cell migration and invasion 
[8] we carried out cell migration and invasion assays in 
cells transfected with the HMGA1Ps. As expected, cell 
migration was significantly higher in HEK293 and 8505c 
cells overexpressing HMGA1P6 or HMGA1P7 than in 
control cells (Figure 5A). Moreover, 8505c-siRNA-
HMGA1P6 and 8505c-siRNA-HMGA1P7 cells migrated 
more slowly than the 8505c-siRNA negative control 
(Figure 5B). Accordingly, the invasion matrigel assay 
revealed invasion activity in HEK293 cells transfected 
with HMGA1P6 or HMGA1P6 (Figure 5C). Similar results 
were obtained with the HMGA1Ps-8505c cells (data not 
shown). These results indicate that cell proliferation, 
motility and invasion is driven by regulation HMGA1Ps-
mediated of HMGA1.
Bioinformatic analysis revealed that HMGA1P6 
and HMGA1P7 contain sequences that can be targeted by 
miRNAs that target High Mobility Group A2 (HMGA2), 
Vascular Endothelial Growth Factor (VEGF) and 
Enhancer of Zeste Homolog 2 (EZH2), all of which 
are known to be involved in carcinogenesis [34-36]. 
Accordingly, we found that HMGA1P6 or HMGA1P7 
Figure 4: HMGA1P6 and HMGA1P7 expression increases cell proliferation and reduces apoptosis. (A) and (B) HEK293 
and 8505c cell proliferation in HMGA1P6- and HMGA1P7-transfected cells. (C) HEK293 cells were transfected with the control, HMGA1P6 
or HMGA1P7 vectors. The DNA content of the transfected HEK293 cells was analyzed by flow cytometry after propidium iodine staining. 
(D) 8505c cell proliferation in siRNA-HMGA1P6- and siRNA-HMGA1P7-transfected cells. (E) HMGA1P6- and HMGA1P7-transfected 
cells were treated with doxorubicin, and apoptosis was assessed by FACS. (F) HEK293 cells were starved, and apoptosis was assessed 
by Western blot analysis of Caspase 9 cleavage. The results are reported as the mean of values; Error bars represent means ± SD; n =3. *, 
P < 0.05 **, P < 0.01 ***, P < 0.001 (t test).
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overexpression increased the level of the proteins coded 
for by these genes (Figure 5D). Consequently, it appears 
that HMGA1P6 and HMGA1P7 expression may contribute 
to cancer progression by acting as decoys for cancer-
related genes other than HMGA1.
Correlation of HMGA1 and the overexpression 
of the HMGA1Ps in human cancer
To verify whether the two HMGA1Ps function as 
decoys in the regulation of HMGA1 protein levels also 
in human cancer, we analyzed the expression of HMGA1 
and of the HMGA1Ps in a panel of differentiated and 
undifferentiated thyroid carcinomas by Western Blotting 
and Real-time PCR. As shown in Figure 6, papillary (PTC) 
thyroid carcinomas, which are well differentiated and 
poorly aggressive, expressed low levels of HMGA1P6 and 
HMGA1P7 (Figure 6A). Conversely, anaplastic thyroid 
carcinoma (ATC), which is one of the most aggressive 
human tumours, expressed very high HMGA1P levels 
that, moreover, correlated with HMGA1 protein levels 
(Figure 6B). Accordingly, HMGA1 expression, which 
was undetectable in normal thyroid tissue, was much 
higher in ATC than in PTC. Similar results were obtained 
in human ovarian carcinomas (see Figure 6C and 6D). 
The direct correlation between HMGA1 and HMGA1P6 
expression (r=0.6553, P<0.0001) and between HMGA1 
and HMGA1P7 expression (r=0.7001, P<0.0001) suggests 
that these genes are co-regulated (Figure 6C and 6D). 
Taken together, these results indicate that HMGA1P6, 
HMGA1P7 and HMGA1 expression is correlated with 
cancer aggressiveness.
HMGA1P7 overexpressing mouse embryonic 
fibroblasts grow faster and senesce later
To establish the role of the HMGA1Ps in vivo, we 
generated transgenic mice overexpressing HMGA1P7. The 
expression of HMGA1P7 in transgenic mice was verified 
by RT-PCR using RNAs extracted from liver, spleen, lung 
Figure 5: The expression of the HMGA1Ps affects cell migration and invasion. (A) Cell migration assays of HEK293 and 
8505c cells transfected with HMGA1P6 or HMGA1P7 or with a control vector. One representative experiment is reported. (B) Cell migration 
assays of 8505c cells transfected with siRNA-HMGA1P6 or siRNA-HMGA1P7 or with a empty vector. One representative experiment is 
reported. (C) Cell invasion assays of HEK293 cells transfected with HMGA1Ps or with the backbone vector. One representative experiment 
is reported. (D) Extracts from HEK293 transfected with HMGA1P6 or HMGA1P7 or with a control vector were analyzed by Western 
blotting.
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and mouse embryonic fibroblasts (MEFs). HMGA1P7 
mRNA levels were high in the tissues of HMGA1P7 
transgenic mice and absent in the WT counterpart 
(Figure 7A). Consistently, HMGA1 transcript and protein 
levels were significantly higher in HMGA1P7-MEFs than 
in the WT control (Figure 7B). Notably, HMGA1P7-MEFs 
also expressed increased levels of the Hmga2, Ezh2 and 
Vegf proteins, which are coded for by genes that share 
miRNAs with HMGA1 (Figure 7C), and increased levels 
of the HMGA1-regulated genes Ccna, Ccnb, Ccnd2 and 
E2f-1 (Figure 7D), which play a critical role in cell cycle 
regulation [8].
As expected from the high HMGA1 expression in 
the HMGA1P7-MEFs, the growth rate of these MEFs 
was significantly higher than that of the WT controls 
(Figure 7E). To determine whether the higher growth rate 
of HMGA1P7-MEFs was caused by altered progression 
through the cell cycle, we examined asynchronously 
growing MEFs by flow cytometry. The number of 
HMGA1P7-MEFs was lower in G1 and higher in the 
S phase of the cell cycle compared with WT MEFs 
(Figure 7F).
We, next, examined the susceptibility of MEFs to 
senescence by measuring senescence-associated β-gal 
(SA-β-gal) activity. At culture passage 6, SA-β-gal 
activity was present in WT MEFs, but not in the 
HMGA1P7 transgenic counterparts (Figure 7G). These 
findings indicate that HMGA1P7 overexpression reduced 
susceptibility to cellular senescence.
Identification of the genes modulated by 
HMGA1P7 expression
To identify the genes regulated by HMGA1P7 
expression, we analyzed the expression profile of WT and 
HMGA1P7 transgenic MEFs in microarray analyses. To 
this aim, RNAs extracted from WT and HMGA1P7-MEFs 
were hybridized to the Affymetrix GeneChip Mouse 
Gene 2.0 ST oligonucleotide arrays. Seventy transcripts 
that had a significant fold change variation (p <0.05) were 
examined as candidate genes involved in HMGA1P7 
tumour-promoting activity. Interestingly, we found 
five upregulated cancer-related genes (Epha3, Hjurp, 
Kif26, S1pr3 and Pde3B) that shared miRNAs with the 
HMGA1P7 transcript. These genes are involved in various 
human cancers (glioblastoma, breast and hematological 
cancers), and are candidate therapeutic targets [37-41]. 
Real-time PCR experiments confirmed upregulation of 
all these genes in HMGA1P7-MEFs (Supplementary 
Figure 1). These results support the concept that 
HMGA1P7 modulates the expression of several cancer-
related genes by acting as a ceRNA.
DISCUSSION
The HMGA proteins play a critical role in 
carcinogenesis. Recently, several miRNAs have been 
demonstrated to target these genes [31-34], and their 
dysregulation may contribute to HMGA1 protein 
Figure 6: HMGA1 protein expression positively correlates with the expression of the HMGA1Ps in ATC. (A) HMGA1P6 
and HMGA1P7 qRT-PCR analysis in normal thyroid tissue (NT), papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma 
(ATC). The results are reported as the mean of expression values. The error bars represent mean ± SD; n = 3. (B) Western blot analysis 
of HMGA1 protein expression in the same samples as in A. (C) and (D) Ovarian sample expression values derived from commercial 
sources were combined for correlation analysis. Linear regressions of HMGA1 versus HMGA1P6 (C) and HMGA1 versus HMGA1P7 (D) 
are shown.
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overexpression in human neoplasias [31, 32, 34]. 
Moreover, an important role in the regulation of protein 
synthesis has recently been ascribed to pseudogenes 
[27, 28]: the presence of the same miRNA-targeted 
seed sequences in the HMGA1 and in the HMGA1Ps 
UTR regions could block the access of miRNAs to their 
protein-coding target genes. Finally, it has been outlined 
a novel gene-expression pathway in which an HMGA  
Figure 7: HMGA1P7 overexpressing MEFs show a higher growth rate, and lower susceptibility to senescence. 
(A) qRT-PCR analysis of total RNA from livers, spleens, lungs, and MEFs of WT and HMGA1P7 transgenic mice. (B) (upper panel) qRT-
PCR analysis of HMGA1 mRNA levels in WT and HMGA1P7 transgenic MEFs. (Lower panel) Western blot analysis of HMGA1 protein 
expression in the same samples. (C) and (D) qRT-PCR and Western blot analysis of genes that share common miRNAs with HMGA1 (Left 
panel) and HMGA1-regulated genes (Right panel). (E) MEFs were prepared from WT and HMGA1P7 overexpressing embryos at 12.5 dpc. 
At culture passage 3, they were plated and counted daily for 8 days. (F) Propidium iodide flow cytometry of asynchronous growing WT 
and HMGA1P7 overexpressing MEFs. (G) Light microscopy of representative WT and HMGA1P7 overexpressing MEFs stained for 
β-galactosidase activity at culture passages 6. The results are reported as the mean of values with error bars indicating SD (mean ± SD); 
n =3. *, P < 0.05 **, P < 0.01 ***, P < 0.001 (t test).
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protein-coding gene, Hmga2, operates largely 
independently of its protein-coding function to promote 
cancer progression as a competing endogenous RNA [42].
We asked whether HMGA1 pseudogenes affect 
HMGA1 protein levels, and, consequently, whether they 
play a critical role in cancer progression. We focused 
on HMGA1P6 and HMGA1P7, which have conserved 
seed matches for miRNAs targeting the HMGA1 gene 
in the high homology regions. We demonstrate that 
overexpression of these HMGA1 pseudogenes increases 
HMGA1 protein levels, and inhibits the suppression 
of HMGA1 protein synthesis by miRNAs that target 
the HMGA1 gene, namely, miR-15, miR-16, miR-214, 
and miR-761 [31-34]. Consistent with these results, 
our functional studies demonstrate that HMGA1P6 and 
HMGA1P7 overexpression increases the cell growth 
rate by decreasing the number of G1-phase cells and 
increasing the number of S-phase cells, compared 
with the backbone vector-transfected cells. Therefore, 
HMGA1P6 and HMGA1P7 affect cell cycle progression, 
as expected, given their ability to increase the protein 
levels of HMGA1, which is involved in the regulation of 
the G1-S transition phase of the cell cycle [34]. Moreover, 
HMGA1P6 and HMGA1P7 overexpression increased 
cell migration and invasiveness, and decreased the 
apoptotic rate.
These results prompted us to verify whether 
HMGA1P6 and HMGA1P7 overexpression is involved 
also in human carcinogenesis. Interestingly, HMGA1P6 
and HMGA1P7 were abundantly expressed in ATC, which 
are very aggressive and express very high HMGA1 protein 
levels [43]. Conversely, HMGA1P6 and HMGA1P7 
expression was low in PTC, which are well differentiated 
and poorly aggressive, and express moderate HMGA1 
protein levels. We obtained similar results in human 
ovarian carcinomas suggesting that HMGA1Ps can 
regulate HMGA1 protein levels also in vivo.
Interestingly, HMGA1P6 and HMGA1P7 seem 
to affect cancer progression also by binding to the same 
miRNAs that target proteins involved in cancer progression. 
Indeed, the overexpression of the HMGA1Ps increased also 
the levels of HMGA2, VEGF and EZH2 that are coded 
for by genes targeted by HMGA1-targeting miRNAs. 
Notably EZH2, which is involved in carcinogenesis, is 
overexpressed in ATC but not in PTC [44].
Data obtained with transgenic mice overexpressing 
HMGA1P7 and with the relative MEFs support the concept 
that HMGA1P7 plays an oncogenic role. Indeed, MEFs 
derived from transgenic mice overexpressing HMGA1P7 
show a higher growth rate, and lower susceptibility to 
senescence with respect to the WT counterpart. Moreover, 
flow cytometry showed an increase of cells in S phase as 
expected given the ability of HMGA1 to increase the E2F1 
activity [45].
In contrast to a report that ectopic overexpression 
of HMGA1 reduces the lifespan of IMR90 cells [46], 
HMGA1P7-MEFs that have more abundant HMGA1 
protein levels, senesce later with respect to WT MEFs. 
In agreement with our findings, we obtained the 
opposite result in Hmga1-null MEFs [47]. It is likely 
that the cellular context influences the effect exerted 
by HMGA proteins on cell growth. Moreover, the 
different experimental approach, one in vivo and one 
in vitro, may account for these contradictory results. In 
fact, discrepancies between in vitro and transfection 
approaches were reported in a study of the p53 pathway 
[48]. The behaviour of the Hmga1-null and HMGA1P7-
MEFs described here supports the oncogenic role of 
HMGA overexpression, which is a feature of malignant 
neoplasias. In conclusion, our finding that HMGA1P7-
overexpressing MEFs grow faster and senesce later 
than their WT counterpart sustains our model in which 
HMGA1Ps act as ceRNAs that regulate HMGA1 and other 
genes by competing for shared miRNAs thus contributing 
to cancer progression.
MATERIALS AND METHODS
Cell culture and transfections
HEK293, MCF7, 8505c, and MEF (from 
12.5-day-old embryos) cells were maintained in DMEM 
supplemented with 10% foetal calf serum (GIBCO; 
Invitrogen), glutamine and antibiotics. Cells were regularly 
tested with MycoAlert (Lonza) to ascertain that cells were 
not infected with mycoplasma. Cells were transfected 
using Lipofectamine plus reagent (Invitrogen) according 
to the manufacturer’s instructions. The transfected cells 
were selected in a medium containing geneticin (Sigma). 
For each transfection, several geneticin-resistant mass 
cell populations were isolated and expanded for further 
analysis. Transfection efficiency was verified for each 
experiment by evaluating GFP expression. To inhibit 
HMGA1P6 and HMGA1P7 expression, small interfering 
RNAs and corresponding scramble small interfering 
RNAs were designed and used as suggested by the 
manufacturer (RIBOXX).
Human thyroid and ovary tissue samples
Neoplastic and normal human thyroid tissues were 
obtained from surgical specimens and immediately frozen 
in liquid nitrogen. Thyroid tumours were collected at 
the Service d’Anatomo-Pathologie, Centre Hospitalier 
Lyon Sud, Pierre Bénite, France. The tumour samples 
were frozen until required for RNA or protein extraction. 
We declare that informed consent for the scientific use 
of biological material was obtained from all patients. 
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TissueScan Ovarian Cancer Tissue Real-time PCR Panel 
were purchased from Origene (HORT302).
RNA extraction and quantitative reverse 
transcription PCR
Total RNA was extracted from tissues and 
cell cultures with Trizol (Gibco) according to the 
manufacturer’s instructions. For mRNA detection, we 
reverse transcribed total RNA from cell lines by using the 
QuantiTect Reverse Transcription Kit (Qiagen), and then 
Real-time PCR was performed by using Power SYBR 
Green PCR Master Mix (Applied Biosystems) and the 
following primers:
HMGA1-Fw 5’-aaggggcagacccaaaaa-3’ 
HMGA1-Rev 5’-tccagtcccagaaggaagc-3’
HMGA1P6-Fw 5’-gcagacccacaaaactgga-3’ 
HMGA1P6-Rev 5’-gagcaaagctgtcccatcc-3’
HMGA1P7-Fw 5’-gctccttctcggctcctc-3’ 
HMGA1P7-Rev 5’-gcttgggcctcttttatgg-3’
G6PD-Fw 5’-acagagtgagcccttcttcaa-3’ 
G6PD-Rev 5’-ataggagttgcgggcaaag-3’
Hmga1-Fw 5’-ggcagacccaagaaactgg-3’ 
Hmga1-Rev 5’-ggcactgcgagtggtgat-3’
Ccna-Fw 5’-cttggctgcaccaacagtaa-3’ 
Ccna-Rev 5’-caaactcagttctcccaaaaaca-3’
Ccnb-Fw 5’-gcgctgaaaattcttgacaac-3’ 
Ccnb-Rev 5’-ttcttagccaggtgctgcat-3’
G6pd-Fw 5’-cagcggcaactaaactcaga-3’ 
G6pd-Rev 5’-ttccctcaggatcccacac-3’
Epha3-Fw 5’-tggctccttggacagtttct-3’ 
Epha3-Rev 5’-ttcccacaagctccatgact-3’
Hjurp-Fw 5’-gagaactggccatcttgcag-3’ 
Hjurp-Rev 5’-aaggtgtttccgggcact-3’
Kif26b-Fw 5’-aagaggcaggctctcaagc-3’ 
Kif26b-Rev 5’-gcagagaaagcaagggtcctt-3’
S1pr3-Fw 5’-agatgcgccttgcagaac-3’ 
S1pr3-Rev 5’-agagtggtggtgggttcct-3’
Pde3B-Fw 5’-ccttgtatttcccgagaacagat-3’ 
Pde3B-Rev 5’-ggtaatgaggtttacaccactgc-3’
Hmga2-Fw 5’-aaggcagcaaaaacaagagc-3’ 
Hmga2-Rev 5’-ttgtggccatttcctaggtc-3’
Ezh2-Fw 5’-tggaagcagcggaggata-3’ 
Ezh2-Rev 5’-gtcactggtgactgaacactcc-3’
Vegf-Fw 5’-aaaaacgaaagcgcaagaaa-3’ 
Vegf-Rev 5’-tttctccgctctgaacaagg-3’
The 2−ΔΔCt formula was used to calculate the 
differential gene expression.
Plasmids
For transfection of miRNA oligonucleotides, cells 
were transfected with 50 nmol/ml of miRNA precursors 
or with a control no-targeting scrambled oligonucleotides 
(Ambion, Austin, TX) using siPORT neoFX Transfection 
Agent (Ambion). For the HMGA1P6 expression construct 
(pCAG-HMGA1P6) and the HMGA1P6 luciferase 
reporter construct (pGL3-HMGA1P6), the entire 
sequence of HMGA1P6 gene (ENST00000418454.1) 
was amplified by using the primers Fw HMGA1P6 
5’-tcctctaattgggactccga-3’ and Rev HMGA1P6 
5’-ttactcagatcccaggcaga-3’. The amplified fragment was 
cloned into pCAG vector kindly given by Dr. S. Soddu, 
and into pGL3-Control firefly luciferase reporter vector 
(Promega), respectively. For the HMGA1P7 construct 
(pCAG-HMGA1P7) and the HMGA1P7 luciferase 
reporter construct (pGL3-HMGA1P6), the entire 
sequence of the HMGA1P7 gene (ENST00000406908.1) 
was amplified by using the primers Fw HMGA1P7 
5’-agccagtcgagctggaggtc-3’ and Rev HMGA1P7 
5’-ctgcaatgtgtactcagagc-3’. The amplified fragment was 
cloned as described for the HMGA1P6 constructs. All 
the generated vectors were confirmed by sequencing. 
The Renilla luciferase vector (pRL-CMV), for transient 
transfection efficiency, was purchased from Promega. The 
3′ UTR region of the HMGA1 gene has been previously 
described [34].
Protein extraction, western blotting 
and antibodies
Protein extraction and Western blotting were 
performed as previously described [49]. The primary 
antibodies used were anti-EZH2 (AC22) and anti-Cyclin 
D2 (2924) from Cell Signaling; anti-Actin (sc-1615), anti-
Vinculin (sc-7649), anti-γ-Tubulin (sc-17787), and anti-
E2f1 (sc-193) from Santa Cruz Biotechnology; anti-VEGF 
(ab46154) from Abcam. Antibodies versus the HMGA1 
and HMGA2 proteins are described elsewhere [50, 51]. 
Blots were visualized by using the Western blotting 
detection reagents (GE Healthcare).
Cell migration and invasion assay
Cell migration and invasion experiments were 
performed as previously described [44].
Dual-luciferase reporter assay
For dual-luciferase reporter assay, 3 × 105 HEK293 
cells were co-transfected in 6-well plates with the pGL3-
HMGA1P6 or the pGL3-HMGA1P7 luciferase reporter 
vectors, together with the Renilla luciferase plasmid and 
miRNA precursors or a control no-targeting scrambled 
oligonucleotides (Ambion), using siPORT neoFX 
Transfection Agent (Ambion). The pRL-TK control 
vector expressing Renilla luciferase (Promega) was 
used for normalization of cell number and transfection 
efficiency. Luciferase activity was measured 48 hours 
after transfection using the Dual-Luciferase Reporter 
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Assay System (Promega) with a Lumat LB 9507 apparatus 
(Berthold Technologies).
Flow cytometric analysis
HEK293 cells were transfected with HMGA1P6, 
HMGA1P7 and the empty vector, and analysed by flow 
cytometry after 48 hours of growth under normal culture 
conditions. Primary MEFs were obtained from 12.5-day-
old embryos. The MEFs were minced and used to 
establish single cell suspensions and then analysed by flow 
cytometry after 48 hours of growth under normal culture 
conditions. Briefly, cells were harvested in PBS containing 
2 mmol/l EDTA, washed once with PBS, and fixed for 
2 hours in cold ethanol (70%). Fixed cells were washed 
once in PBS and treated with 40 μg/ml RNase A in PBS 
for 30 minutes. They were then washed once in PBS and 
stained with 50 μg/ml propidium iodide (Roche). Stained 
cells were analysed with a fluorescence activated cell sorter 
(FACS) Calibur (Becton-Dickinson), and the data were 
analysed using a mod-fit cell cycle analysis programme.
Generation and genotyping of mutant mice
The 3.5 kb HMGA1P7 of the pCAG-HMGA1P7 
expression plasmid was excised with SalI & HindIII 
restriction endonucleases by cleaving 10 μg of the 
plasmid. The fragment was purified from SeaKem 
GTG agarose (avoiding exposure to UV light) using the 
Qbiogene Geneclean Spin kit, then dialysed 24 h against 
2 l microinjection buffer (10 mM Tris.HCl pH 7.2, 0.1 
mM EDTA), and diluted to a concentration of 4 ng/μl. 
The DNA was injected in three sessions into C57BL/6N-
derived zygotes. For this purpose, C57BL/6N female mice 
(bred at PolyGene from parents obtained from Charles 
River) were superovulated at 28-34 days of age and mated 
in the PolyGene mouse facility to C57BL/6N breeder 
males, originally also obtained from Charles River. 
Injected zygotes were cultivated overnight and transferred 
into pseudopregnant B6CBAF1 females, also from Charles 
River. The animals were kept in individually ventilated 
cages. Injections were performed at the PolyGene labs in 
Rümlang, Switzerland. Pups were biopsied at weaning 
and analysed for transgene integration by PCR, using the 
PCR primer combination: Fw 5’-ggcatgtcccactctatt-3’; 
Rev 5’-caattcctgcaatgtgtactc-3’. All mice were maintained 
under standardized nonbarrier conditions in the 
Laboratory Animal Facility of the Istituto dei Tumori di 
Napoli (Naples, Italy), and all studies were conducted in 
accordance with Italian regulations for experimentations 
on animals.
SA-β-gal assay
4 × 104 MEFs, plated 24 hours before the assay, were 
washed twice with PBS and immersed in fixation buffer 
(2% [w/v] formaldehyde, 0.2% [w/v] glutaraldehyde in 
PBS) for 7 minutes. After 3 additional PBS washes, the 
cells were allowed to stain overnight in staining solution 
(40 mM citric acid/sodium phosphate, pH 6.0; 150 mM 
NaCl; 2.0 mM MgCl2; 1 mg/ml X-gal) at 37°C without 
CO2 to avoid changes in pH. The next day, the staining 
solution was replaced with PBS, and the stained and 
unstained cells were counted by light microscopy (at least 
24 fields).
Microarray analyses
RNAs extracted from HMGA1P7 transgenic and 
WT MEFs (two biological replicates for each sample) 
were hybridized to the Affymetrix GeneChip Mouse 
Gene 2.0 ST oligonucleotide arrays. Hybridization, 
washing, staining, scanning, and data analysis were 
performed by the Affymetrix Microarray Unit at the 
IFOM-IEO campus, Milan, Italy, according to the 
manufacturer’s instructions. Data were analyzed using 
Partek Genomics Suite version 6.6. Transcripts showing 
a significant fold change variation (p<0.05) were 
examined.
Statistical analysis
Data were analyzed using a two-sided unpaired 
Student’s t test (GraphPad Prism, GraphPad Software, 
Inc.). Values of P<0.05 were considered statistically 
significant. The mean +/− s.d. of three or more independent 
experiments is reported. Regression analyses and 
correlation coefficients were generated using GraphPad 
Prism, GraphPad Software, Inc.
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HMGA1-pseudogene overexpression contributes to cancer progression
Francesco Esposito1, Marco De Martino1, Floriana Forzati1, and Alfredo Fusco1,2,*
1Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Scuola di Medicina e Chirurgia di
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Two pseudogenes for HMGA1, whoseoverexpression has a critical role in
cancer progression, have been identified.
They act as decoy for miRNAs that are
able to target the HMGA1 gene then
enhancing cell proliferation and migra-
tion. Moreover, these pseudogenes con-
tain sequences that are potential target
sites for cancer-related miRNAs. Interest-
ingly, HMGA1 pseudogenes are highly
expressed in human anaplastic thyroid
carcinomas, that is one of the most
aggressive tumor in mankind, but almost
undetectable in well differentiated thy-
roid carcinomas.
The human genome has been
sequenced, and no more than 2% codes
for proteins building our bodies.1 There-
fore, a key question is to identify which is
the meaning of the other 98% of the
genome. Many evidences show that the
mammalian genome is able to generate
numerous previously undiscovered tran-
scripts called “non coding RNA”
(ncRNA).1 However, the role of these
ncRNAs remains largely unknown. The
ncRNAs include different classes: the
“short interfering RNAs” (siRNAs),
the “Natural Antisense Transcripts”
(NATs), the “microRNAs” (miRNAs),
long non coding RNAs (lncRNAs), and
pseudogenes.2
siRNAs are double-stranded small
interfering RNAs of »21 base pairs in
length that serve as effector molecules of
sequence-specific gene silencing. They are
highly conserved across species.3
NATs are RNAs that are at least in part
complementary to other endogenous
RNAs. They might be transcribed in cis
from opposing DNA strands at the same
genomic locus (cis-NATs) or in trans at
separate loci (trans-NATs).4 NATs
biological role is based on gene knock-
down induced by base-pairing of sense
and anti-sense strands. To date, in human
have been identified cis-encoded exon-
overlapping sense-antisense (SA) in a
number of 7356 NATs.4
Among trans-NATs the most studied
are miRNAs. They are small RNAs (18-
21 nt) that can inhibit mRNA expression
by binding to 30 Untranslated Region
(30UTR) with perfect or imperfect match,
suppressing mRNA translation or affect-
ing RNA stability.5 Krek et al. reported
that vertebrate microRNAs target, usually,
almost 200 transcripts each one.6,7
Long non coding RNAs (lncRNAs) are
non-protein coding transcripts longer
than 200 nucleotides.8 This rather arbi-
trary limit distinguishes lncRNAs from
small regulatory RNAs such as miRNAs,
siRNAs, Piwi-interacting RNAs (piR-
NAs), small nucleolar RNAs (snoRNAs),
and other short RNAs.8
Pseudogenes are dysfunctional relatives
of genes that have lost their protein-cod-
ing skill or are otherwise no longer
expressed in the cell.9-11 They are charac-
terized by a mixture of homology to a
known gene and nonfunctionality: every
pseudogene has a DNA sequence that is
similar to some functional genes, but they
are unable to produce functional final pro-
tein products.9-11
There are 3 major families of pseudo-
genes: processed (or retrotransposed),
non-processed (or duplicated), and dis-
abled pseudogenes. Processed pseudogenes
originate from a segment of mRNA tran-
script of a gene that is spontaneously
reverse transcribed back into DNA and
inserted into chromosomal DNA. Once
these pseudogenes are inserted back into
the genome, they generally include a
poly-A tail, and their introns are
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frequently spliced out.12 Non-processed
pseudogenes arise as a consequence of a
gene duplication event and then acquire
mutations making them nonfunctional.
Duplicated pseudogenes usually include
all the same characteristics of genes from
they originate, as well as an intact exon-
intron structure and promoter sequen-
ces.12 Disabled genes (or unitary pseudo-
genes) present different mutations that
stop a gene from being productively tran-
scribed or translated.13
Recently, Esposito et al. have identified
2 processed pseudogenes, HMGA1P6 and
HMGA1P7, belonging to the HMGA1
gene family. They are placed at 13q12.12
and 6q23.2, respectively, and have been
reported to have a critical role in the
process of carcinogenesis.14 The High
Mobility Group A1 (HMGA1) gene codes
for the HMGA1 proteins,
HMGA1a andHMGA1b.15
These proteins are non-his-
tone chromatinic proteins
that bind to DNA and orga-
nize chromatin architecture,
interacting with several tran-
scription factors, and then
regulate the expression of
several genes, positively or
negatively.15 Their role in
carcinogenesis is widely
accepted. Indeed, these pro-
teins are expressed at high
levels for the duration of
embryogenesis and in malig-
nancies where their expres-
sion levels point out a poor
prognosis of the cancer
patients, whereas their
expression is brought down
in adult normal tissues.16-18
Moreover, the knock-down
of HMGA1 expression pre-
vents thyroid cells transfor-
mation and leads cancer cells
of diverse tissue origin to
apoptosis.19-21 On the con-
trary, their overexpression
in vitro induces mouse and
rat fibroblast transforma-
tion,22 and transgenic
mice overexpressing hmga1
develop several neoplasias
including pituitary adeno-
mas, Natural Killer (NK)/
T-cell lymphomas,24 lipo-
mas, cervix and body
adenocarcinomas.15
HMGA1 pseudogenes,
HMGA1P6 and HMGA
1P7, show just few mis-
matches all over the coding
sequence and the 5’ and 3’
UTRs of HMGA1. They
have conserved seed
matches for miRNAs that have been previ-
ously confirmed to target the HMGA1
gene. Subsequently, the authors show that
these pseudogenes equally operate as
decoys for HMGA1-targeting miRNAs
(Fig. 1). Indeed, HMGA1P6 and
HMGA1P7 overexpression increases
HMGA1 protein levels whereas their
silencing results in decreased HMGA1
mRNA and protein levels.14 Consistently
Figure 1. Decoy function of HMGA1Ps. Several RNA transcripts have seed sequences for the same miRNAs (A). As pro-
posed by Esposito et al., overexpression of HMGA1Ps mRNAs increases cellular concentrations of particular seed
sequences (B), resulting in the derepression of HMGA1 transcripts that contain the same seed sequences (C).
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with the HMGA1P6 and HMGA1P7
decoy function, cells overexpressing them
show an enhanced migration, invasiveness,
and a faster proliferation ability.14 Oppo-
site results are obtained when these pseu-
dogenes are silenced with also an increase
in apoptotic cells following a reduced
HMGA1 protein levels, as already
observed when HMGA1 is knocked down
in thyroid cells.21
The generation of transgenic mice over-
expressing HMGA1P6 or HMGA1P7 has
confirmed their oncogenic activity. Indeed,
mouse embryonic fibroblasts (MEFs)
deriving from HMGA1P6
or HMGA1P714 overex-
pressing mice grow faster
and senesce later than their
wild-type counterparts.
However, we retain that
the key point of this study
is the finding of a role of
these pseudogenes in
human carcinogenesis. In
fact, anaplastic thyroid car-
cinoma (ATC), that repre-
sents one of the most
aggressive tumors in the
mankind, evidenced a
exceptionally high expres-
sion of the HMGA1
pseudogenes essentially
correlating with the
HMGA1 protein levels.14
Conversely, their expres-
sion is almost undetectable
in papillary and follicular
thyroid carcinomas, that
are well differentiated and
much less aggressive. Anal-
ogous results were obtained
when HMGA1Ps expres-
sion was analyzed in
human ovarian14 and lar-
ynx carcinomas, and pitui-
tary adenomas (manuscript
in preparation).
Remarkably, the pres-
ence in the HMGA1P6,
HMGA1P7, and also
HMGA1 UTR regions of
sequences that are potential
target sites for cancer-
related miRNAs targeting
genes such as High Mobility
Group A2 (HMGA2),
Enhancer of Zeste Homolog 2 (EZH2), Vas-
cular Endothelial Growth Factor (VEGF),
and Ephrin Type-A Receptor 3 (Epha3),
that are effectively upregulated in
HMGA1P6 and HMGA1P714 overex-
pressing cells and MEFs with respect to
the control cells. This has important con-
sequences. In fact, it means that high
HMGA1 gene or its pseudogene expres-
sion allows an increase in HMGA2 and
EZH2 protein levels then contributing to
cancer progression.14 Such a mechanism is
likely to occur in ATC where the overex-
pression of EZH2 has been detected in
ATC but not in the undifferentiated thy-
roid carcinomas.25,26
Interestingly, Kumar et al. have
recently demonstrated that the HMGA2
30 UTR contains 7 conserved seed sequen-
ces for let-7, which has been previously
demonstrated to constrain lung cancer
development. They identified 6 ceRNA
targets that are regulated by hmga2 in a
let7-dependent manner: Transforming
growth factor b receptor III (tgfbr3),
Angiopoietin-related protein 2 (Angptl2),
Fibronectin Type III Domain Containing
Protein 3 (Fndc3), Ski-like protein (Skil)
Figure 2. A ceRNA model for the HMGA gene family. HMGA RNA transcripts have seed sequences for the same miR-
NAs shared with other transcripts (A). As proposed by Esposito and Kumar, in malignancies, the HMGA gene family
overexpression increases cellular concentrations of particular seed sequences, resulting in the derepression of several
cancer-related gene transcripts that contain the same seed sequences (B).
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and Hmga1.27 Then, on the basis of these
results also HMGA1, through its 3’UTR,
may function as decoy for HMGA2 and
other cancer-related gene expression.
Therefore, a synergism between members
of HMGA protein family might be envis-
aged based not only on common functions
but also on the ability of the HMGA
mRNAs to act as decoy for miRNAs able
to target themselves.
In conclusion, the results published by
Esposito et al. indicate that also the
expression of the HMGA1 pseudogenes
contribute to carcinogenesis and, together
with the paper by Kumar et al., reveal
another mechanism by which HMGA
gene family has a critical role in cancer
progression based on the ability to regu-
late gene expression also as non-coding
RNAs (Fig. 2). Therefore, these new
reports make even more important the
HMGA gene family in cancer diagnosis
and prognosis, and as potential target for
an innovative cancer therapy.
References
1. Furuno M, Pang KC, Ninomiya N, Fukuda S, Frith
MC, Bult C, Kai C, Kawai J, Carninci P, Hayashizaki
Y, et al. Clusters of Internally Primed Transcripts
Reveal Novel Long Noncoding RNAs. PLoS Genet
2006; 2:e37; PMID:16683026; http://dx.doi.org/
10.1371/journal.pgen.0020037
2. Ponting CP, Oliver PL, Reik W. Evolution and
functions of long noncoding RNAs. Cell 2009;
136:629-41; PMID:19239885; http://dx.doi.org/
10.1016/j.cell.2009.02.006
3. Hammond SM, Boettcher S, Caudy AA, Kobayashi R,
Hannon GJ. Argonaute2, a link between genetic and
biochemical analyses of RNAi. Science 2001; 293:
1146-50; PMID:11498593; http://dx.doi.org/10.1126/
science.1064023
4. Zhang Y, Li J, Kong L, Gao G, Liu QR, Wei L.
NATsDB: Natural Antisense Transcripts DataBase.
Nucl Acids Res 2007; 35:D156-61; PMID:17082204;
http://dx.doi.org/10.1093/nar/gkl782
5. Zeng Y, Yi R, Cullen BR. MicroRNAs and small inter-
fering RNAs can inhibit mRNA expression by similar
mechanisms. Proc Natl Acad Sci U S A 2003;
100:9779-84; PMID:12902540; http://dx.doi.org/
10.1073/pnas.1630797100
6. John B, Enright AJ, Aravin A, Tuschl T, Sander C,
Marks DS. Human MicroRNA targets. PLoS Biol
2004; 2:e363; PMID:15502875; http://dx.doi.org/
10.1371/journal.pbio.0020363
7. Krek A, Gr€un D, Poy MN, Wolf R, Rosenberg L,
Epstein EJ, MacMenamin P, da Piedade I, Gunsalus
KC, Stoffel M, et al. Combinatorial microRNA target
predictions. Nat Genet 2005; 37:495-500;
PMID:15806104; http://dx.doi.org/10.1038/ng1536
8. Kornienko AE, Guenzl PM, Barlow DP, Pauler FM.
Gene regulation by the act of long non-coding RNA
transcription. BMC Biol 2013; 11:59;
PMID:23721193; http://dx.doi.org/10.1186/1741-
7007-11-59
9. Mighell AJ, Smith NR, Robinson PA, Markham AF. Ver-
tebrate pseudogenes. FEBS Lett 2000; 468:109-14;
PMID:10692568; http://dx.doi.org/10.1016/S0014-5793
(00)01199-6
10. Harrison PM, Hegyi H, Balasubramanian S, Luscombe
NM, Bertone P, Echols N, Johnson T, Gerstein M.
Molecular fossils in the human genome: Identification
and analysis of the pseudogenes in chromosomes 21 and
22. Genome Res 2002; 12:272-80; PMID:11827946;
http://dx.doi.org/10.1101/gr.207102
11. Balakirev ES, Ayala FJ. Pseudogenes: Are they “junk” or
functional DNA? Annu Rev Genet 2003; 37:123-51;
PMID:14616058; http://dx.doi.org/10.1146/annurev.
genet.37.040103.103949
12. Poliseno L, Salmena L, Zhang J, Carver B, Haveman
WJ, Pandolfi PP. A coding-independent function of
gene and pseudogene mRNAs regulates tumour biol-
ogy. Nature 2010; 465:1033-38; PMID:20577206;
http://dx.doi.org/10.1038/nature09144
13. Zhang ZD, Frankish A, Hunt T, Harrow J, Gerstein
M. Identification and analysis of unitary pseudogenes:
historic and contemporary gene losses in humans and
other primates. Genome Biol 2010; 11:R26;
PMID:20210993; http://dx.doi.org/10.1186/gb-2010-
11-3-r26
14. Esposito F, De Martino M, Petti MG, Forzati F, Tor-
nincasa M, Federico A, Arra C, Pierantoni GM, Fusco
A. HMGA1 pseudogenes as candidate proto-oncogenic
competitive endogenous RNAs. Oncotarget 2014;
5:8344-54; PMID:25268743.
15. Fusco A, Fedele M. Roles of the HMGA proteins in
cancer. Nat Rev Cancer 2007; 7:899-910;
PMID:18004397; http://dx.doi.org/10.1038/
nrc2271
16. Chiappetta G, Avantaggiato V, Visconti R, Fedele
M, Battista S, Trapasso F, Merciai BM, Fidanza V,
Giancotti V, Santoro M, et al. High level expres-
sion of the HMGA1 gene during embryonic devel-
opment. Oncogene 1996; 13:2439-46; PMID:
8957086
17. Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F,
Zimmermann A, Diamantis I, Terracciano L, Fusco A,
Karamitopoulou E. HMGA1 and HMGA2 protein
expression correlates with advanced tumour grade and
lymph node metastasis in pancreatic adenocarcinoma.
Histopathology 2012; 60:397-404; PMID:22276603;
http://dx.doi.org/10.1111/j.1365-2559.2011.04121.x
18. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y,
Rosato A, Sgarra R, Del Sal G, Manfioletti G. HMGA1
promotes metastatic processes in basal-like breast cancer
regulating EMT and stemness. Oncotarget 2013;
4:1293-1308; PMID:23945276
19. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A,
Visconti R, Giancotti V, Fusco A. Inhibition of
HMGI-C protein synthesis suppresses retrovirally
induced neoplastic transformation of rat thyroid cells.
Mol Cell Biol 1995; 15:1545-53; PMID:7862147
20. Berlingieri MT, Pierantoni GM, Giancotti V, San-
toro M, Fusco A. Thyroid cell transformation
requires the expression of the HMG1 proteins.
Oncogene 2002; 21:2971-80; PMID:12082527;
http://dx.doi.org/10.1038/sj.onc.1205368
21. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A.
Adenovirus mediated suppression of the HMGI(Y) pro-
tein synthesis as a potential therapy of human malignant
neoplasias. Proc Natl Acad Sci USA. 2000; 97:4256-61;
http://dx.doi.org/10.1073/pnas.070029997
22. Vallone D, Battista S, Pierantoni GM, Fedele M, Casa-
lino L, Santoro M, Viglietto G, Fusco A, Verde P. Neo-
plastic transformation of rat thyroid cells requires the
junB and fra-1 gene induction which is dependent on
the HMGI-C gene product. EMBO J 1997; 16:5310-
21; PMID:9311991; http://dx.doi.org/10.1093/emboj/
16.17.5310
23. Palmieri D, Valentino T, De Martino I, Esposito F,
Cappabianca P, Wierinckx A, Vitiello M, Lombardi G,
Colao A, Trouillas J, et al. PIT1 upregulation by
HMGA proteins has a role in pituitary tumorigenesis.
Endocr Relat Cancer 2012; 19:123-35;
PMID:22199144; http://dx.doi.org/10.1530/ERC-11-
0135
24. Fedele M, Pentimalli F, Baldassarre G, Battista S,
Klein-Szanto AJ, Kenyon L, Visone R, De Martino I,
Ciarmiello A, Arra C, et al. Transgenic mice overex-
pressing the wild-type form of the HMGA1 gene
develop mixed growth hormone/prolactin cell pituitary
adenomas and natural killer cell lymphomas. Oncogene
2005; 24:3427-35; PMID:15735694; http://dx.doi.
org/10.1038/sj.onc.1208501
25. Borbone E, Troncone G, Ferraro A, Jasencakova Z,
Stojic L, Esposito F, Horning N, Fusco A, Orlando V.
Enhancer of zeste homolog 2 overexpression has a role
in the development of anaplastic thyroid carcinomas. J
Clin Endocrinol Metab 2011; 96:1029-38;
PMID:21289264; http://dx.doi.org/10.1210/jc.2010-
1784
26. Esposito F, Tornincasa M, Pallante P, Federico A, Bor-
bone E, Pierantoni GM, Fusco A. Down-regulation of
the miR-25 and miR-30d contributes to the develop-
ment of anaplastic thyroid carcinoma targeting the pol-
ycomb protein EZH2. J Clin Endocrinol Metab 2012;
97:E710-8; PMID:22399519; http://dx.doi.org/
10.1210/jc.2011-3068
27. Kumar MS, Armenteros-Monterroso E, East P, Chakra-
vorty P, Matthews N, Winslow MM. HMGA2 functions
as a competing endogenous RNA to promote lung cancer
progression. Nature 2014; 505:212-17; PMID:24305048;
http://dx.doi.org/10.1038/nature12785
www.landesbioscience.com 3639Cell Cycle
D
ow
nl
oa
de
d 
by
 [D
ipa
rtm
en
to 
di 
St
ud
i E
 R
eic
erc
he
], 
[M
arc
o D
e M
art
ino
] a
t 0
1:2
9 0
7 J
an
ua
ry
 20
15
 
This article was downloaded by: [Md Anderson Cancer Center]
On: 04 May 2015, At: 07:56
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
Click for updates
Cell Cycle
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/kccy20
HMGA1-pseudogene expression is induced in human
pituitary tumors
Francesco Espositoa, Marco De Martinoa, Daniela D'Angeloa, Paula Mussnicha, Gerald
Raverotbc, Marie-Lise Jaffrain-Reade, Filippo Fraggettaf, Jacqueline Trouillasbg & Alfredo
Fuscoah
a Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Medicina
Molecolare e Biotecnologie Mediche; Scuola di Medicina e Chirurgia di Napoli; Università
degli Studi di Napoli “Federico II”, Naples, Italy
b U1028; CNRS UMR 5292; Lyon Neuroscience Research Center; Neuro-oncology and
Neuroinflammation Team; Lyon, France
c Department of endocrinology; Groupement Hospitalier Est; Hospices Civils de Lyon, Lyon,
France
d Department of Clinical Applied Sciences and Biotechnology; University of L'Aquila; L'Aquila,
Italy
e Neuromed; IRCCS, Pozzilli, Italy
f Department of Pathology; Ospedale Cannizzaro; Catania, Italy
g Centre of pathology; Groupement Hospitalier Est; Hospices Civils de Lyon; Lyon, France
h Instituto Nacional de Câncer - INCA; Rio de Janeiro, Brazil
Accepted author version posted online: 20 Apr 2015.
To cite this article: Francesco Esposito, Marco De Martino, Daniela D'Angelo, Paula Mussnich, Gerald Raverot, Marie-Lise
Jaffrain-Rea, Filippo Fraggetta, Jacqueline Trouillas & Alfredo Fusco (2015) HMGA1-pseudogene expression is induced in
human pituitary tumors, Cell Cycle, 14:9, 1471-1475
To link to this article:  http://dx.doi.org/10.1080/15384101.2015.1021520
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained
in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no
representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the
Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and
are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and
should be independently verified with primary sources of information. Taylor and Francis shall not be liable for
any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever
or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of
the Content.
This article may be used for research, teaching, and private study purposes. Any substantial or systematic
reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any
form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://
www.tandfonline.com/page/terms-and-conditions
HMGA1-pseudogene expression is induced
in human pituitary tumors
Francesco Esposito1, Marco De Martino1, Daniela D’Angelo1, Paula Mussnich1, Gerald Raverot2,3, Marie-Lise Jaffrain-Rea4,5,
Filippo Fraggetta6, Jacqueline Trouillas2,7, and Alfredo Fusco1,8,*
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Keywords:HMGA1P6, HMGA1P7, HMGA1, ceRNA, miRNA
Numerous studies have established that High Mobility Group A (HMGA) proteins play a pivotal role on the onset of
human pituitary tumors. They are overexpressed in pituitary tumors, and, consistently, transgenic mice overexpressing
either the Hmga1 or the Hmga2 gene develop pituitary tumors. In contrast with HMGA2, HMGA1 overexpression is not
related to any rearrangement or ampliﬁcation of the HMGA1 locus in these tumors. We have recently identiﬁed 2
HMGA1 pseudogenes, HMGA1P6 and HMGA1P7, acting as competitive endogenous RNA decoys for HMGA1 and other
cancer related genes. Here, we show that HMGA1 pseudogene expression signiﬁcantly correlates with HMGA1 mRNA
levels in growth hormone and nonfunctioning pituitary adenomas likely inhibiting the repression of HMGA1 through
microRNAs action. According to our functional studies, these HMGA1 pseudogenes enhance the proliferation and
migration of the mouse pituitary tumor cell line, at least in part, through their upregulation. Our results point out that
the overexpression of HMGA1P6 and HMGA1P7 could contribute to increase HMGA1 levels in human pituitary tumors,
and then to pituitary tumorigenesis.
Introduction
The High Mobility Group A (HMGA) proteins are non-his-
tone chromatinic proteins involved in transcriptional regulation
of gene expression.1 The HMGA protein family consists of 3
proteins: HMGA1a, HMGA1b, and HMGA2 encoded by 2 dif-
ferent genes, with the HMGA1 proteins being products of the
same gene generated through alternative splicing.1 HMGA over-
expression is a feature of malignant neoplasias and its causal role
in cell transformation and cancer progression is supported by
many studies.1-3
We have already reported several evidences that HMGA pro-
teins act as drivers of human pituitary tumors (PT),4-8 with both
the HMGA proteins overexpressed. However, in these tumors,
only the overexpression of HMGA2 is associated to gene rear-
rangement and amplification following trisomy of chromosome
12.4 Consistently, it is well known that transgenic mice overex-
pressing either hmga1 or hmga2 develop PT,5-7 and that the
HMGA overexpression is associated to the downregulation of
several miRNAs able to target both HMGA1 and HMGA2
mRNAs in PT (miR-15, miR-16, miR-23b, miR-26a, miR-34b,
miR-130b, miR-196a2, miR-326, miR-432, miR-548c-3p,
miR-570, miR-603, and Let-7a).9-11
We have recently identified 2 HMGA1 non-coding pseudo-
genes, HMGA1P6 and HMGA1P7, having conserved seed
matches for miRNAs targeting the HMGA1 gene. The overex-
pression of HMGA1 pseudogene (HMGA1Ps) increases HMGA1
protein levels, working as competitive endogenous RNA
(ceRNA), thereby inhibiting the suppression of HMGA1 protein
synthesis by miRNAs.12,13 Since the HMGA1Ps untranslated
regions (UTRs) contain also seed sequences for miRNAs able to
target HMGA2, their overexpression leads also to increased
HMGA2 protein levels. HMGA1Ps also show oncogenic activity
by inhibiting apoptosis and increasing cell proliferation and
migration.12,13
The aim of this study has been to investigate the expression
and the role of HMGA1Ps in PT.
HMGA1 andHMGA1Ps expression positively correlates
in pituitary tumors
Briefly, we analyzed the expression of HMGA1Ps by qRT-
PCR in a panel of 41 human PT, including 14 growth hormone
(GH) tumors with acromegaly and 27 nonfunctioning pituitary
adenomas (NFPA) or gonadotroph FSH-LH tumors detected by
immunohistochemistry (IHC). As shown in Fig. 1 (Panels A and
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B), HMGA1P6 and HMGA1P7 were differently expressed with
regard to the IHC type, when compared with the normal pitui-
tary gland. To verify whether the 2 HMGA1Ps may also function
as ceRNAs in the regulation of HMGA1 mRNA levels in PT, we
analyzed HMGA1 expression in these same samples (Fig. 1C).
As indicated in Figure 1, Panel D, a significant linear correla-
tion was found between HMGA1 and HMGA1P6 expression (r
D 0.5952, P < 0.0001), suggesting that these genes are co-regu-
lated, while there is no correlation between HMGA1 and
HMGA1P7 expression in the whole tumor series. However, fur-
ther analysis of HMGA1 and HMGA1Ps co-regulation disclosed
some differences according to tumor type. Indeed, in the subset
of GH tumors, HMGA1 strongly correlated with HMGA1P6
expression (r D 0.8593, P < 0 .0001), and also with HMGA1P7
expression (r D 0.6772, P < 0.0001) (Fig. 1E). Taken together,
these data strongly support the hypothesis that HMGA1Ps could
act as ceRNAs in PT and represent a novel potential mechanism
of HMGA1 upregulation in these tumors, in particular in GH
tumors with acromegaly.
HMGA1Ps expression increases AtT20 cell proliferation and
migration acting as ceRNAs for HMGA1
Subsequently, we examined the ability of HMGA1P6 and
HMGA1P7 to function as a decoy forHMGA1-targeting miRNAs
in the pituitary cell line AtT20. Figure 2, Panel A, confirms suc-
cessful transfection of both genes. As shown in Figure 2, Panel B,
overexpression of either HMGA1P6 or HMGA1P7 was associated
with HMGA1 protein overexpression. As expected from our
previously results,12 overexpression of HMGA1P6 or HMGA1P7
reduced the effects exerted by miRNA on the HMGA1 levels
(Fig. 2B). Then, to evaluate the functional consequences of
HMGA1P6 andHMGA1P7 overexpression in PT, we investigated
their role in cellular proliferation, and migration in AtT20 cells.
To this aim, AtT20 cells were transfected with the HMGA1P6,
HMGA1P7, and the control vector, and counted each day for 9 d.
Figure 2C, shows that the growth rate of AtT20 following the
transfection of the HMGA1Ps was higher compared with the cells
transfected with the control vector. Finally, we carried out cell
migration assays in the same HMGA1Ps overexpressing cells espe-
cially considering that HMGA1 promotes cell migration.1 As
expected from the increased HMGA1 protein levels in the pseudo-
gene-transfected cells,12 cell migration was significantly higher in
AtT20 cells overexpressing HMGA1P6 or HMGA1P7 than in
control cells (Fig. 2D).
Discussion
The critical role of High Mobility Group A proteins on the
onset of human PT has been widely accepted. In fact, the overex-
pression of both HMGA genes in PT has been reported by
numerous studies,4-8 and consistently the development of GH-
PRL tumors is a feature of transgenic mice overexpressing either
the Hmga1 or the Hmga2 gene.5, 6
The results reported here indicate that HMGA1Ps, which act
as miRNA sponges for HMGA1 genes, also contribute to
Figure 1. HMGA1 and HMGA1Ps expression positively correlates in pituitary tumors. (A) HMGA1P6, (B) HMGA1P7 and (C) HMGA1 qRT-PCR analysis in nor-
mal pituitary gland (N), GH, FSH/LH and null cell tumors. (D, E) The obtained values were then combined for correlation analysis. (D) Linear regression of
HMGA1 versus HMGA1P6 in the whole series of PT. (E) Linear regressions of HMGA1 vs. HMGA1P6 (left panel) and HMGA1 (right panel) versus HMGA1P7 in
GH tumors.
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pituitary tumorigenesis by enhancing pituitary cell proliferation
and migration.
Since no rearrangement or amplification of the HMGA1 locus
have been detected in PT, where HMGA1 is overexpressed,4-8
HMGA1Ps overexpression contributes to high HMGA1 protein
levels detected in PT together with tumor downregulation of
miRNAs targeting HMGA1 (miR-15, miR-16, miR-23b, miR-
26a, miR-34b, miR-130b, miR-196a2, miR-326, miR-432, miR-
548c-3p, miR-570, miR-603, and Let-7a).9-11
Indeed, we found a direct correlation between HMGA1 and
HMGA1Ps expression in a series of human PT, in particular in
the somatotroph ones. Then, functional assays revealed that
HMGA1P6 and HMGA1P7 increase cell proliferation and migra-
tion in pituitary cell line AtT20. This is in agreement with effects
of HMGA1, which accelerates the G1-S transition by increasing
E2F1 activity, and enhances cell migration in pituitary cell lines.
Noteworthy, HMGA1P6, HMGA1P7, as well as HMGA1 3’
UTR are potential ceRNAs for other cancer-related genes such as
High Mobility Group A2 (HMGA2) and Vascular Endothelial
Growth Factor (VEGF) which may further contribute to pituitary
tumorigenesis.
In conclusion, the results reported here clearly evidence
that HMGA1 pseudogene overexpression contributes to
pituitary tumor behavior, thereby disclosing an additional
mechanism accounting for the high expression of HMGA1
(and likely HMGA2) in PT. Consequently, these results fur-
ther support the perspective of an innovative molecular ther-
apy of PT by restoring the expression of miRNAs able to
target the HMGA genes and/or blocking that of the HMGA1
pseudogenes.
Methods
Cell culture and transfections
AtT20 cells were maintained in DMEM supplemented with
10% foetal calf serum (Euroclone; Milan, Italy), glutamine and
antibiotics. Cells were repeatedly tested with MycoAlert (Lonza;
Slough, UK) to ensure that cells were not infected with myco-
plasma. Cells were transfected using Lipofectamine plus reagent
(Life Technologies Italia; Monza, Italy) according to the man-
ufacturer’s instructions. The transfected cells were selected in a
medium containing geneticin (Sigma; St. Louis, USA). For each
transfection, several geneticin-resistant mass cell populations
were isolated and expanded for additional analysis. Transfection
efficiency was established for each experiment by evaluating GFP
Figure 2. HMGA1Ps expression increases AtT20 cell proliferation and migration acting as ceRNAs for HMGA1. (A) qRT-PCR analysis of HMGAP6 and
HMGA1P7mRNA levels in AtT20 cells transfected with the empty, HMGA1P6 or HMGA1P7 vectors. (B) Western blot analysis of HMGA1 protein levels from
the same samples shown in A. (C) AtT20 cell proliferation in HMGA1P6- and HMGA1P7-transfected cells. (D) Cell migration assays of AtT20 cells trans-
fected with HMGA1P6, HMGA1P7 or with a control vector (Upper panel). Migrated cells were quantiﬁed and expressed as mean § SD *, P < 0.05 (t test)
(Lower panel).
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expression. HMGA1P6 and HMGA1P7 expression vectors have
been previously described.12
Tissue collection and RNA isolation
Surgical samples of PT were obtained from patients operated
in 2 centers: Lyon, France (29 tumors - n1 to n29) and at the
Neuromed Institute, Pozzilli, Italy (12 tumors - n30 to n41).
Among these, 14 presented with acromegaly and 27 with clini-
cally non-functioning tumors, respectively. According to diag-
nostic immunohistochemistry with pituitary hormones,
immunostaining for GH was confirmed in tumors from acrome-
galic patients whereas the large majority of clinically non-func-
tioning tumors showed some degree of immunopositivity for
FSH and/or LH and the few immunonegative samples were
assimilated to gonadotroph tumors. For each tumor, fragments
were fixed in the Bouin-Holland fluid or formol and embedded
in paraffin for pathological diagnosis, including IHC. Other frag-
ments were immediately frozen and stored at ¡80C. We declare
that informed consent for the scientific use of biological material
was obtained from all patients.
RNA extraction and quantitative reverse transcription PCR
Total RNA was extracted from tissues with Trizol (Life Tech-
nologies Italia; Monza, Italy) according to the manufacturer’s
instructions. For mRNA detection, total RNA was reverse tran-
scribed by using the QuantiTect Reverse Transcription Kit (Qia-
gen; Valencia, USA), and then Real-time PCR was performed by
using Power SYBR Green PCR Master Mix (Applied Biosys-
tems-Life Technologies Italia; Monza, Italy) and the following
primers:
HMGA1-Fw 50-aaggggcagacccaaaaa-30
HMGA1-Rev 50-tccagtcccagaaggaagc-30
HMGA1P6-Fw 50-gcagacccacaaaactgga-30
HMGA1P6-Rev 50-gagcaaagctgtcccatcc-30
HMGA1P7-Fw 50-gctccttctcggctcctc-30
HMGA1P7-Rev 50-gcttgggcctcttttatgg-30
G6PD-Fw 50-acagagtgagcccttcttcaa-30
G6PD-Rev 50-ataggagttgcgggcaaag-30
The 2¡DDCt formula was used to calculate the differential gene
expression.
Protein extraction, western blotting and antibodies
Protein extraction and Western blotting were performed as
before described.14 Antibodies against the HMGA1 proteins are
described elsewhere.15 Blots were visualized by using the Western
blotting detection reagents (Thermo Scientific, Waltham, USA).
Cell migration assay
Cell migration experiments were performed as previously
described.16
Statistical analysis
Data were analyzed using a 2-sided unpaired Student’s t test
(GraphPad Prism, GraphPad Software, Inc.). Values of P < 0.05
were considered statistically significant. Regression analyses and
correlation coefficients were generated using GraphPad Prism,
GraphPad Software, Inc.
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ABSTRACT
Pseudogenes are DNA sequences with high homology to the corresponding 
functional gene, but, because of the accumulation of various mutations, they have 
lost their initial functions to code for proteins. Consequently, pseudogenes have 
been considered until few years ago dysfunctional relatives of the corresponding 
ancestral genes, and then useless in the course of genome evolution. However, several 
studies have recently established that pseudogenes are owners of key biological 
functions. Indeed, some pseudogenes control the expression of functional genes 
by competitively binding to the miRNAs, some of them generate small interference 
RNAs to negatively modulate the expression of functional genes, and some of them 
even encode functional mutated proteins. Here, we concentrate our attention on the 
pseudogenes of the HMGA1 gene, that codes for the HMGA1a and HMGA1b proteins 
having a critical role in development and cancer progression. In this review, we 
analyze the family of HMGA1 pseudogenes through three aspects: classification, 
characterization, and their possible function and involvement in cancer.
INTRODUCTION
The term “pseudogene” comes from the Greek word 
“pseudo” meaning false. Pseudogenes are also identified as 
“genomic fossils”[1]. They are outdated DNA sequences 
that lack protein coding ability because of the presence of 
frame shift mutations and early or delayed stop codons, 
even though they look like functional genes [2]. They are 
considered nonfunctional relatives of ancestral functional 
genes that might have lost their function during evolution 
[3]. Pseudogenes have been found in plants [4], bacteria 
[5], yeast [6], insects [7], nematodes [8] and mammals [9]. 
Based on their origins, pseudogenes have been classified 
into: (i) Processed pseudogenes - produced by mRNA 
retrotransposition [10]; (ii) Duplicated pseudogenes 
(called unprocessed pseudogenes) - originated from 
the duplication of functional genes that than become 
nonfunctional because of acquired mutations [10]; (iii) 
Unitary or Disabled pseudogenes - originated by mutations 
in the functional protein coding sequences [2].
Nowadays, pseudogene origin, evolution and 
function are only partially understood. The first paper 
about the biological role of a pseudogene was published 
about 16 years ago [11]. In fact, Korneev et al. reported 
that the neuronal nitric oxide synthase pseudogene worked 
as natural antisense in regulating neuronal nitric oxide 
synthase gene expression. However, recent studies have 
shown more functional roles for pseudogenes, associating 
them to long non-coding RNAs (lncRNAs) family 
[10, 12-14]. In fact, Poliseno et al. reported that PTEN 
pseudogene 1 (PTENpg1) is transcribed in human tissues 
and cancers and harbor microRNA (miRNA) response 
elements (MREs) for some of the same miRNAs that 
target its corresponding protein-coding gene, PTEN [12]. 
By sequestering miRNAs that would modulate PTEN, the 
corresponding pseudogene derepresses the protein-coding 
genes from miRNA regulation [12]. In this way transcripts 
could talk each other by competing for the same miRNAs, 
acting as competitive endogenous RNAs (ceRNAs) 
[15, 16]. In addition, Johnsson et al. characterized two 
PTENpg1 antisense RNA isoforms, alpha and beta. The 
alpha isoform acts on the PTEN promoter inhibiting PTEN 
transcription by epigenetic mechanisms. On the contrary, 
the beta isoform directly interacts with PTENpg1 RNA, 
Oncotarget2www.impactjournals.com/oncotarget
which influences PTEN protein by changing PTENpg1 
stability and miRNA decoy activity [17]. Therefore, the 
overexpression of PTENpg1 sustains PTEN expression 
acquiring oncosuppressive functions [12]. 
Moreover, the human BRAF pseudogene (BRAFP1) 
has been recently found overexpressed in various tumor 
types, suggesting that it may contribute to cancer 
development. Karret et al. demonstrated the ceRNA role of 
both mouse Braf-rs1 pseudogene (Braf-rs1)and its human 
ortholog, BRAFP1, eliciting the expression of BRAF 
and the activation of MAPK cascade both in vitro and in 
vivo. Indeed, miRNA bioinformatic analysis showed that 
murine Braf-rs1 and B-Raf share 53 miRNAs, equally 
human BRAFP1 and BRAF share 40 miRNAs. Thus, the 
BRAF pseudogene, via sequestration of common miRNAs, 
may work as a decoy for BRAF in mice and humans then 
upregulating BRAF and promoting MAPK signaling and 
tumorigenesis. Furthermore, mice overexpressing Braf-rs1 
develop an aggressive tumor similar to the human diffuse 
large B cell lymphoma. In addition, several transcriptional 
or genomic aberrations of BRAFP1 were frequently found 
in multiple human cancers, including B cell lymphomas 
[18]. Taken together, pseudogenes are deeply involved in 
ceRNA hypothesis and give rise to large-scale controlling 
system across the transcriptome, critically increasing the 
functional data of human genome and acquiring main roles 
in physiological and pathological conditions [19].
Besides pseudogene-derived small RNAs have been 
demonstrated to have a role in chromatin repression [20]. 
Latest evidences show contribution of pseudogenes in 
regulating development and disease by encoding peptides 
or proteins [21-23]. Interestingly, Kandouz et al. detected 
the expression of Cx43 pseudogene (psiCx43) in several 
cancer cell lines demonstrating its translationability 
in a protein of 43 kDa. Moreover, the psiCx43 protein 
overexpression was able to induce translational inhibition 
of Cx43 acting as a posttranscriptional regulator of Cx43, 
whose expression in cancer slows growth and renders the 
cells more sensitive to cytotoxic chemotherapeutics [23]. 
Finally, it has been reported that pseudogenes produce 
small interfering RNAs (siRNAs) in African Trypanosoma 
brucei and suppress several kinds of functional protein-
coding genes through RNA interference pathway [24]. 
The family of High-Mobility Group A (HMGA) 
is composed of four proteins, HMGA1a, HMGA1b, 
HMGA1c, encoded by HMGA1 gene at the end of 
alternative splicing, and HMGA2, encoded by the HMGA2 
gene [25]. HMGA1 is located on chromosome 6p21 in 
humans and in the t-complex locus on mouse chromosome 
17, whereas HMGA2 is found on chromosome 12q13-15 
in humans and at the pigmy locus on chromosome 10 in 
mice [26]. HMGA1 and HMGA2 genes are well conserved 
through the species, in fact, only few differences have been 
found between the human and the murine HMGA sequence 
Figure 1: Structure of HMGA1Ps and their main mutations with respect to HMGA1 proteins. Diagrams illustrating the 
domain structures of HMGA1a, HMGA1b, HMGA1P1, HMGA1P2 and HMGA1P3. Known post-traductional modifications of human 
HMGA1a and HMGA1b proteins impaired in HMGA1Ps are highlighted (Phosphorylation in blue, methylation in red). The three AT-hooks 
are in red and the acidic tail in blue. 
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[26]. They are non-histone chromosomal proteins, also 
identified as “architectural transcriptional factors” since 
they do not show a direct transcriptional activity, but 
modify the chromatin structure thanks to their DNA-
binding domains, called “AT hooks”, by which they bind 
the DNA minor groove at AT-rich nucleotide sequences 
modulating the gene transcription [27-29]. HMGA 
proteins are expressed at low levels in adult tissues, but 
their expression is copious during embryogenesis [26], 
suggesting their important role in development. Indeed, 
the phenotypic study of Hmga1 knock out mice showed 
that this protein has a critical role in different aspects of 
development [26, 30]. In particular, cardiac hypertrophy 
and type 2 diabetes were reported in Hmga1-null and 
heterozygous mice meaning that a correct quantity of 
HMGA1 protein is necessary for cardiomyocytic cell 
growth and regulation of the insulin pathway [26, 31-33]. 
In fact, the downregulation of HMGA1 protein leads to 
a reduced insulin receptor (INSR) expression in patients 
with insulin resistance and type 2 diabetes. The recovery 
of HMGA1 levels improved INSR gene transcription, 
restoring both expression of insulin receptor protein on 
cell surface and insulin-binding capacity [31].
It is worth noting that HMGA1 has been found 
abundantly expressed in all human neoplastic tissues 
analyzed, including, prostate [34-36], colon [37-39], 
breast [40-42], gastric [43-45], lung [46-48], testis [49-
51], pancreas [52-54], ovary [55-57], thyroid carcinomas 
[58-60] and also in some forms of leukemia [61-63]. 
Importantly, HMGA1 expression level has been correlated 
with an advanced stage, occurrence of distant metastases 
and reduced survival in colorectal carcinomas [64-
67]. To further sustain the HMGA1 function in cancer 
development, its expression levels have been associated 
with histologic grade of breast and ovarian carcinomas, 
where HMGA1 expression gradually enhances from no 
expression in normal breast tissue, to modest expression 
in hyperplastic lesions to overexpression in ductal 
carcinomas [67, 68], and augments from faintly expressed 
in ovarian carcinomas with low invasive potential to 
extremely expressed in invasive carcinomas [55, 69]. 
Importantly, HMGA overexpression plays a causal role in 
cell transformation. Indeed, their upregulation is able to 
transform rat fibroblasts [70] and human epithelial breast 
cells [71] and the block of HMGA1 protein expression 
prevented thyroid cell transformation induced by Kirsten 
Murine Sarcoma Virus, and it induced cell death into 
human thyroid anaplastic cell lines [72, 73]. Furthermore, 
the silencing of HMGA1 expression in colon cancer stem 
cells restores normal stem cell characteristics, reducing 
sphere-forming efficiency and recovering the asymmetric 
division pattern [39]. Finally, HMGA1 transgenic mice 
develop several benign or malignant neoplasias, such 
as GH/PRL-secreting pituitary adenomas, T-cell acute 
lymphoblastic leukemia and T/NK lymphomas [26, 37, 
74]. 
The molecular processes involved in cell 
transformation induced by the HMGA genes are based 
on their capacity to positively or negatively control the 
expression of genes and miRNAs, small noncoding RNAs 
engaged in gene regulation [75, 76] and implicated in the 
regulation of cellular proliferation, invasion and apoptosis 
[77-79].
The upregulation of the HMGA genes in cancer 
Table 1: HMGA1 Pseudogenes family
Gene Location Function Main mutations Reference
HMGA1P1 Xp21.3
Competitor protein for HMGA1 
with different post-translational 
modifications.*
arg25, thr53, arg57, ser64 91-95,99
HMGA1P2 4q13.3
Competitor protein for HMGA1 
with different post-translational 
modifications.*
arg57, arg59 94,99
HMGA1P3 12q24.11
Truncated form of HMGA1 with 
all molecular activities mentioned 
above.*
arg59, c-terminal tail 
deletion 94,96,97,99
HMGA1P4 9q34.11 - - -
HMGA1P5 10q22.2 HMGA1  non-homologous peptide* - -
HMGA1P6 13q12.12
Sustains the overexpression of 
several cancer-related genes by 
ceRNA mechanism
Stop codon 100-102
HMGA1P7 6q23.2
Sustains the overexpression of 
several cancer-related genes by 
ceRNA mechanism.
Start codon 100-102
HMGA1-p 2p13.2
Competes with HMGA1 3’ UTR 
for the binding to αCP1 RNA 
stability factor.
Few mutations 106
*The function of these pseudogenes still  needs to be validated.
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may occur through oncofetal transcriptional mechanisms, 
which have not been elucidated yet. It is known that 
the high expression of HMGA1 in cancer cells needs 
a close cooperation between SP1 family elements 
and AP1 proteins, stimulated by the activation of Ras 
GTPase cascade [80]. Furthermore, recent studies have 
demonstrated the miRNAs HMGA proteins regulation 
by binding its 3’ untranslated region (UTR), provoking 
mRNA degradation or inhibition of its translation [81, 
82]. In particular, several studies reported a strong HMGA 
regulation by miRNAs in pituitary adenomas (mir-15, 
mir-16, miR-34b, mir-214, miR-326, miR-432, miR-548c-
3p, miR-570, miR-603 and mir-761) [83-85], in thyroid 
carcinomas (let-7) [86], in breast cancer (mir-26a, miR-
33b) [87, 88]. Moreover, the loss of HMGA2 3’UTR, 
commonly found in benign tumors of mesenchymal 
origin, abolishes the inhibition of HMGA2 expression 
by several miRNAs [89, 90], leading to HMGA2 protein 
overexpression that accounts for neoplastic transformation. 
HMGA1 PSEUDOGENES
The analysis of the human genome by bioinformatic 
database revealed the presence of eight processed HMGA1 
pseudogenes (HMGA1Ps): HMGA1-p, HMGA1P1, 
HMGA1P2, HMGA1P3, HMGA1P4, HMGA1P5, 
HMGA1P6, and HMGA1P7 (Table 1). 
HMGA1P1 AND HMGA1P2
HMGA1P1 and HMGA1P2 pseudogenes, classified 
as processed pseudogenes, are located on Xp21.3 and 
4q13.3 chromosome, respectively. They are not conserved 
during the evolution, but are only found in human genome. 
There are few mutations that distinguish HMGA1P1 and 
HMGA1P2 from HMGA1a. These changes in DNA cause 
few errors in protein sequence that importantly do not 
affect their translationability. Indeed, our preliminary 
data show that expressing vectors for HMGA1P1 and 
HMGA1P2 are able to code for proteins detectable by 
western blotting analysis. In fact, lysates from HMGA1-
null cells transfected with the both vectors were positive 
to HMGA1 antibodies, which recognize the N-terminal 
aminoacids shared by HMGA1P1, HMGA1P2 and 
HMGA1. As shown in Figure 1, some HMGA1P1 and 
HMGA1P2 mutations hit aminoacidic residues that are 
frequently modified at post-translational level along 
the HMGA1 protein. Indeed, HMGA1P1 is mutated at 
position 25 where a tryptophan residue substitutes an 
arginine, within the first AT-hook of HMGA1, which has 
been shown to be a major site of modification in tumor 
cells [91]. In fact, Sgarra et al. demonstrated that the 
arginine residue 25 is strictly related to the execution of 
programmed cell death in tumor cell lines [92]. HMGA1P1 
is also mutated at threonine residue 53 that is substituted 
Figure 2: HMGA1P6 and HMGA1P7 mRNA sequence shares HMGA1-targeting miRNAs. HMGA1 (top), HMGA1P6 
(middle) and HMGA1P7 (bottom) mRNA sequences are shown in blue. HMGA1-targeting miRNA seed matches (red boxes) within the 
high homology regions are shared among HMGA1, HMGA1P6 and HMGA1P7. 
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with a lysine residue. Interestingly, threonine 53 was 
previously known as the main site of phosphorylation by 
cdc2 kinase during the cell cycle [93]. Compared with 
unphosphorylated protein, stoichiometric phosphorylation 
of recombinant human HMGA1 by cdc2 kinase strongly 
decreases the binding to DNA. Moreover, the HMGA1 
protein arginine residue at position 57, along the second 
AT-hook, is replaced by a glutamine in HMGA1P1. It 
has been reported that PRMT6 methylates HMGA1 at 
the level of arginine 57, which is involved in the affinity 
for DNA binding and also in protein-protein interaction, 
thus implying an important role for arginine methylation 
in modulating HMGA functions [94]. Finally, HMGA1P1 
brings a mutation at serine 64 where it shows an arginine 
residue. This is a Protein Kinase C (PKC) phosphorylation 
site [95]. Phosphorylation of HMGA1 by PKC resulted in 
a reduction of DNA-binding affinity as compared with that 
caused by the phosphorylation with cdc2 kinase, which 
phosphorylates threonine 53 [91, 95]. Therefore, HMGA1 
could be additively phosphorylated by cdc2 kinase and 
PKC, and the resulting doubly phosphorylated protein 
exhibits a strong reduction in binding affinity [91, 95].
HMGA1P2 is mutated at arginine residues 57 
and 59 where it shows a tryptophan and a glutamine 
residue, respectively (Figure 1). As well as arginine 57 
methylation, it has been reported that HMGA1 arginine 59 
is methylated by PRMT6 modulating its ability to bind to 
DNA and also the protein-protein affinity [94]. Therefore, 
if HMGA1P1 and HMGA1P2 pseudogenes coded for 
proteins, they could represent a sort of competitor proteins 
for HMGA1 wild-type with different post-translational 
modifications, altering HMGA1 properties in chromatin 
remodeling and protein-protein interactions. 
HMGA1P3
HMGA1P3 pseudogene, only found in human 
genome, is classified as processed pseudogene and it is 
located on chromosome 12q24.11. Even though classified 
as non-coding RNA, it has only four aminoacidic 
mutations along the protein sequence compared to 
HMGA1 sequence, without affecting its translationability 
Figure 3: miRNA decoy function of HMGA1Ps. In the steady state, equilibrium exists between the miRNAs and their targets 
HMGA1 and HMGA1Ps. By contrast, the overexpression of HMGA1P6 and HMGA1P7 results in fewer miRNAs free to bind to HMGA1, 
and thus HMGA1 levels increase. 
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(Figure 1). Interestingly, arginine 59 is replaced with a 
glutamine residue as mentioned above for HMGA1P2 
[95]. Moreover, HMGA1P3 pseudogene lacks the 
C-terminal acidic tail that is a feature of HMGA proteins 
[26]. In fact, it has been revealed that HMGA1a and 
HMGA1b are phosphorylated by Casein kinase II (CK2) 
on three serines situated in the C-terminal tail (S98, S101 
and S102) [96, 97]. Moreover, it is believed that the 
HMGA C-terminal tail may be important in modulating 
protein-protein interactions [97] and could be involved 
in enhancing transcription factor activity, but the role of 
these phosphorylations has been not completely uncovered 
yet [97]. Finally, expression of a truncated Hmga1b gene, 
without both the acidic tail and the 3’ UTR, significantly 
enhances growth rate and impairs adipocytic 
differentiation, also suggesting that the Hmga1/T mutant 
works in a contrasting manner [98]. Indeed, transgenic 
mice overexpressing the HMGA1 wild-type protein 
showed a reduction of the fat tissue in contrast with the 
obese phenotype of the Hmga1/T, mice even though there 
are no data that could explain why the wild-type and the 
truncated form of Hmga1 operate in opposite ways [98].
Given this scenario, if HMGA1P3 pseudogene 
coded for protein, it could represent a truncated form of 
HMGA1 wild-type with all molecular activities mentioned 
above.
Interestingly, previous studies showed that 
HMGA1P1, HMGA1P2 and HMGA1P3 can be affected 
by chromosomal rearrangements in benign human 
tumors [99]. In particular, significantly higher frequency 
of chromosomal breaks within the chromosomal bands 
containing these pseudogenes were observed in uterine 
leiomyomas, lipomas, pleomorphic adenomas, and 
pulmonary chondroid hamartomas [99]. This study unveils 
the existence of an interesting pseudogene activation 
mechanism in tumor, since they could translocate, after 
chromosomal rearrangements, under a promoter region 
or within a functional gene, then coding for new fusion 
proteins. 
However, no studies have evaluated HMGA1P1, 
HMGA1P2 and HMGA1P3 expression in human normal 
and malignant tissues where their possible deregulated 
Figure 4: HMGA1-p function model. In normal condition, the RNA-binding protein αCP1 stabilizes HMGA1 mRNA by binding to 
its 3’ UTR. In diabetes, the HMGA1-p overexpressed transcript competes with HMGA1 mRNA for the binding to αCP1, increasing the 
degradation of HMGA1 mRNA.
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expression might have consequences on the function of 
the wild type HMGA1 protein and then influence cancer 
progression. 
HMGA1P4 AND HMGA1P5
The non-coding RNA HMGA1P4 pseudogene is 
classified as processed pseudogene and is located on the 
human chromosome 9q34.11. Differently from the above 
mentioned pseudogenes, HMGA1P4 genomic sequence 
shows low homology with HMGA1. Moreover, further 
bioinformatics analysis confirms its untranslationability. 
Therefore, it could not be classified either as ceRNA or as 
peptide related to HMGA1. 
Another processed pseudogene related to HMGA1 is 
HMGA1P5. It is present only in humans and located on the 
chromosome 10q22.2. As HMGA1P4, HMGA1P5 has low 
homology along HMGA1 sequence and it may code for 
a peptide not related to HMGA1 protein. At the moment 
there are no published studies about these pseudogenes.
HMGA1P6 AND HMGA1P7
The processed pseudogenes HMGA1P6 and 
HMGA1P7 are sited on 13q12.12 and 6q23.2 chromosome, 
respectively. They are not conserved through the evolution, 
but are present only in human genome [100-102]. These 
pseudogenes have high sequence homology with HMGA1 
both in the 5’ and 3’ UTRs and in the coding region 
(Figure 2). A missense mutation of the start methionine 
codon avoids HMGA1P7 mRNA translation whereas 
HMGA1P6 bears a mutation in the stop codon, which 
is postponed several aminoacidic residues downstream, 
producing a non-translatable mRNA [100-102]. In the 
homology sequences, among HMGA1, HMGA1P6 and 
HMGA1P7, we retrieved conserved seed matches for 
miRNAs that have been predicted (miR-103, miR-142-
3p, miR-370, and miR-432) or previously validated (miR-
15 [83], miR-16 [83], miR-26a [103], miR-214 [104], 
miR-548c-3p [84] and miR-761 [104]) able to target the 
HMGA1 gene (Figure 2). 
It has been reported that both HMGA1P6 and 
HMGA1P7 act as decoys for HMGA1-targeting miRNAs. 
In fact, their overexpression enhances HMGA1 protein 
levels whereas their knocking down results in the 
reduction of HMGA1 mRNA and protein amounts (Figure 
3) [100-102].
Consistently, these HMGA1Ps have also 
oncogenic action by preventing apoptosis and enhancing 
cell proliferation and migration [100, 101]. Indeed, 
overexpression of HMGA1P6 or HMGA1P7 increases 
the growth rate and migration of different cell lines, 
contributing to tumor development [100-102]. Moreover, 
the generation of HMGA1P6 or HMGA1P7 transgenic 
mice confirms their oncogenic activity. In fact, mouse 
embryonic fibroblasts (MEFs) obtained from HMGA1P6 
or HMGA1P7 [100] transgenic mice grow more rapidly 
and senesce later than their wild-type counterparts. 
Remarkably, in HMGA1P6 and HMGA1P7 overexpressing 
cells and MEFs we detected the upregulation of several 
cancer-related genes such as High Mobility Group A2 
(HMGA2), Enhancer of Zeste Homolog 2 (EZH2), 
Vascular Endothelial Growth Factor (VEGF), and Ephrin 
Type-A Receptor 3 (Epha3), with respect to the control 
cells [100]. This happens because of shared miRNAs 
targeting HMGA1P6, HMGA1P7, HMGA1 and other 
cancer related genes. Therefore, high HMGA1 gene 
or its pseudogene expression allows to increase other 
oncogene protein levels then contributing to cancer 
progression. Finally, a direct correlation among HMGA1, 
HMGA1P6 and HMGA1P7 expression in a group of 
human thyroid and ovary tumors has been shown [97-
99]. Indeed, papillary thyroid carcinomas (PTC), which 
are fine differentiated and weakly aggressive, express 
low levels of HMGA1P6, HMGA1P7 and HMGA1. On 
the contrary, anaplastic thyroid carcinomas (ATC), which 
are one of the most malignant human cancers, express 
very high HMGA1Ps levels that, moreover, correlated 
with HMGA1 protein levels [100]. Similar results were 
obtained in human ovarian carcinomas [100] and in 
endometrial carcinomas, where the HMGA1P6 and 
HMGA1P7 expression correlates with the malignancy 
rate. Interestingly, HMGA1P6 and HMGA1P7 were also 
overexpressed in human pituitary adenomas where the 
HMGA proteins play a critical role in their development 
[105]. In particular, HMGA1P6 and HMGA1P7 
expression significantly correlates with HMGA1 mRNA 
in somatotropic and nonfunctioning pituitary adenomas. 
Moreover, functional studies show that the enforced 
expression HMGA1P6 and HMGA1P7 enhances the 
proliferation of a pituitary adenoma cell line. Therefore, 
HMGA1P6 and HMGA1P7 overexpression contributes 
to keep high HMGA1 protein levels enhancing, then, its 
oncogenic ability.
HMGA1-p
HMGA1-p is located on chromosome 2p13.2. Its 
expression is able to induce destabilization of HMGA1 
mRNA [83]. Indeed, it has been demonstrated that the 
HMGA1-p RNA competes with HMGA1 3’ UTR for a 
critical RNA stability factor, the alpha C-binding protein 
(αCP1) [106]. The HMGA1-p was found overexpressed 
in diabetic patients then causing a significant 
destabilization of HMGA1 mRNA with consequent loss 
of INSR expression, which is regulated by HMGA1, 
then generating the insulin resistance phenotype (Figure 
4). Moreover, targeted knockdown of HMGA1-p mRNA 
results in an increase of HMGA1 mRNA stability and 
expression levels, with a parallel correction in cell-surface 
INSR expression and insulin binding capacity [106]. 
Therefore, this study established a novel mechanistic 
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linkage between HMGA1-p pseudogene expression and 
type 2 diabetes mellitus.
CONCLUSIONS AND PERSPECTIVES
The mammalian genome contains an high number 
of pseudogenes (about 20,000 in humans) [107, 108] more 
than those present in other organisms. The biological 
meaning of pseudogenes was completely obscure until 
few years ago, whereas recent studies have shown their 
critical role in regulating gene transcription mainly 
functioning as decoy for miRNAs, and also evidenced 
a role of pseudogenes in carcinogenesis [109-116]. 
Interestingly, we have identified, by bioinformatic search, 
eight pseudogenes for the HMGA1 gene whose expression 
is a feature of human malignancies with a key function 
in promoting cancer progression. From the analysis 
of the HMGA1P sequences it comes up that they could 
be able to regulate HMGA1 expression and function. 
Indeed, HMGA1P6 and HMGA1P7 act on the stability 
of HMGA1 mRNA or by protecting them from miRNAs 
able to target this gene, whereas HMGA1-p competes 
with HMGA1 3’ UTR for a critical RNA stability factor, 
the αCP1. Conversely, HMGA1P1, HMGA1P2 and 
HMGA1P3 could represent a sort of competitor proteins 
for HMGA1 wild-type with different post-translational 
modifications, altering HMGA1 properties in chromatin 
remodeling and protein-protein interactions. So far, the 
role of HMGA1-p in type 2 diabetes and HMGA1P6 and 
HMGA1P7 in the progression of some human neoplasias 
appears well documented, but further analysis of their 
expression in embryonic and adult tissues, and in human 
carcinomas is required to be deeper investigated. Recently, 
it has been observed that transgenic mice overexpressing 
either HMGA1P6 and HMGA1P7, develop lymphomas, 
infiltrating different organs likely working as ceRNAs for 
their oncogenic related genes.
Therefore, HMGA1Ps represent an epigenetic 
event, as well as miRNAs, able to regulate HMGA1 
activity, and then play a critical role in all the processes 
such as cancer progression, development, metabolism 
and many other function in which HMGA1 is involved. 
The involvement of HMGA1 in all these important 
cellular processes likely accounts for the need of its 
fine regulation by using different molecular approaches. 
Interestingly, recent studies unveil a correlation between 
HMGA1P6 and HMGA1P7 and some clinico-pathological 
features, opening the perspective of using the evaluation 
of HMGA1Ps expression as diagnostic and prognostic 
marker, and maybe also in tumor classification. Therefore, 
the studies summarized here rehabilitate the HMGA1Ps 
from “junk” to a multifunctional pseudogene family that 
needs to be extensively studied.
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HMGA1P7-pseudogene regulates 
H19 and Igf2 expression by a 
competitive endogenous RNA 
mechanism
Marco De Martino1, Floriana Forzati1, Marianna Marfella1, Simona Pellecchia1, Claudio Arra2, 
Luigi Terracciano3, Alfredo Fusco1 & Francesco Esposito1
Recent studies have revealed that pseudogene transcripts can function as competing endogenous 
RNAs, and thereby can also contribute to cancer when dysregulated. We have recently identified two 
pseudogenes, HMGA1P6 and HMGA1P7 for the HMGA1 gene whose overexpression has a critical role in 
cancer progression. These pseudogenes work as competitive endogenous RNA decoys for HMGA1 and 
other cancer related genes suggesting their role in carcinogenesis. Looking for new HMGA1 pseudogene 
ceRNAs, we performed RNA sequencing technology on mouse embryonic fibroblasts deriving from 
transgenic mice overexpressing HMGA1P7. Here, we report that HMGA1P7 mRNA sustains the H19 and 
Igf2 overexpression by acting as miRNA decoy. Lastly, the expression of HMGA1P7 was significantly 
correlated with H19 and IGF2 levels in human breast cancer thereby suggesting a role for HMGA1P7 
deregulation in this neoplasia.
Pseudogenes are a subclass of long non coding RNA (lncRNA) sharing high sequence identity with protein-coding 
parental counterparts. As stated by the GENCODE pseudogene annotations (v.17), there are almost 15,000 
human pseudogenes1. They frequently possess features, such as premature stop codons, deletions/insertions, or 
frame shift mutations, that impede them to produce functional proteins. There are three groups of pseudogenes: 
processed, duplicated, and unitary1,2. Processed pseudogenes do not have introns and are thought to arise from 
reverse transcription of mRNA followed by reinsertion into the genome1,2. Duplicated pseudogenes contain 
introns and sometimes even upstream regulatory elements since they are produced by gene duplication. For 
each pseudogene belonging to these two classes there is an associated protein-coding gene that is highly similar 
in sequence1,2. The last type of pseudogenes are the unitary ones, which take place when protein-coding genes 
accumulate mutations and lose their coding potential1,2. Consequently, unitary pseudogenes do not have paren-
tal genes. From the time of their discovery in 1977, pseudogenes have commonly been thought as “biologically 
inconsequential” and non-functional3. However, recent studies have unveiled different mechanisms by which 
pseudogenes control gene expression such as the generation of siRNAs4,5, competition for RNA-binding proteins 
or the translation apparatus6–8, and engagement of proteins by pseudogene antisense RNAs to corresponding 
sites in the parental gene to modify chromatin transcription and remodeling9,10. The latest function identified for 
pseudogenes is post-transcriptional regulation of mRNA levels by competing for microRNAs (miRNAs). Indeed, 
processed pseudogenes maintain 5′ and 3′ untranslated region (UTR) sequences of their parental genes11. Given 
that miRNAs inhibit target gene expression by binding to the 3′ UTR, pseudogenes can be targeted by miRNAs 
that modify the expression of coding genes. Definitely, pseudogene transcripts exert regulatory control of their 
parental gene expression levels by competing for the same miRNAs12.
We have recently characterized two processed pseudogenes, HMGA1P6 and HMGA1P7, for the HMGA1 gene 
that codes for the HMGA1a and HMGA1b proteins highly overexpressed in most of the human malignancies13,14. 
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Moreover, it has been previously demonstrated an association between HMGA1 overexpression and a poor 
patient survival13, and that their overexpression is even required for cell transformation15,16, and is able to induce 
benign and malignant neoplasias in mice13. HMGA1P6 and HMGA1P7 pseudogenes, present only in human 
genome, have preserved seed matches for miRNAs targeting the HMGA1 oncogene. HMGA1 pseudogenes 
(HMGA1Ps) overexpression, working as competitive endogenous RNA (ceRNA), increases HMGA1 protein 
levels by blocking the suppression of HMGA1 protein synthesis exerted by miRNAs17–20. HMGA1Ps have also 
oncogenic activity by suppressing apoptosis and promoting cell proliferation and migration17–20. Moreover, we 
have previously show that HMGA1Ps are overexpressed in anaplastic thyroid carcinomas but not in the differ-
entiated ones, indicating a critical role of them in cancer progression17. Since the HMGA1Ps contain several 
seed sequences for miRNAs, their overexpression derepresses the expression of different cancer-related genes, 
as already demonstrated for HMGA2, VEGF, EZH217–20. Therefore, the aim of this study has been to find novel 
ceRNA interactors differentially expressed in HMGAP7 transgenic mouse embryonic fibroblasts (MEFs) with 
respect to the wild-type (WT) ones, which do not express HMGA1 pseudogenes, using a RNA sequencing 
(RNA-seq) approach. By this analysis, we found a set of mRNAs up- or down-regulated in HMGA1P7 overex-
pressing MEFs in comparison with WT cells. Among them, we focused our attention on two of the most overex-
pressed and HMGA1P7 miRNA-sharing genes: H19 and insulin-like growing factor 2 (Igf2).
H19 and IGF2 genes are closely linked, showing highly similar patterns of gene expression, but they are recip-
rocally imprinted. In fact, H19 is expressed solely from the maternally inherited chromosome, whereas IGF2 
expression is from the paternal chromosome. In particular, the noncoding H19 has a critical role in genomic 
imprinting during cell growth and development21. The loss of imprinting results in misexpression of H19 and was 
detected in many tumors including hepatocellular22, bladder23, gastric24,25 and colon26 cancer. IGF2 codes for a 
mitogenic growth factor that is active in early development and has a critical role in embryonic and fetal growth27. 
Increased expression of IGF2 is a common feature of both pediatric and adult malignancies27, and mounting evi-
dence implicates IGF2 as a major factor contributing to oncogenesis27–29. Here, we report that HMGA1P7 mRNA 
induces the H19 and Igf2 overexpression by acting as miRNA decoy.
Results
RNA-seq on HMGA1P7 transgenic MEFs. To identify the genes regulated by HMGA1P7 expression, we 
analyzed the whole transcriptome of WT and HMGA1P7 transgenic MEFs by RNA-seq analyses. To this aim, the 
entire population of RNA transcripts extracted from WT and HMGA1P7-MEFs were sequenced. The genome-
wide RNA expression profiles studies reveal that about one hundred fifty transcripts (32 upregulated and 116 
downregulated) were regulated by HMGA1P7 expression with a significant fold-change variation (FDR adjusted 
p-value of 0.05). To validate the results obtained by RNA-seq, we analyzed the expression of some upregulated 
genes such as Collagen Type VI Alpha 3 (Col6a3), Marker of Proliferation Ki-67 (Mki67), H19, Igf2 and downreg-
ulated genes such as Glutathione Peroxidase 3 (Gpx3), Leprecan-Like 1 (Leprel1) by Real-time PCR (qRT-PCR). 
As shown in Fig. 1, the quantitative qRT-PCR analyses confirmed the data obtained from the RNA-seq analyses. 
Interestingly, these genes have been related to several human cancers (colon, gastric, liver, breast and hematolog-
ical cancers), and are considered possible therapeutic targets30–35.
Figure 1. Validation of RNA-seq analyses on HMGA1P7 MEFs. qRT-PCR analysis of selected deregulated 
genes from RNA-seq performed on WT and HMGA1P7 transgenic MEFs. The results are reported as the mean 
of values. The error bars represent mean ± SE; *P < 0.05 **P < 0.01 ***P < 0.001 (t test).
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Among the differentially expressed mRNAs found in MEFs overexpressing HMGA1P7, we focused our atten-
tion on H19 and Igf2 since they, other than to be involved in carcinogenesis, showed the highest fold change 
among the upregulated genes, and are also targeted by several miRNAs that are able to bind to the HMGA1P7 
mRNA. Western blot analysis for Igf2 confirmed the qRT-PCR data (Fig. 2). Moreover, qRT-PCR and Western 
blot analysis showed that H19 and Igf2 were also upregulated in heart, spleen and kidney from HMGA1P7 adult 
transgenic mice (Fig. 3A,B and C). As expected from previous results, qRT-PCR shows upregulation of H19 and 
Igf2 following HMGA1P7 pseudogene overexpression in NIH3T3 cells (Fig. 3D). Western blot confirms Igf2 
upregulation also at protein level in tissues from HMGA1P7 and in the HMGA1P7-transfected NIH3T3 cells 
(Fig. 3C and D).
Taken together, these results strongly support the hypothesis that HMGA1P7 could act as ceRNA for H19 and 
Igf2.
HMGA1P7 act as decoy for H19 and Igf2 targeting miRNAs. To test whether the effect of the 
HMGA1P7 pseudogene on H19 and Igf2 expression is dependent on sharing targeting-miRNAs, we evaluated 
the ability of HMGA1P7-targeting miRNAs17 to bind to H19 and Igf2. To this aim, we transfected miR-15, miR-
16, miR-214 and miR-761 (already reported to target HMGA1P7)17 into NIH3T3 cells, and analyzed H19 and 
Igf2 mRNA levels by qRT-PCR. As presented in Fig. 4A, the transfection of the HMGA1P7-targeting miRNAs 
yield a significant reduction of H19 and Igf2 mRNA levels. Western blot confirms Igf2 downregulation also at 
protein level following the transfection of the HMGA1P7-targeting miRNAs (Fig. 4A). To define whether the 
HMGA1P7-targeting miRNAs straightly interacted with Igf2 mRNA, we cloned the Igf2 3′ UTR downstream of 
the luciferase open reading frame. This reporter vector was transfected into NIH3T3 cells together with miRNA 
precursors and a control non-targeting scrambled oligonucleotide. The luciferase signal was considerably lower 
after transfection with miR-15, miR-16, miR-214 and miR-761 in comparison with the cells transfected with the 
scrambled oligonucleotide (Fig. 4B). The overexpression of H19 and Igf2 induced by upregulation of HMGA1P7 
was depleted in Dicer-knockdown cells (Fig. 4C) then supporting the hypothesis that HMGA1P7, H19 and Igf2 
follow the same miRNA-mediated post-transcriptional regulation. In fact, silencing of Dicer, the enzyme that 
leads miRNA maturation process, results in reduced levels of mature miRNAs compared to control. Moreover, 
to verify whether H19 and Igf2 can act as ceRNA each-other, we transfected siRNA-Igf2 into NIH3T3 cell line 
in combination or not with Anti miR-16, which is able to block miR-16 repression on HMGA1P7, Igf2 and H19, 
and a siRNA-control, then evaluating the H19 mRNA levels. As proposed by our model, siRNA-Igf2 transfection 
induces a significant H19 downregulation, that is reverted by the transfection with the Anti miR-16 oligonucle-
otide, suggesting that both H19 and Igf2 transcripts can talk each-other through miRNAs mediation (Fig. 4D). 
These data are consistent with the hypothesis that HMGA1P7 requires mature miRNAs to regulate H19 and Igf2 
levels.
HMGA1P7, H19 and IGF2 expression positively correlates in human breast cancer. Then, we 
investigated whether HMGA1P7 functions as ceRNA through, or partially through H19, IGF2 and HMGA1 in 
breast cancer human cells. As expected, we found upregulation of H19, IGF2 and HMGA1 following HMGA1P7 
overexpression in MCF7 cells (human breast adenocarcinoma cell line) (Fig. 5A). Moreover, MCF7-HMGA1P7 
cells grow faster than the control transfected cells as consequence of HMGA1P7 ceRNA pathway activation 
(Fig. 5B).
To confirm whether HMGA1P7 works as miRNA sponge for the regulation of H19 and IGF2 expression levels 
also in human cancer, we evaluated the expression of H19, IGF2 and HMGA1P7 in a panel of breast carcinoma 
samples by qRT-PCR, since H19 and IGF2 have been reported to be overexpressed in this type of tumor36,37. As 
shown in Fig. 5C, HMGA1P7 was overexpressed in most of the carcinoma samples as well as H19 and IGF2. 
Moreover, the direct correlation between HMGA1P7 and H19 expression (Spearman r = 0,8656; p < 0,001) 
and between HMGA1P7 and IGF2 expression (Spearman r = 0,7958; p < 0,001) underlines that these genes are 
co-regulated (Fig. 5D). Altogether, these results strongly support the idea that HMGA1P7 could act as ceRNAs 
in human breast cancer and represent a novel potential mechanism accounting for H19 and IGF2 upregulation 
in these tumors.
Figure 2. Igf2 is upregulated in HMGA1P7 MEFs . Western blot analysis of Igf2 from WT and HMGA1P7 
transgenic MEFs.
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Discussion
lncRNAs are involved in regulating the complexity of biological processes with specific regulatory mecha-
nisms, thereby, attracting considerable research interest38. We have previously isolated and characterized two 
pseudogenes, HMGA1P6 and HMGA1P7, for the HMGA1 gene and demonstrated that they act as decoys for 
Figure 3. H19 and Igf2 are positively regulated by HMGA1P7. (A) qRT-PCR analysis of H19 from hearts, 
spleens and kidneys of WT and HMGA1P7 transgenic mice. (B) qRT-PCR analysis of Igf2 from hearts, spleens 
and kidneys of WT and HMGA1P7 transgenic mice. (C) Western blot analysis of Igf2 from heart, spleen 
and kidney of WT and HMGA1P7 transgenic mice. (D) Left Panel, qRT-PCR analysis of H19 and Igf2 from 
control and HMGA1P7 overexpressing NIH3T3 cells. Right Panel, Western blot analysis of Igf2 from control 
and HMGA1P7 overexpressing NIH3T3 cells. The results are reported as the mean of values. The error bars 
represent mean ± SE; *P < 0.05 **P < 0.01 ***P < 0.001 (t test).
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HMGA1-targeting miRNAs17. In fact, their overexpression enhances HMGA1 protein levels whereas their knock-
ing down results in the reduction of HMGA1 mRNA and protein amounts. Moreover, their decoy activity pro-
tected the synthesis of other proteins involved in carcinogenesis17,18. In this study, we used RNA-seq technology 
to identify additional mRNAs differentially expressed in MEFs transgenic for HMGA1P7.
We found that the expression of several genes were influenced by HMGA1P7 including also genes involved 
in cancer progression such as Col6a3, Mki67, H19, Igf2, Gpx3 and Leprel130–37. Indeed, oncomine analyses and 
tissue-microarray immunohistochemistry showed overexpression of COL6A3 in colorectal carcinomas that was 
significantly and directly correlated with Dukes stage, T stage, stage, recurrence and smoking status and then with 
a poor prognosis30. The MKi-67 protein (also known as Ki67) is a cellular marker for proliferation. Ki-67 protein 
is expressed during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from resting cells (G0)32. 
GPX3 gene codes for the Glutathione peroxidase 3, also known as plasma glutathione peroxidase (GPx-P), the 
variations in activity of GPX1, GPX2, and GPX3 isoforms may be associated with the development of cancers, for 
example, prostate cancer or even colon cancer39. Leprecan-like 1 is a potential tumor suppressor gene since it has 
been demonstrated to be downregulated in the hepatocarcinoma tissues and its overexpression inhibits cancer 
cell proliferation and colony formation through regulation of the cell cycle by downregulation of cyclins40.
Figure 4. H19 and Igf2 are targeted by HMGA1P7-targeting miRNAs. (A) qRT-PCR analysis of H19 (left 
Panel) and Igf2 (middle Panel) mRNA from the NIH3T3 cells transfected with scrambled-oligonucleotide, 
miR-15, miR-16, miR-214 and miR-761. Right Panel, Western blot analysis of Igf2 in the same samples as in 
the middle panel. (B) Igf2 was cloned into the pGL3 control vector. Relative luciferase activity in HEK293 cells 
transiently transfected with miR-15, miR-16, miR-214, miR-761 and a control scrambled oligonucleotide.  
(C) H19 and Igf2 mRNA levels 24 h after the transfection of HMGA1P7 in scrambled oligonucleotide or siRNA-
Dicer NIH3T3 transfected cells. (D) qRT-PCR analysis of H19 mRNA levels from the NIH3T3 cells transfected 
with siRNA-control, siRNA-Igf2 alone or in in combination with the Anti miR-16 oligonucleotide.
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Deregulation of H19 noncoding gene was found in many tumors such as hepatocellular and bladder cancer22,23. 
Finally, IGF2 overexpression is widely reported in pediatric and adult tumors27, and several studies involve IGF2 
as a key factor leading to cancerogenesis27–29.
Among the most deregulated genes, we selected and studied H19 non-coding gene and Igf2, that share sev-
eral miRNAs with HMGA1P7. Here, we report the ceRNA relationship between HMGA1P7, H19 and Igf2. We 
demonstrate that HMGA1P7 overexpression increases H19 and Igf2 levels inhibiting their mRNA suppression by 
miRNAs that target HMGA1P7 gene, namely, miR-15, miR-16, miR-214, and miR-761. Interestingly, preliminary 
results show an analogous ceRNA connection between H19, Igf2 and HMGA1P6, supporting the oncogenic role 
of the both HMGA1 pseudogenes.
Figure 5. H19 and IGF2 expression positively correlates with HMGA1P7 in breast cancer. (A) Left Panel, 
Western blot analysis of HMGA1 and IGF2 protein levels in control and HMGA1P7-overexpressing MCF7 
cells. Right Panel, qRT-PCR analysis of H19 expression of control and HMGA1P7-overexpressing MCF7 cells. 
(B) MCF7 cell proliferation of control and HMGA1P7-overexpressing cells (C) qRT-PCR analysis in tumor 
and normal breast tissues. The fold change indicates the relative change in expression levels between tumor 
samples and normal samples, assuming that the value of normal sample is equal to 1. (B) Correlation analysis 
of HMGA1P7 versus H19 and HMGA1P7 versus IGF2 are shown. The Spearman’s rank correlation coefficient is 
shown.
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Finally, we show that expression of HMGA1P7 significantly correlates with H19 and IGF2 levels in human 
breast cancer, suggesting the upregulation of HMGA1P7 may increase H19 and IGF2 expression by a ceRNA 
mechanism then contributing to cancer progression. Interestingly, the oncogenic role of HMGA1P7 is also sup-
ported by the development of malignant hematological neoplasias in HMGA1P7 transgenic mice (manuscript in 
preparation).
Then, the data reported here confirm the oncogenic role of the HMGA1P7 pseudogene that is exerted by the 
increased expression through a ceRNA mechanism of HMGA1 and other cancer-related genes. Future studies 
need, however, to characterize other genes regulated by the HMGA1 pseudogenes and thereby better define the 
mechanisms by which they can contribute to cancer progression.
Materials and Methods
Cell culture and transfections. MEFs and MCF7 were cultured in DMEM supplemented with 10% foetal 
calf serum (Thermo Fisher Scientific Inc). NIH3T3 cells were maintained in DMEM supplemented with 10% 
calf serum (Thermo Fisher Scientific Inc), glutamine and antibiotics. MycoAlert (Lonza) was regularly used 
to test that cells were not infected by mycoplasma. Lipofectamine plus reagent was used to transfect the cells 
(Thermo Fisher Scientific Inc) according to the manufacturer’s instructions. The transfected cells were selected in 
a medium containing geneticin (Sigma). Transfection efficiency was tested for each experiment by assessing GFP 
signal. To inhibit Dicer and Igf2 expression, small interfering RNAs and corresponding scramble small interfering 
RNAs were designed and used as suggested by the manufacturer (RIBOXX).
RNA-sequencing. RNA samples were initially checked for quality and quantity using a Bioanalyzer with the 
total RNA Pico chip (Agilent Technologies, Inc) and a Qubit® with RNA Assay Kit (Thermo Fisher Scientific Inc) 
respectively.
Spike-In Mix 1 and Spike-In Mix 2, each containing the full complement of 92 polyadenylated transcripts 
from the ERCC plasmid reference library, were added to samples.
mRNA was selected from total RNA preparation using MicroPolyA Purist kit (Ambion, Inc).
SOLiD™ Total RNA-Seq Kit (Life Technologies Corporation) was used to convert RNA transcripts into 
a cDNA library, starting from low input amounts of poly(A) RNA, for analysis on the 5500 Genetic Analysis 
System. First of all, mRNA was incubated in a thermal cycler at 95 °C for 10 minutes to fragment the RNA by 
chemical hydrolysis. The RNA digested was hybridized and ligated with Solid specific adaptors. Two rounds 
of size selection using Agencourt® AMPure® XP Reagent were performed to increase the percentage of library 
inserts that were in the desired size range, >150 bp. The purified DNA was amplified and barcoded by 18 PCR 
cycles to enable sequencing of all the samples in a single multiplexed SOLiD System sequencing run.
The yield and size distribution of the amplified DNA libraries was assessed running the samples on an 
Agilent® 2100 Bioanalyzer™ Instrument with the DNA HS Kit following the manufacturer’s instructions and 
Qubit® dsDNA HS kit.
Ninety nanograms of each library was pooled together and one E80 emulsion was prepared following SOLiD® 
EZ Bead™ System. About 400 millions of pooled templated beads were deposited on a 4 lanes of a 6 lanes slide 
and the sequencing was performed up to a read length of 50 bp, based on 5500 Genetic Analysis System Run 
sequencer protocol.
Bioinformatic Analysis. Four samples were analysed: two from WT and two from HMGA1P7 transgenic 
MEFs. The comparison performed was WT versus transgenic, two biological replicates for condition.
Sequencing reads in SOLiD “xsq” format were mapped against the reference genome (UCSC GRC38/mm10); 
reference gene structure was Refseq from the refGene.txt file of the UCSC genome browser FTP site; the mapping 
software was the Whole Transcriptome Analysis module from the Lifescope 2.5.1 Genomic Analysis Software 
analysis suite from Applied Biosystems/ThermoFisher Scientific.
A filter file, containing 6415 sequences (sequencing adaptors; barcodes; tRNAs; rRNAs; rRNA fragments; 
repetitive sequences; ERCC RNA sequences) was used (1) to filter the transcripts for non-significant reads and 
(2) to quantify the absolute expression using the External RNA Controls Consortium (ERCC) RNA Spike-In Mix.
The genome-mapped reads were then correlated with Refseq genes and the resulting gene-associated read 
counts were analysed with a Genomnia proprietary procedure based on the Bioconductor library edgeR41. The 
chosen limit for evaluating differential expression was 5 counts per millions in at least half of the examined 
samples. The normalization procedure used was the standard for edgeR (TMM). Genes were called differentially 
expressed when the comparison was evaluated with a FDR < 0.05. Absolute gene expression was evaluated from 
the read counts in RPKM (Reads per kilo base per million mapped reads).
Primary gene annotation was performed using the Bioconductor libraries biomaRt and GOstats, while func-
tional clustering of the genes was performed using the DAVID functional annotation web site (https://david.
ncifcrf.gov/).
Mouse embryo and tissue samples. The use of mouse embryos and tissues and the experiments per-
formed in this study were approved by the Ministero della Salute; the methods and experiments were carried out 
in accordance with the approved guidelines by the Ministero della Salute.
Human breast tissue samples. Normal and neoplastic human breast tissues were obtained from surgi-
cal specimens and immediately frozen in liquid nitrogen. 32 breast samples were collected at the Institute of 
Pathology, University of Basel, Switzerland. The tumor samples were frozen until required for RNA extrac-
tion. The use of human tissues and the experiments performed in this study were approved by the Institute of 
Pathology, Molecular Pathology Division, University of Basel; the methods and experiments were carried out 
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in accordance with the approved guidelines by the University of Basel. We declare that informed consent for the 
scientific use of biological material was obtained from all patients.
RNA extraction and quantitative reverse transcription PCR. Total RNA was extracted from cells or 
tissues with TRIsure (Aurogene) according to the manufacturer’s instructions. For mRNA trascripts detection, 
we reverse transcribed total RNA from samples by using the QuantiTect Reverse Transcription Kit (Qiagen), and 
then Real-time PCR was performed by using Power SYBR Green PCR Master Mix (Bio-Rad) and the following 
primers:
HMGA1P7-Fw 5′ -gctccttctcggctcctc-3′ 
HMGA1P7-Rev 5′ -gcttgggcctcttttatgg-3′ 
mIgf2 Fw 5′-cctccttacccaacttcaggt-3′ 
mIgf2 Rv 5′ -aagagatgagaagcaccaacatc-3′ 
mh19 Fw 5′ -atgtcttcatttctccctatagcc-3′ 
mh19 Rv 5′ -gtcatcctcgccttcagtg-3′ 
mG6pd-Fw5′ -cagcggcaactaaactcaga-3′ 
mG6pd-Rev 5′ -ttccctcaggatcccacac-3′ 
mCol6a3 Fw 5′ -ggaggtgtacaggaagttccac-3′ 
mCol6a3 Rev 5′ -gactgagccgtcaaagagga-3′ 
mMki67 Fw 5′ -gctgtcctcaagacaatcatca-3′ 
mMki67 Rev 5′ -ggcgttatcccaggagact-3′ 
mGpx3 Fw 5′ -gtgaacggggagaaagagc-3′ 
mGpx3 Rev 5′ -tgagcccaggagttctgc-3′ 
mLeprel1 Fw 5′ -tggaccctctttaccgagaa-3′ 
mLeprel1 Rev 5′ -tgatccaagatggcaatcac-3′ 
hActin Fw 5′ -ccaaccgcgagaagatga-3′ 
hActin Rv 5′ -ccagaggcgtacagggatag-3′ 
hH19 Fw 5′ -ttacttcctccacggagtcg-3′ 
hH19 Rv 5′ -gagctgggtagcaccatttc-3′ 
hIGF2 Fw 5′ -gctggcagaggagtgtcc-3′ 
hIGF2 Rv 5′ -gggattcccattggtgtct-3′ 
The 2−∆∆CT formula was used to calculate the differential gene expression, and described elsewhere42.
Plasmid and miRNA oligonucleotides. For transfection of miRNA oligonucleotides, cells were trans-
fected with 50 nmol/ml of miRNA precursors or with a control no-targeting scrambled oligonucleotides (Thermo 
Fisher Scientific Inc) using siPORT neoFX Transfection Agent (Thermo Fisher Scientific Inc). For transfec-
tion of Anti miR-16 oligonucleotides, cells were transfected with 50 nmol/ml of Anti miR-16 or with a control 
no-targeting scrambled oligonucleotides (Thermo Fisher Scientific Inc).
For Igf2 luciferase reporter construct (pGL3-Igf2), the miRNA seed sequence conteining fragment of Igf2 gene 
(ENSMUST00000000033) was amplified by using the primers:
Igf2 Fw 5′ -aatttctagacccaaaatctcacttttccc-3′ 
Igf2 Rev 5′ -aatttctagagatggcccataggtgtgctc-3′ .
The amplified fragment was cloned into pGL3-Control luciferase reporter vector (Promega).
All the generated vectors were confirmed by sequencing. The Renilla luciferase vector (pRL-CMV), for tran-
sient transfection efficiency, was purchased from Promega.
Protein extraction, western blotting and antibodies. Protein extraction and Western blotting were 
performed as previously described43,44. The primary antibodies used were anti-IGF2 (#32592) from Sabbiotech; 
anti-GAPDH (sc-32233) and anti-γ -Tubulin (sc-17787) from Santa Cruz Biotechnology. Blots were visualized by 
using the Western blotting detection reagents (Thermo Fisher Scientific Inc).
Dual-luciferase reporter assay. For dual-luciferase reporter assay, 3 × 105 NIH3T3 cells were 
co-transfected in 6-well plates with the pGL3- Igf2 or the pGL3-H19 luciferase reporter vectors, together with the 
Renilla luciferase plasmid and miRNA precursors or a control no-targeting scrambled oligonucleotides (Thermo 
Fisher Scientific Inc), using siPORT neoFX Transfection Agent (Thermo Fisher Scientific Inc). The pRL-TK con-
trol vector expressing Renilla luciferase (Promega) was used for normalization of cell number and transfection 
efficiency. Luciferase activity was measured 48 hours after transfection using the Dual-Luciferase Reporter Assay 
System (Promega) with a Lumat LB 9507 apparatus (Berthold Technologies).
Growth curve assay. For each experimental point 3 × 104 cells were plated in a 60 mm plate. Cells were 
counted in triplicate for 5 days with Burker hemocytometer chamber.
Statistical analysis. Data were analyzed using a two-sided unpaired t test (GraphPad Prism, GraphPad 
Software, Inc.). Values of P < 0.05 were considered statistically significant. Regression analysis, correlation coeffi-
cients and statistical analysis were generated using GraphPad Prism, GraphPad Software, Inc.
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